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INHALATION – A BRIEF OVERVIEW OF PULMONARY DRUG DELIVERY 
Aerosol inhalation as a route for pulmonary drug delivery is currently experiencing a 
period of tremendous growth. Indeed, the combination of a better understanding of lung 
pathogenesis and the overcoming of a number of issues related to aerosol delivery has 
presented new opportunities in the field of inhalation therapy [1, 2]. The significant  growth in 
new technologies for drug delivery via inhalation has fuelled interest in employing 
aerosolized drugs for the treatment of respiratory diseases as well as systemic disorders [3, 4]. 
A large number of topical, respiratory drugs for an inhalation therapy already exists 
encompassing different classes (Table 1), and still the number of such formulations is rising 
[5, 6]. The disadvantages associated with the parenteral administration of drug substances, 
such as high doses or injection-related side reactions, pain, patient compliance and cost, have 
motivated researchers and manufacturers to develop pulmonary delivery systems for systemic 
drugs. In this respect, different non-peptide and peptide-based drugs such as insulin or the 
human growth hormone (hGH) have been reported to reach the systemic circulation following 
aerosol administration (Table 2). One recent breakthrough in pulmonary drug delivery, 
causing local and systemic reaction, is the development of cyclosporine, which was recently 
approved by the FDA as an immunosuppressant for post- lung transplantation patients [7]. 
Controlled drug delivery systems are becoming increasingly attractive options for 
inhalation therapies. The rationale of controlled drug delivery is to change the 
pharmacokinetic and pharmacodynamic behaviour of a drug substance by controlling its 
liberation, absorption and distribution [8]. Traditionally, the successful delivery of complex 
biomolecules, such as proteins, peptides or nucleotides, was only possible parenterally as such 
molecules are often temperature sensitive, instable at physiological pH and display a short 
half life. However, the development of novel drug carrier systems such as lipid- and polymer-
based particles, chemical and biological drug-modification have been proposed to obtain 
controlled drug delivery systems for the lung [9-11]. It was demonstrated that the pulmonary 
administration of such new micro- and nano- scaling delivery systems is a suitable alternative 
to injection, even though the drugs must overcome numerous barriers in the lung to reach the 
site of action.  
Utilizing such novel technologies, the lung as been recently explored as an important 
target organ for gene therapy of many acute and chronic diseases, including cancer, asthma, 
cystic fibrosis, alpha-1-antitrypsin deficiency and respiratory distress syndrome, among others 
[12, 13]. Of particular interest in this respect, is the polycation polyethylenimine, since it was 
 General introduction  
  3 
observed to serve as effective and protective vehicle for nucleotides. More detailed 
information concerning these topics will be introduced further on in this chapter.  
 
Table 1. Aerosol drugs for topical treatment of pulmonary diseases (Abbreviations see page 
185), approved or under development in human trials (*). 
drug drug class trade name diseases references 
tiotropium-
bromid 
anticholinergic-
bronchodilator 
Spiriva COPD [14] 
budesonide corticosteroid Pulmicort asthma, COPD [15-17] 
fenoterol ß2-sympathomimetic  Berodual asthma [18] 
iloprost prostaglandins Ventavis PAH [19] 
cromolyn 
sodium 
mast cells 
stabilizer 
Intal allergic asthma [20] 
tobramycin aminoglycoside-
antibiotic  
TOBI CF, PAI [21, 22] 
pentamidine chemotherapeutic  Pentacarinat HIV, PCP [23] 
ribavirin virus-static  Virazole respiratory virus 
infection 
[24, 25] 
surfactant phospholipid, protein 
mixture 
Alveofact ARDS [26-28] 
colistin cyclopeptide-
antibiotic  
* CF, PAI [21, 23] 
amphotericin 
B 
peptide-fungicide Amphotericin 
B 
CF, HIV, 
fungal pneumonia 
[4, 23] 
alpha 1- 
antitrypsin  
alpha 1-protease 
inhibitor 
* lung emphysema, 
CF, ARDS 
[27, 29] 
 
Table 2.  Aerosol drugs for systemic treatment, approved or under development in human 
trials (*). 
drug drug class trade name diseases references 
insulin peptide-hormone Exubera diabetes [30, 31] 
heparin anticoagulants * thrombosis, 
emphysema 
[32] 
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cyclosporine immunosuppressant Pulminiq lung 
transplantation 
[7, 33] 
alpha 1- 
antitrypsin  
alpha 1-protease 
inhibitor 
* alpha 1-anti- 
trypsin deficiency, 
congenital 
emphysema 
[34, 35] 
calcitonin peptide-hormone * osteoporosis [2, 36] 
ergotamin vasoconstrictor * migraine [37] 
hGH peptide-hormone * growth hormone 
deficiency 
[38] 
leuprolide 
acetate 
synthetic analogue 
of GnRH 
* infertility, breast 
& prostate cancer 
[39, 40] 
 
CELLULAR AND EXTRA CELLULAR BARRIERS IN PULMONARY DRUG 
DELIVERY – AN OVERVIEW OF THE LUNG ANATOMY AND PHYSIOLOGY 
The lung is a complex organ, which forms a border between the external and internal 
environment. Its primary function is to enable rapid uptake of oxygen, required for metabolic 
processes, and the elimination of the toxic product carbon dioxide. The respiratory tract 
consists of a conducting region and a respiratory area, and is anatomically characterized by 
extens ive bifurcations. According to Weibel’s bronchial tree (Figure 2), the conducting 
airways are classified into 16 bifurcations, comprising the trachea, the bronchi and the 
bronchioles [41]. The terminal bronchioles represent the passage to the respiratory region, 
which is classified into other 6 bifurcations. The respiratory region includes the respiratory 
bronchioles, from which the alveolar ducts with alveolar sacs branch off. The human lung 
consists of approximately 30000 terminal bronchioles and each of those branches into 10000-
15000 alveoli. This region comprises a surface area of approximately 100 m2 where air and 
blood come into intimate contact and gas-exchange takes place across a thin epithelial and 
endothelial barrier (~ 0.5 µm) [42]. Although the bronchial and alveolar epithelia display high 
permeability to water, various gases and lipophilic substances, whereas the permeation of 
many hydrophilic substances of large molecular size and ionic species is limited [43].  
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Figure 2. Left: Schematic of the bronchial tree [41]. Right: section through terminal 
bronchioles and the following bifurcations [42]. 
 
The conduction airways consist of the epithelial lining, the basement membrane, the sub-
epithelial connective tissue and the smooth muscles. Three cell types predominate in the 
stratified bronchial epithelia of the conducting region: ciliated, secretory and basal cells. 
Whilst the goblet cells and the submucosal gland cells are responsible for the secretion of 
mucus (100 ml per day), the major function of the ciliated cells is the propulsion of mucus 
upwards and out of the lung. Each ciliated cell contains circa 40 cilia of 3- 6 µm length. The 
mucus consists of oligomeric mucin glycoproteins as the major component, and it forms two 
layers - a gel like layer on the outside and a more fluid layer on the cell side. During the cilia 
beat in direction to the pharynx the cilia are stretched and thus they reach the gel layer. The 
backwards movement of the cilia occurs in the curved position in the fluid layer. Due to this 
propulsion the mucus moves 2.5 mm per minute in direction to the pharynx and thus the lung 
will be cleared of foreign substances.  
The bronchioles represent the passage to the respiratory airways and the epithelium 
transit to single cell layer, consisting of ciliated cells and Clara cells that are the progenitors 
of the bronchial epithelium. The thick mucus lining (1 – 10 µm) fades to the surfactant lining 
(0.1 – 0.2 µm), and constitutes the physical barriers to pulmonary absorption [42].  
The alveolar epithelium is primarily composed of type I and type II pneumocytes. Type I 
cells have a very thin cell body (0.2 µm) with long membranous extensions. Due to their large 
cell diameter of approximately 200 µm, they occupy an area of approximately 95 % of the 
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alveolar surface even though they represent only 33 % of the total number of alveolar 
epithelia cells. The type I pneumocytes border on a single layer of basal membrane that is 
connected to the capillary endothelium on the opposite side. Because of their thin cell body, 
the distance between alveolar lumen and blood is lowest (0.5 to 0.6 µm), making their main 
function the gas-exchange and transport of molecules possible. The type II pneumocytes are 
characterized by a more cuboidal morphology, and due to their small diameter (~ 15 µm) they 
cover only 5 % of the total alveolar surface. Their main functions are the production of 
surfactant and the differentiation into type I cells when the epithelium is damaged. 
Furthermore, it was reported that pneumocytes express a variety of transport proteins such as 
calveolin or clathrin, which are able to internalize macromolecules or even nanoparticles by 
endocytosis [44].  
In the respiratory airways the alveolar epithelium is covered by the surfactant lining layer 
which is composed of phospholipids and proteins. Beside its function in the host defence, the 
surfactant is primarily responsible for the stabilization of the alveoli structure. Due to the 
surface tension between alveolar air and the wet cell surface the alveolar sacs run the risk of 
collapsing (the smaller sacs) or bursting (larger sacs). The phospholipids of the surfactant are 
bipolar molecules and act as an interface between a myelin containing hypophase (on the cell 
surface) and the alveolar air, thus reducing the surface tension and stabilizing the alveoli [45]. 
The surfactant proteins (A, B, C & D) have been identified as playing a fundamental role in 
innate immunity (A & D) and lipid packing of the interface (B & C) [46]. 
Among the different respiratory cells, the ciliated epithelia cells of the larger and smaller 
airways and the type I and type II pneumocytes are the key players in the pulmonary drug 
transport [3]. The transport of drugs into the pulmonary circulation occurs through different 
routes. Whereas lipophilic drugs pass the epithelium via the transcellular transport, 
hydrophilic drugs are transported mainly via the intercellular passage. The small pore sizes 
between the alveolar cells (0.6-1nm) and the tight junction depth (0.261 µm) limiting their 
drug transport. The mechanisms of macromolecular transports are the subject of genuine 
interest and vesicular trafficking was studied intensively [47]. Recently, a putative alternative 
transport pathway within the type I pneumocytes has been described comprising plasma 
membrane vesicles or invaginations called caveolae. The key structural and functional protein 
for the caveolae is the caveolin. Caveolae are morphologically evident as omega-shaped 
invaginations of the plasma membrane and form discrete functional vesicles with a diameter 
of 50-100 nm within the cell cytoplasm. Caveolae undertake transport functions including that 
of the endocytic and transcytotic movement of macromolecules, and indeed microbes and 
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microbial toxins [47, 48]. Therefore, caveolae might permit vascular targeting to achieve 
theoretical expectations of tissue-specific pathway for overcoming key cell barriers to many 
drug and gene therapies in vivo [49].  
Approximately 80-85 % of the alveolar walls are covered with capillaries and these 
receive the first passage of the whole cardiac output of venous blood to assure the oxygen 
supply of the body [42]. With respect to these considerations, studies were undertaken to use 
the pulmonary endothelium as targeting tissue for pulmonary drug delivery from the vascular 
side. In support of this notion, native and modified antibodies to angiotensin-converting 
enzyme, thrombomodelin, intercellular adhesion molecule and platelet endothelial cell 
adhesion molecule were studied and it was postulated that they possibly could serve as 
carriers for drug/gene targeting to the pulmonary endothelium [50, 51]. Whereas calveolae 
forms recycling endosomes in particular for transcellular transport, the clatrin-coated pits 
ensure to uptake of molecules into the cells by endocytosis [52]. 
The mucociliary clearance represents the first barrier in the lung for inhaled substances 
and is particularly successful in the clearance of larger particles. In the respiratory tract the 
pulmonary barrier consist of pulmonary enzymes and alveolar macrophages. Pulmonary 
enzymes, such as proteases and peptidases, will be excreted by pneumocytes type II cells as 
component of the surfactant (protein A & D) or they are located inside macrophages, 
lymphocytes, neutrophils and mast cells and they readily degrade inhaled macromolecules. 
Alveolar macrophages play an important role in the host defence, and are strategically located 
in the alveolar ducts and sacs. The human lung is estimated to contain 2.3 x 1010 
macrophages, with 50-100 per alveolus. Several types of receptor on the macrophage cell 
surface identify and mediate the internalization of inhaled substances and particles. 
Macrophages may also phagocytose particles or molecules opsonized by the surfactant 
proteins, immunoglobulins and complement components. Once internalized foreign 
substances are targeted to the phagolysomal compartment and destroyed [53].  
The immune response generated in the respiratory system is confined to the region 
exposed to antigen stimulation. The upper and lower respiratory tract are associated with their 
own specialized immune surveillance system. Whereas the conducting airways are associated 
with the nasal associate lymphoid tissue (NALT), the respiratory area encompasses the  
bronchus associate lymphoid tissue (BALT). The BALT contains lymphoreticular aggregates 
with B cells and T cells situated under the lung epithelium. The lung is also comprised of non-
lymphoid cells, such as dentritic cells and alveolar macrophages and they are mainly found in 
the areas of maximum antigen presentation. Macrophages, dentritic cells and also B 
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lymphocytes are antigen presenting cells and the immune response of the lung depends on the 
interaction between those and T- and B-lymphocytes respectively. Dentritic cells are regarded 
as the main antigen presenting cells involved in the stimulation of antigen specific native T 
lymphocytes, whereas macrophages (by secretion of interleukin 1) and B cells my be involved 
in restimulating pre-existing or memory T- lymphocytes [54]. 
INHALATION DEVICES  
Aerosolization devices have to fulfil several requirements to ensure safe and efficient 
drug transport to the site of action: reproducible dosing, high efficiency of drug delivery, ease 
of device operation, short duration of treatment, minimized risk to patient, environmental 
protection and cost-effectiveness [55]. Three types of devices are commonly used for the 
administration of drugs to the respiratory tract: pressurized metered dose inhalers (MDI), dry 
powder inhalers (DPI) and nebulizers. An adequate understanding of the advantages and 
disadvantages of the different systems is required to make a proper choice between them [56]. 
A MDI contains the drug in suspension, emulsion or solution to which a propellant has been 
added. When the device is activated, a metered dose is released at high velocity, which 
requires a simultaneous inhalation by the patient. To overcome this challenge, more recent 
developments, require a breath actuated drug release [57]. A DPI consists of a dry powder 
formulation, a dosing principle and an inhaler device. It operates by using the inspiratory flow 
of the patient for dose entrainment and disintegration of the powder formulation [58]. 
Nebulizers are used to aerosolize drug solutions and sometimes drug suspension for 
inhalation. They are typically used in situations when severe obstruction of the airways or 
insufficient coordination by the patient does not allow the use of other systems. A significant 
advantage of nebulizers in comparison to MDIs and DPIs, is their universal availability, 
hence, the same device can be employed for different drug solutions or dispersions. 
There are two basic types of nebulizers, the air-jet and the ultrasonic nebulizer. For a 
typical air-jet nebulizer (Figure 1A) compressed air (1) passes through a narrow hole (2) and 
entrains the drug solution (3) from one or more capillaries (4) mainly by momentum transfer. 
The aerosol droplets are formed by a break-up process of the liquid from the liquid column 
and their size is mainly dependent on the design of the capillaries. Large droplets impact on 
one or more baffles (5), in order to refine the droplet size distribution to the required range for 
inhalation. Only smaller droplets with less inertia can follow the streamlines of air (6) and 
pass the baffle. In practise, there exists a wide variation in the performance of different types 
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of nebulizers [59, 60]. PARI GmbH is the world’s leading manufacturer of aerosol delivery 
apparatuses. They manufacture numerous air-jet nebulizers for infants and adults for use in 
hospitals or at home, e.g. Pari boy®, Pari LC® or Pari Sole® [61].  
In an ultrasonic nebulizer (Figure 1B), droplets are produced by a rapid vibrating 
piezoelectric crystal (1). The frequency of the vibrating crystal determines the droplet size for 
a given solution. In the most nebulizers the ultrasonic vibrations are transferred directly to the 
surface of the drug solution in a drug reservoir. In some ultrasonic nebulizers, such as the 
illustrated Optineb® (Nebu-tec) apparatus, the vibrations are transferred to a connecting liquid 
(2) before reaching the drug reservoir (3). Hence, these nebulizers reduce the shear forces 
applied to the drug, and minimize any heat applied to the formulation in the process of 
nebulization [62]. As previously described, whilst the smaller droplets follow the airstreams 
(4) the larger impact on the baffle (5). 
 
 
  
  
 
Figure 1. A schematic presentation of the nebulizers utilized in this work: A) Pari LC® [61] , 
B) Optineb® and C) Aeroneb® [63]. The working principles are detailed in the text.  
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Several manufacturers, such as Aerogen(Figure 1C), Omron, ODEM and Pari, have 
developed new aerosol devices that utilize a vibrating mesh or plate (1) with multiple 
apertures to produce a liquid aerosol. Such devices display a number of beneficial features 
including: the generation of fine aerosol particles, no internal baffling system is required, they 
are portable and  battery operated (2), they efficiently aerosolize solutions and suspensions, 
and they have minimal residual volume of medication left in the drug reservoir (3). As a 
consequence thereof, their efficiency of delivering drugs to the respiratory tract is higher than 
conventional air-jet or ultrasonic nebulizers [64]. The Aeroneb® (Aerogen), utilized in the 
studies of this thesis, was developed for the nebulization of sensitive drugs such as proteins or 
peptides. In contrast to common ultrasonic nebulizers, the frequency is low and the 
temperature in the Aeroneb® is constant and thus there is a minimal risk of denaturing 
biomolecules such as proteins, peptides or nucleotides [63].  
There are two main parameters that determine the nebulizer performance: the droplet size 
distribution of the aerosol and the drug output rate. However, it should be taken into account 
that the performance of the nebulizer is also influenced by the patient’s inspiration flow (7), 
the air flow rate from the compressor, and  the physical properties of the drug solution [56].  
The droplet size distribution is important for the actual deposition in the lung. Therefore, 
aerosol particle sizes are commonly characterised by the mass median aerodynamic diameter, 
which can be determined using e.g. laser diffraction analysis [65]. Diameters measured by 
laser diffraction technique are based upon geometric particle dimension. For the spherical 
droplets in the aerosol cloud from nebulizers, the equivalent volume diameter equals the 
measured mass median geometric diameter. The aerodynamic particle diameter is the 
diameter of a unit density sphere that has the same terminal settling velocity in still air as the 
considered particle. From spherical particles of aqueous  drug solution, also the dynamic shape 
factor and droplet density have unity, and so the aerodynamic diameter equals the measured 
geometric diameter. No corrections are necessary and the volume distribution curve from 
laser diffraction analysis yields a correct mass median aerodynamic diameter [57].  
The three principal mechanisms that lead to pulmonary deposition are internal impaction, 
sedimentation and diffusion. Internal impaction occurs during the passage through the 
oropharynx and the large conducting airways for particles that pose a size > 3 µm, or have a 
high mass and velocity. Due to the small diameter of the alveoli, particles < 3 µm sediment 
mainly by gravitational force in the respiratory airways. Additionally, sedimentation increases 
by breath-holding. In the range below 0.5 – 1 µm, particles are deposited by diffusion, which 
is based on Brownian motion.  
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Besides the aerosol droplet size, particle geometry and charge, lung morphology as well 
as ventilatory parameters can all influence the site, extent and efficiency of drug deposition. 
Therefore, particle features such as source (solution, powder or suspension), diameter, 
density, electrical charge, hygroscopy or shape are often determining parameters for the 
aerosol deposition [57, 66].  
In respect to achieve drug deposition in the lower airways and circumvent macrophageal 
clearance porous microparticles have been developed. These are characterized by a large 
geometric diameter, which acts to both improve drug loading and circumvent clearance by 
alveolar macrophages. However, due to their hollow porous structure the aerodynamic 
diameter of these microparticles is much smaller than the geometric diameter. Therefore, the 
amount and the retention period of the particles deposed in the respiratory airways could be 
improved [9, 67, 68].  
The drug output rate is another important factor in regard to confine the nebulization time 
and thus improving the patient compliance. The output rate (mg/min) is the mass of drug 
converted to aerosol per unit time. It can be determined either by weighing the nebulizer 
before and after use, or more exactly by measuring the drug concentration in the nebulized 
fraction [69].  
 
Taken together, the knowledge of the cellular aspects, the pulmonary clearance and 
immune response, the characterization of delivery devices and the pulmonary deposition 
display major targets to pulmonary drug delivery. An optimal delivery system would transport 
the drug safely and specifically to its pulmonary target region or into the systemic circulation 
and than realize the drug at the side of action in a given kinetic. To optimize current delivery 
systems or developing novel systems, future studies addressing the unique molecular, 
biological and physiological characterization of both the various respiratory regions and the 
drug formulations have to be carried out.  
GENE THERAPY 
The treatment of disease at the genetic level was first proposed over 30 years ago [70, 
71]. The “gene therapy rollercoaster” started in1990 with the treatment of the first patient in a 
gene therapy clinical trial for sever combined immunodeficiency using a retroviral vector 
[72]. Since then, gene therapy has reached a point of serious pharmaceutical developments as 
evidenced by the 1020 clinical trials that have already been initiated worldwide [73]. The 
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genetic material of interest can be either DNA or RNA, and the altered function can be an 
increase or decrease in the production of a protein. Fundamental problems involved in gene 
therapy are (i) the selection and isolation of the appropriate gene, (ii) the delivery to and into 
the cells of interest, and (iii) the efficient gene expression or suppression [74]. A typical gene 
delivery protocol utilises plasmid DNA (pDNA) amplified and isolated from bacteria that 
contains the sequence of interest, a viral promoter for expression in the eukaryotic cells and 
an antibiotic resistance gene for selection stringency and amplification of the bacterial host 
[75, 76]. In the present work, pDNA under the promoter control of Cytomegalovirus, 
containing 4000-5000 base pairs was utilized. From a technological point of view, the 
physico-chemical properties of pDNA, such as high molecular weight (= 2500 kDa), 
hydrophilicity, extensive anionic charge density, and susceptibility to enzymatic degradation 
makes it a difficult compound for delivery across several cellular barriers [77, 78]. Obviously, 
delivery of naked DNA would lead to poor transfection efficiency. Therefore, the 
development of gene delivery vehicles play a predominate role  in gene therapy. These 
vehicles have to fulfil several requirements including minimal side effects, providing effective 
DNA condensation and protection, transport through the cell membrane and finally DNA 
release and nuclear entry [52, 79].  
Gene delivery vehicles 
On the whole two different approaches have been utilized to achieve delivery of nucleic 
acid to cell nuclei, namely viral and non-viral vectors. Viral vectors represent the majority of 
gene delivery vehicles employed in published studies and clinical trials to date (Figure 3), 
since they are known to be extremely efficient in effecting transgene expression [73, 80]. 
Such vectors have their genome altered to prevent viral replication, reduce their cytotoxicity 
and permit incorporation of the resulting therapeutic transgene  [81]. In early 2004, the 
world’s first human gene therapy product, Gendicine®, an adenoviral vector expressing the 
tumor-suppressor gene p53, obtained market approval by the Chinese FDA for the treatment 
of head and neck squamous cell carcinoma [78]. However, the problems of low-virus titer, 
inability to transfect non-dividing cells, induction of strong immune response and significant 
toxicity must still be overcome and have led to the development of alternative approaches in 
gene delivery, including non-viral vectors [82].  
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Figure 3. Gene delivery vehicles employed in clinical trials since 1989. 
 
Non-viral gene delivery vehicles are receiving increasing attention as they hold several 
advantages over other approaches, such as ease of manipulation, stability, low cost, safety and 
high flexibility regarding the size of the transgene delivered [83]. A variety of effective non-
viral gene delivery approaches have been developed including: naked DNA injection [84-86], 
biological techniques such as hybridized DNA (bioplexes) [87] or peptides [88], physical 
techniques such as electroporation [89, 90], sonoporation [91], laser irradiation [91], gene gun 
[92] or magnetofection [91], and synthetic transfection reagents including polymer based 
nanoparticles [93-95], cationic lipids (lipoplexes) [96-98] or cationic polymers (polyplexes) 
[99]. Among the cationic polymers employed, polyethylenimines (PEIs) have exhibited 
particularly promising results in both transgene delivery and the following transfection 
efficiency in many cell culture models, as well as in numerous in vivo applications [100, 101]. 
Polyethylenimine mediated gene transfer 
PEI is a synthetic cationic polymer that was first described in 1995 as non-viral gene 
delivery vehicle [102]. Since then, it has gained significant popularity due to its ability to 
form nanoscale complexes with DNA, and subsequent ly releasing these polyplexes into the 
cytosol. As depicted in Table 3, such polyplexes have been utilized over a broad spectrum of 
applications. In an attempt to improve the efficiency and biocompatibility of the vector, 
numerous modifications have been synthesized and studied for a variety of therapeutic 
applications (Table 3). 
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Table 3: In vivo delivery of different PEI/pDNA polyplexes. 
gene delivery 
vector 
transgene targeting tissue/ 
therapeutic applications 
reference 
25 kDa branched 
polyethylenimine 
(BPEI) 
p53, IL-12 
 
reporter gene 
reporter gene 
porphobilinogen 
deaminase 
IL-2, Hepatitis B Ag 
lung metastases, inhibition 
of tumor growth 
lung 
brain  
liver, hepatic porphyria 
 
muscle, vaccination 
[103-106] 
 
[107] 
[108]  
[109] 
 
[110] 
25 kDa linear 
polyethylenimine 
(linPEI) 
reporter gene 
somastatin receptor 
protein 
lung, cystic fibrosis  
pancreatic cancer 
[107, 111, 112]  
[113] 
polyethylenglycol-
graft PEI 
(PEGPEI) 
reporter gene 
reporter gene 
reporter gene 
tumor targeting  
spinal cord disorders 
lung 
[114] 
[115]  
[116, 117] 
transferin-PEI or   
-PEGPEI 
reporter gene 
reporter gene 
TNF-alpha 
tumor targeting 
lung 
tumor necrosis, inhibition 
of tumor growth 
[118, 119]  
[116]  
[120] 
epithelial growth 
factor -PEGPEI 
reporter gene tumor targeting, liver [120] 
galactosylated PEI reporter gene liver [121] 
cyclodextrin-PEI marker gene liver  [122] 
 
 
PEI is highly water soluble and positively charged due to its high density of protonatable 
amino groups. Every third atom in the molecule is a nitrogen, with approximately 20% of 
these being protonated under physiological conditions [123]. As a result, the polymer can 
change ionization state over a broad pH range thus providing a high buffer capacity. This 
property is a considerable advantage of PEI over other cationic polymers in terms of gene 
delivery into the cytoplasm, as explained below.  
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The interaction of pDNA with PEI to form a gene delivery system is demonstrated 
schematically in Figure 4. Condensation of the anionic DNA with the cationic PEI is based on 
electrostatic interactions, and leads to the formation of compact particles of approximately 
100 nm in diameter, depending upon the PEI modification [100]. The degree of condensation, 
and thus the net charge of the resulting particle, is strongly dependant on the cation-to-anion 
ratio, or more precisely the PEI nitrogen-to-DNA phosphate ratio (N/P ratio). Complete 
condensation of DNA (fully explo it cation-anion interactions) seems to occur at N/P ratios of 
3-5 depending upon the PEI modification [124]. However, maximum accessible DNA 
condensation is obtained only with a high PEI extend at N/P ratios > 6, resulting in small 
polyplexes that exhibit a strong positive net charge. This charge induces the polyplexes to 
bind to the negatively charged glycosaminoglycans, which are present on cell membranes, 
and leads to the subsequent polyplex internalization by endocytosis [125]. Post endocytotic 
uptake, the complexed PEI acts as so called proton sponge. The amino groups buffer the 
protons in the endo- lysosomal compartment, leading to an influx of chloride anions, a 
subsequent increase in the osmolarity and eventually to endosomal rupture [126]. The 
released polyplexes must then either enter the nucleus whole, or release the DNA to enter the 
nucleus alone. The precise mechanisms involved in the DNA migration to the nucleus through 
the cytoplasm and passage through the nuclear membrane are still unknown.  Recent 
localization experiments suggest that the pDNA-PEI polyplexes can penetrate into the 
nucleus, suggesting that dissociation of the polycation DNA may not be prerequisite for 
nuclear translocation [127, 128]. In contrast energy-dependent uptake of pDNA alone into the 
nucleus via the nuclear pore complexes was shown recently [129]. However, transport of the 
DNA from the cytosol into the nucleus is certainly one of the major limitations for efficient 
gene transfer mediated by non-viral vectors [52, 83]. Recent studies have proposed a 
mechanism for PEI polyplexes that involves protein-driven transport through the cytoplasm 
towards the nucleus on microtubules. This active transport led to efficient perinuclear 
accumulation within minutes, suggesting PEI displays nuclear targeting activity [130]. The 
passage of polyplexes through the nuclear membrane is also poorly understood and it was 
discussed that the passage appears only in dividing cells [83, 131]. The in vivo investigations 
presented in chapter 4 of this thesis suggest pDNA released from PEI enter the nucleus of 
pulmonary epithelial cells alone.  
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Figure 4. Formation of PEI-DNA polyplexes and their cellular uptake. 
 
Pulmonary gene therapy 
The lung possesses inherent advantages for gene therapy since it is easily accessible via 
the airways , offers a large surface area for transfection and reduces the risk of systemic side 
effects. Pulmonary gene therapy may lead to new treatment strategies for life-threatening 
respiratory diseases such as cystic fibrosis, lung cancer, asthma, pulmonary fibrosis and 
pulmonary hypertension. However, the gene delivery systems have to overcome considerable 
barriers (Figure 5) before cell binding and entry can take place, as described in detail above. 
Various strategies, including the route of administration, have been evaluated to overcome 
these barriers and ensure an efficient gene transfer to the lung cells. In an attempt to bypass 
the pulmonary barriers, several lung targeting vectors, as described in detail below, have been 
administered intravenously. However, this route inevitably precludes some of the advantages 
associated with pulmonary administration, such as the reduced side effects.   
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Figure 5. Routes and barriers of pulmonary gene delivery. Gene delivery system administered 
to the airways have to pass the lung bifurcations, than the mucus layer (produced by the 
goblet cells (G)) and the cilia of the bronchial epithelium or the surfactant of the alveolar 
epithelium before cell uptake can occur. Via the intravenous route the vectors come in contact 
with the blood corpuscles and sever agglomeration or inflammation can be induced. The 
continuous endothelium and the basement membrane have to be overcome by the delivery 
systems before reaching the lung cells. 
Pulmonary gene delivery by viral vectors  
Viral vectors are generally particularly efficient in mediating gene transfer and expression 
in vivo [81]. However, results of clinical trials have demonstrated the inefficiency of 
adenoviral and adeno-associated virus (AAV) vectors mediating gene expression in airway 
epithelial cells [132, 133]. This was explained by the low transduction efficiency of these 
vectors due to the pulmonary defence and the lack of viral receptors at the apical surface of 
the airways [134-136]. Recombinant AAV vectors are unique among viral vectors, since they 
commonly inhabit a human host without causing any pathology. Therefore, intensive efforts 
have been undertaken to identify new types of AAV. Such studies have resulted in the recent 
Inflammation 
Agglomeratio
Antibodies 
Intravenious 
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development of AAV2 vectors, which appeared to be safe and have superior duration profiles 
of the expressed genes [137, 138]. Therefore, AAV2 have been applied in clinical trials phase 
I and II for the inhalation therapy of cystic fibrosis. The trials indicated a lack of any vector-
mediated toxicity, a surprisingly efficient DNA transfer and an increase in pulmonary 
function. However the effect lasted only 30 days and repeated administration did not appear 
to be capable of sustaining the positive effects [139].  
The recombinant Sendai virus (SeV) is currently the most efficient viral vector for airway 
gene transfer in vivo. SeV has been demonstrated to produce efficient transfection throughout 
the respiratory tract of animals, as well as in human nasal epithelial cells in vitro [140-142]. 
Unfortunately, a lack of efficiency after repeated administration was also observed for this 
vector, demonstrating again the limitation of viral vectors as a consequence of the activation 
of the immune system. Therefore, several strategies have been adopted in order to limit 
immune response. In the lung this can be obtained either through pharmacological 
interventions aimed at reducing the host immune responses, or through modifications of the 
viral vector in order to make it less immunogenic [54, 81]. 
The development of lentiviral vectors has been a recent advance in the field of viral gene 
transfer. These integrating vectors appear to be promising vehicles for gene delivery into 
respiratory epithelial cells by virtue of their ability to infect non-dividing cells and mediate 
long-term persistence of transgene expression. Studies in human airway tissues and animal 
models have highlighted the possibility of achieving gene expression by lentiviral vectors, 
which outlasted the normal lifespan of the respiratory epithelium, indicating targeting of a 
'stem cell' compartment [143, 144]. Thus, re-administration would not be necessary, making it 
the most interesting viral vector for pulmonary therapy of inherent diseases to date. 
Pulmonary gene delivery by non-viral vectors - a brief overview  
Generally, non-viral vectors are less efficient gene delivery vehicles than viral vectors. 
However, due to challenges involved in the use of viral vectors in the lung, non-viral vectors 
have been considered as realistic alternatives.  
Cationic liposomes complexed with DNA (lipoplexes) have been extensively studied as 
transfection agent of lung epithelial cells both in vitro and in vivo. As a consequence of their 
low toxicity and immunogenicity they have been utilized in several clinical trials for the 
treatment of cystic fibrosis (CF) [145-150]. Three double-blind studies demonstrated 
efficiency and safety of dipalmitoyl-phosphatidylcholin/cholesterol [145, 147] and dioleoyl-
trimethyl-ammonium-propane [148] liposomes in the nasal epithelium of cystic fibrosis 
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patients. In addition to detecting vector-specific DNA and mRNA, all three studies showed 
partial corrections of CF transmembrane conductance regulator defect in the nose, in one case 
extending out to 15 days post-administration [147]. Importantly, one study evaluated the 
effects of three doses lipoplex doses to the nose at one month intervals, and recorded no 
evidence of lung inflammation or immune response [146]. In addition, the efficiency after the 
third dose was comparable to earlier doses, suggesting that unlike viral vectors, repeated 
delivery of lipoplexes was effective, at least in the nose. Due to their low efficiency in the 
lung of cystic fibrosis patients, new cationic lipids have been designed. Significantly 
improved gene expression was evaluated in the patient’s lung post- inhalation of lipoplexes 
between pDNA and Genenzyme lipid 67® (GL-67®) [151, 152]. However, both studies 
reported side-effects in the form of lung inflammation consisting of fever and increased levels 
of TNF-alpha as well as IL-6 in the bronchial and alveolar lining fluid.  
Nanoparticles, peptides and a variety of cationic polymers such as PEI, poly-L-lysine or 
polyamidoamines, complexed with plasmid DNA have all been explored for pulmonary gene 
therapy. The suitability of nanoparticles synthesised from porcine gelatin, human serum 
albumin and polyalkylcyanoacrylate as drug and gene carriers for pulmonary application was 
investigated on airway epithelium cells in vitro. Such nanoparticles displayed low cytotoxicity 
and no inflammation, in combination with an efficient uptake in human bronchial epithelial 
cells, indicating their suitability as gene carriers for pulmonary application [153]. 
Several advantages in mediating gene transfer to lung epithelial cells were demonstrated 
for protein transduction domains. As such, numerous TAT peptides were applied to lung 
epithelial cells in cell culture, either alone, in combination with lipids or BPEI, or covalently 
linked to liposomes. TAT was able to improve transfection efficiency, although the 
mechanism remains controversial, and energy independent as well as endocytotic pathways 
were discussed. [154-157] 
The group of Davies et al. developed polylysine conjugates for targe ting to the airway 
epithelium. They generated small sized anti-pIg Fab-polylysine polyplexes, resulting in 
successful transgene expression in lung epithelial cells of rats. However, the immunoglobulin 
fragment led to immunological response in the animals lung, thus reducing the transfection 
efficiency [158]. In an alternative approach they developed a polylysine conjugate as targeting 
structure to the serpin-enzym complex receptor by utilizing a new synthetic peptide, derived 
from alpha-1-antitrypsin. These polyplexes led to partial correction of the chloride transport 
defect in nose epithelium of cystic fibrosis mouse model [159, 160]. Recently, they described 
the development of a PEG-substituted polylysine. This new polymer was able to form discrete 
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unimolecular (with respect to pDNA) stable nanoparticles with a small diameter < 20 nm. 
Intrapulmonary application of these particles in mice resulted in transgene expression in the 
airway epithelium and endothelium, whereas unmodified polylysine did not result in 
pulmonary gene expression [161]. 
Beyond the non-viral approaches, PEI holds particular advantages in pulmonary gene 
delivery since it was observed to both, overcome the pulmonary barriers unspoiled and 
encourages high levels of gene expression [12, 162-164]. 
Pulmonary gene delivery by polyethylenimine 
The linear form of PEI (linPEI) has been successfully implemented in systemic gene 
delivery, resulting in very high levels of gene expression in the mouse lung [165]. These 
polyplexes were observed to cross the endothelial barrier, resulting in transgene expression in 
bronchial and alveolar epithelium [166]. When utilizing the intravenous route, linPEI 
mediated far higher levels of transfection activity than the branched form (BPEI). However, 
as discussed at length above, a positive charge ratio for PEI polyplexes is required, and this 
can lead to the formation of aggregates with blood bodies and to interactions with the 
endothelium of the small lung vessels, both of which can result in toxic side effects [167, 
168]. Orson et al. developed a novel intravenous method to deliver small quantities of plasmid 
to lung tissue by using non-toxic quantities of polyethylenimine conjugated to serum albumin. 
The resulting aggregates led to highly efficient gene expression in lung interstitial and 
endothelial tissues when injected intravenously in mice. Using human growth hormone as the 
encoded foreign antigene for immunization, administration of the particle-bound plasmid 
elicited both pulmonary mucosal and systemic immune responses [169-171]. 
The delivery of polyplexes to the airways is a relatively new field, being less than a 
decade old. In this short period of time significant developments in aerosol delivery systems 
and vectors have resulted in major advances toward potential applications for a variety of 
pulmonary diseases [12]. Numerous PEIs have been investigated in vitro in order to prove  
their stability during nebulization and in the airways surface liquid [124, 172, 173]. In 
comparison to lipid vectors and polyamidoamines, PEI was observed to be more stable, 
indicating it may be more suitable in overcoming the lung barriers [172]. In fact, linPEI and 
BPEI have been observed to be more efficient in gene transfer to lung epithelial cells than 
cationic lipids or polyamidoamines [107, 112, 174-176]. Furthermore, distribution studies of 
BPEI polyplexes administered to mice via inhalation or instillation demonstrated effective 
pulmonary delivery of these vehicles, whilst intravenous application caused unspecific 
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distribution in different organs and short half lives [174, 177]. Various genes, formulated with 
BPEI, were expressed at high levels in the lung epithelial cells of mice upon aerosol 
administration [178, 179]. Furthermore, aerosol administration led to significant inhibition of 
tumor growth when plasmid DNA, coded for the apoptosis- inducing protein p53 [104, 180, 
181] or interleukin IL-12 [105, 106], was utilized in experimental lung tumor models. 
However, this delivery system was limited by the lung inflammation observed in mice treated 
with linPEI or BPEI polyplexes. The inflammation, evidenced by neutrophil infiltration and 
cytokine response, was more pronounced when polyplexes were administered via instillation 
compared to inhalation [111, 176, 182]. 
In an attempt to reduce the toxic ity of PEI vectors, PEGPEI copolymers have been 
investigated as possible pulmonary gene transporters. The application of these vectors to the 
mouse lung resulted in improved lung compatibility due to a reduced interaction with the 
airways surface liquid [116, 117]. However, the levels of gene expression remained at the 
level of naked DNA, indicating the need for further developments, such as ligand targeting to 
improve the uptake into lung epithelial cells [99, 183].  
 
Consequently, clinical trials have indicated that transgene expression is limited and 
declines over time for both viral and non-viral vectors. The re-administration of viral vectors 
leads to a less pronounced degree of corrections [54]. Cationic lipids can be re-administrated, 
but suffer from low transfection efficiency. In contrast, PEI-based polymers are considerably 
more stable and efficient for pulmonary gene therapy. However, their use in animal models 
has only recently begun and requires further developmental work, particularly with a view to 
decreasing their cytotoxicity. Rudimental advances in the design of targeting structures for 
receptor mediated gene delivery have been made, and represent another challenge in efficient 
and safe pulmonary gene therapy. 
LIPOSOMAL DRUG DELIVERY SYSTEMS 
Liposomes, first mentioned in 1968 [184], consist of lipid bilayers that form spherical 
particles with diameters in the range of 50-5000 nm. The lipids can either be naturally 
occurring substances, or synthetic modifications of these. Commonly used liposomes are 
prepared using lipids that occur naturally in biomembranes of living cells, such as 
phospholipids, making the liposomes biocompatible and thus ideal drug carriers in 
pharmaceutical technology. The first drug loaded liposomes were developed in 1972, and 
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intravenous application to rats demonstrated their potential in improving the 
pharmacodynamics and biocompatibility of the encapsulated drug [185]. Since then, interest 
in the field of liposomal drug delivery has increased, with the first products  now being on the 
market [186-189]. Besides medical application, liposomes have become widely used in the 
cosmetic industry, where less strict regulations for stability and reproducibility permit a 
greater number of products to reach the market [190].  
The level of liposomal stability and permeability to both hydrophilic and hydrophobic 
ions or molecules is strongly dependent on the chemical structure of the lipids utilized for 
their preparation. The most commonly used lipids in liposomal preparation are phospholipids. 
These have been studied extensively as they are one of the major components of cell 
membranes in animal, plant and bacterial cells. Biological membranes contain a complex 
mixture of a variety of lipids, whereas the liposomes used in pharmaceutical applications are 
normally composed of either a single lipid, or a mixture of two or three different lipids. Figure 
6 displays the typical structures of liposomal formulations. The amphiphilic phospholipid 
molecules are arranged in one or more concentric bilayers separated by aqueous channels, 
surrounding an aqueous core. Hydrophilic drug molecules are dissolved in the aqueous phase, 
whereas lipophilic drug molecules reside inside the bilayers.  
 
Figure 6. Types of liposomes, depending on size and number of bilayers [191]. 
 
There are literally an infinite number of lipids that could be used to prepare liposomes. 
Within these, there exist many different categories, including cationic, neutral, and anionic 
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lipids. The lipid chosen for use in a liposomal formulation is dependant on what will be 
encapsulated, and the therapeutic approach taken. As explained above, cationic lipids are 
commonly used in the field of gene therapy, whereas anionic and neutral lipids are generally 
employed in the preparation of drug- loaded vehicles. Neutral lipids are particularly important 
for intravenous and pulmonary applications as they reduce unspecific interactions with blood 
corpuscles, proteins or proteolipids of the blood and the lung lining fluid respectively. Thus, 
there are a number of phospholipids that may be used to manufacture liposomes. These are 
broadly classified into natural phospholipids (e.g. phosphatidylcholine, phosphatidylserin and 
phosphatidylglycerol from egg yolk or soya beans and sphingomyelin) and synthetic 
phospholipids (e.g. dipalmitoyl-phosphatidylcholin or dipalmitoyl-phosphatidylethanol-
amine). The lipids used in this work are depicted in Figure 7. Cholesterol has often been 
included in liposomal formulations as a number of positive effects have been recorded 
including increased in vitro and in vivo stability and the ability to control the release of 
entrapped hydrophilic materials [192, 193]. Non-ideal mixing or immiscibility of lipids can 
lead to liposomal bilayers those are highly permeable. Therefore, differential scanning 
calorimetry is a very helpful tool to study their thermotropic behaviour, and thus the 
liposomal stability [194].  
 
cholesterol      dipalmitoyl-phosphatidylcholin 
               
 
 [methoxy (polyethylenglycol)-2000]-pipalmitoyl-phosphatidylethanolamin 
 
Figure 7. Lipids utilized in the present work (Chapter 6). 
 
The most common method of liposome production requires the preparation of a thin lipid 
film by vacuum evaporation, prior to the addition of an aqueous medium containing the drug 
compound to the film at an appropriate temperature [195]. Agitation results in the generation 
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of multilamellar vesicles (MLVs), which have more than one bilayer surrounding the aqueous 
core (Figure 6). These liposomes are comparatively large, having diameters ranging between 
0.5 µm and 5 µm. Other types of liposome include small unilamellar vesicles (SUVs), which 
contain only one lipid bilayer and have diameters between 20 nm and 100 nm and may be 
produced by sonicating MLVs. Large Unilamellar vesicles (LUVs) range in size between 0.1 
µm and 1 µm and may be produced by extrusion of MLVs through defined filter pores [195].  
We can distinguish four mechanisms of liposomes-cell interaction by which liposomes 
can deliver their contents to cells (Figure 8). The occurrence of any of these interactions 
depends largely on the liposomes characteristics, such as the lipid composition, the size, the 
charge, and the presence of targeting structures. For example, by altering the lipid 
components, and thus the liposomal membrane stability, the release kinetics of the lipid 
vehicle can be controlled. Other major factors that determine the type of mechanism involved 
in liposome-cell interaction are the cell and environmental factors such as the presence of 
blood, serum or lung lining fluid [195]. 
 
 
Figure 8. Possible mechanisms by which liposomes can interact with cells and deliver their 
contents. 1. Adsorption followed by extracellular release of the liposome contents and 
subsequent transport of these into the cell. 2. Adsorption followed by transfer of the lipophilic 
compounds from the liposomal bilayer to the plasma membrane. 3. Endocytotic 
internalization followed by endolysosomal degradation and intracellular drug release. 4. 
Fusion of the liposomal membrane with the cell or endosomal membrane, thereby releasing 
the contents into the cytoplasm [195] . 
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A primary objective in the recent developments of liposomes as drug carriers has been to 
achieve selective localization of the drug at a specific site of action. With this aim in mind, 
both passive and active targeting structures have been linked to the liposomes (Figure 9). 
Similar to the approach in gene therapy with PEGPEI copolymers, liposomes were also 
modified with PEG as a passive targeting structure. Lipids with a PEG residue linked to the 
lipid headgroup were used to formulate liposomes that displayed an increased circulation time 
in the blood stream. This was achieved as a consequence of the sterically stabilized liposomes 
being able to circumvent the reticuloendothelial system [189, 196, 197]. Cationic lipids, 
which are generally utilized in gene transfer, significantly increase the interactions of the 
liposomes with the cell membrane, thus increasing unspecific cellular uptake (passive 
targeting). In contrast, active targeting can be achieved with antibodies or antibody fragments, 
which can increase the cellular uptake into defined cells. Active targeting structures, such as 
antibodies [198], antibody fragments [199, 200], lectines [201], folate [202] or peptides [203] 
attached to the liposome surface have the potential to become low toxic, highly specific and 
potent drug carriers. 
 
 
Figure 9. Different approaches of liposome modification and passive or active targeting 
[204] . 
PEG  
 
proteins or peptides 
hydrophilic contents 
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Liposomes as pulmonary drug delivery vehicles 
Aerosolized liposomes offer the advantages of controlled drug release for both local and 
systemic therapy with much reduced systemic side effects. When liposomes were first applied 
to the animal lung via instillation, extended drug release combined with high biocompatibility 
was reported [205]. The first aerosolization, using a commercial air-jet nebulizer, was the 
proof-of-principle that liposomes can serve as colloidal drug carriers for sustained release in 
pulmonary therapy [206]. Neither acute nor chronic  effects of inhaled liposomes on 
pulmonary function in animals and healthy human volunteers were detected [207, 208]. 
Furthermore, in contrast to the rapid clearance of soluble drug from the lung, 50–60 % of 
phosphatidylcholine liposomes are retained in the lung for up to 24 hours after inhalation and 
thus can sustain the drug release [209]. As such, research in the field of liposome nebulization 
attained significant growth making it an important, highly biocompatible method of drug 
therapy for the lung [210-213]. 
Different therapeutic approaches led to the development of various liposomal 
formulations, encapsulating drugs such as amikacin [214], beclomethasone [215], 
ciprofloxacin [216], salbutamol [216], triamcinolone [217, 218], fentanyl [219], interleukin-2 
[220, 221], amphotercin B [222] and morphine [223]. The influences of numerous liposomes 
upon the nebulizer characteristics of  a number of air-jet and ultrasonic nebulizers were 
investigated. The influence of different nebulizers upon the liposome stability were also 
studied, since sheer forces (air-jet) and frequency (ultrasonic) can alter aerosolized 
compounds [218, 224, 225]. Depending upon the lipid composition and concentration, the 
liposomal stability varied, and drug release during the aerosolization process was sometimes 
observed [214]. Such liposomal leakage was more pronounced during nebulization with 
ultrasonic apparatus, and for liposomes containing only phosphatidylcholine [214, 226]. 
When cholesterol was used in the liposome preparation, improved bilayer stability was 
observed [201, 225, 226]. Lyophilization of the liposomes led to inc reased drug encapsulation 
efficiency and improved nebulization stability, however the formation of larger aggregates (1-
5 µm) was observed, indicating reduced deposition in respiratory airways [215, 227].  
Hung et al. reported a significant advance in aerosol therapy using liposomes. They 
developed an inhalative liposomal formulation encapsulating fentanyl (AeroLEFTM) [219], 
which was recently approved for Phase IB clinical trial [228]. Saari et al. observed a sustained 
release kinetic for nebulized beclomethasone liposomes in humans [229]. However, not all 
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liposomal formulations accomplished the expectations of controlled drug release for 
inhalation therapy [220, 230].  
Interesting developments in aerosol delivery of liposomes are described in the studies of 
Desai et al. Their approach involves dispersion of the physical mixture of phospholipid(s) and 
drug in saline, which results in spontaneous formation of liposomes and, thus, drug 
encapsulation in the lung lining fluid. Various phospholipids containing antimicrobial agents 
were investigated. Encouraging results were obtained in terms of high levels of lipid/drug 
nebulization in a short period of time and lower levels of drug leakage. This facile approach is 
expected to overcome problems associated with stability upon aerosolization, storage and 
high production costs [216]. 
 
Inhalative liposomes reveal the potential of sustaining and controlling the release of drugs 
for local and systemic therapy. Thus, systemic side effects could be reduced, drug distribution 
could be better controlled and the compliance of the patient is likely to be enhanced due to the 
non- invasive route and the low application frequency. However, before the full promise of 
such formulations can be revealed, many hurdles must be overcome such as the need for 
improved nebulizer techniques and apparatus, and improved liposome formulations that 
reveal more efficient drug loading, better stability during storage and nebulization, and a 
better understanding of the mechanisms of drug release from such formulations.  
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AIMS OF THIS THESIS 
The respiratory tract is a barrier that exists between an organism and its environment that 
can be exploited for the aerosol administration of synthetic or biologically active drug 
substances. The administration of nanoscale carriers containing drugs or nucleic acids to the 
lung is an important, rapidly expanding field in the treatment of various pulmonary diseases. 
The overall aim of this thesis was to develop a number of effective polycationic- and lipid-
based nano-carriers to act as delivery systems in aerosol therapy. Suc h nanoparticles should 
fulfil several requirements, including: (i) efficient encapsulation of the active drug molecule, 
(ii) providing sufficient protection of this drug, both during the aerosolization process and in 
the airways lining fluid, and (iii) to efficiently deposit the active molecule into the conducting 
and respiratory airways. Three different nebulizers will be employed throughout this work 
with a view to identifying device most suitable to achieving our aims, depending upon the 
material to be nebulized.  
The first four chapters in this thesis will concentrate on the investigation of numerous 
polyethylenimine modifications as vehicles for pulmonary gene therapy, with the fifth study 
centred on the use of liposomal formulations in aerosol therapy. 
Whilst it is well known that nebulization can alter the properties of macromolecules and 
PEI is able to transport DNA into the lung cells of mice,  it is not well understood exactly how 
the aerosolization process effects the morphology of PEI polyplexes. In Chapter 2, a number 
of PEI modifications will be employed to investigate how effectively they condense and 
protect DNA. This will be achieved by utilizing atomic force microscopy to study any 
alterations that occur in polyplex morphology post-aerosolization. Alongside this, we will 
investigate  if the physico-chemical properties of the polyplexes (hydrodynamic diameter & 
particle charge) have been altered post-nebulization.  
Low toxicity has been reported for both low molecular weight PEI and the PEGPEI [231, 
232]. As such, chapter 3 focuses on the in vitro and in vivo study of these polymers as 
prospective pulmonary gene vectors.We believe that these PEI modifications might display 
improved biocompatibility when compared to the commonly used BPEI polymer. Prior to 
transfection studies in the mouse lung, the PEI polyplexes will be investigated in terms of 
their size, structure, charge, DNA protection, cytotoxicity and transfection efficiency in a lung 
epithelial cell line. 
The work contained in chapter 4 builds on the studies discussed in chapter 3. Our aim 
here will be to investigate the in vivo toxicity of low molecular weight PEI and PEGPEI in 
 General introduction  
  29 
the mouse lung. This will be achieved by investigating typical indicators of inflammatory 
response in the mouse lung post-administration of the polyplex formulation. In an attempt to 
identify the type of cells targeted by the different PEIs, the distribution of the gene vectors 
and the location of the gene expression will be determined. The development of a 
nebulization system for the application of polyplexes into the mouse lung will also be 
investigated, as previous studies utilized whole body nebulization systems, making the 
application of a definite dose impossible. 
Recent advances have demonstrated that utilizing protein transduction domains, such as 
TAT peptides, as gene vectors may result in highly efficient, non-toxic gene transfer [155, 
157]. Therefore, we will attempt to synthesise a novel polymer containing TAT peptide linked 
to PEGPEI (Chapter 5). As it is assumed that the TAT peptide could lead to an enhanced cell 
uptake thus improving transgene expression in lung epithelial cells. A range of in vitro and in 
vivo studies will be undertaken in an attempt to investigate the pDNA condensation and 
protection, the transfection efficiency, the distribution and the toxicity of this new gene 
vector. 
The work in Chapter 6 of this thesis describes the development of liposomes as sustained 
release formulations for an aerosol therapy of pulmonary hypertension. The aim of this study 
is to uncover liposomal formulations that are stable during nebulization, and are able to 
encapsulate high quantities of a prostacyclin. 
 Chapter 1  
   30 
REFERENCES 
1. R. Dhand. Aerosol therapy during mechanical ventilation: getting ready for prime 
time. Am J Respir Crit Care Med 168: 1148-1149 (2003). 
2. R. U. Agu, M. I. Ugwoke, M. Armand, et al. The lung as a route for systemic delivery 
of therapeutic proteins and peptides. Respir Res 2: 198-209 (2001). 
3. D. A. Groneberg, C. Witt, U. Wagner, et al. Fundamentals of pulmonary drug 
delivery. Respir Med 97: 382-387 (2003). 
4. R. J. Kuhn. Formulation of aerosolized therapeutics. Chest 120: 94S-98S (2001). 
5. E. Kondili and D. Georgopoulos. Aerosol medications. Respir Care Clin N Am 8: 309-
334 (2002). 
6. P. J. Barnes and T. T. Hansel. Prospects for new drugs for chronic obstructive 
pulmonary disease. Lancet 364: 985-996 (2004). 
7. A. T. Iacono, T. E. Corcoran, B. P. Griffith, et al. Aerosol cyclosporin therapy in lung 
transplant recipients with bronchiolitis obliterans. Eur Respir J 23: 384-390 (2004). 
8. S. Conti, L. Polonelli, R. Frazzi, et al. Controlled delivery of biotechnological 
products. Curr Pharm Biotechnol 1: 313-323 (2000). 
9. A. I. Bot, T. E. Tarara, D. J. Smith, et al. Novel lipid-based hollow-porous 
microparticles as a platform for immunoglobulin delivery to the respiratory tract. 
Pharm Res 17: 275-283 (2000). 
10. K. M. Taylor and J. M. Newton. Liposomes for controlled delivery of drugs to the 
lung. Thorax. 47: 257-9 (1992). 
11. J. Fiegel, J. Fu, and J. Hanes. Poly(ether-anhydride) dry powder aerosols for sustained 
drug delivery in the lungs. J Control Release 96: 411-423 (2004). 
12. A. Gautam, J. C. Waldrep, and C. L. Densmore. Aerosol gene therapy. Mol Biotechnol 
23: 51-60 (2003). 
13. D. R. Gill, L. A. Davies, I. A. Pringle, et al. The development of gene therapy for 
diseases of the lung. Cell Mol Life Sci 61: 355-368 (2004). 
14. S. J. Keam and G. M. Keating. Tiotropium bromide. A review of its use as 
maintenance therapy in patients with COPD. Treat Respir Med 3: 247-268 (2004). 
15. B. H. Rowe, M. L. Edmonds, C. H. Spooner, et al. Corticosteroid therapy for acute 
asthma. Respir Med 98: 275-284 (2004). 
16. E. J. O'Connell. Review of the unique properties of budesonide. Clin Ther 25 Suppl: 
42-60 (2003). 
17. D. D. Sin and S. F. Man. Inhaled corticosteroids in the long-term management of 
patients with chronic obstructive pulmonary disease. Drugs Aging 20: 867-880 (2003). 
18. F. Kassner, R. Hodder, and E. D. Bateman. A review of ipratropium bromide/fenoterol 
hydrobromide (Berodual) delivered via Respimat Soft Mist Inhaler in patients with 
asthma and chronic obstructive pulmonary disease. Drugs Aging 64: 1671-1682 
(2004). 
19. H. Olschewski, H. A. Ghofrani, D. Walmrath, et al. Inhaliertes Prostazyclin und 
Iloprost bei schwerer sekundärer pulmonaler Hypertonie durch Lungenfibrose. 
Pneumologie 54: 133 - 142 (2000). 
20. T. J. Kallstrom. Evidence-based asthma management. Respir Care 49: 783-792 
(2004). 
21. M. E. Klepser. Role of nebulized antibiotics for the treatment of respiratory infections. 
Curr Opin Infect Dis 17: 109-112 (2004). 
22. S. M. Cheer, J. Waugh, and S. Noble. Inhaled tobramycin (TOBI): a review of its use 
in the management of Pseudomonas aeruginosa infections in patients with cystic 
fibrosis. Drugs Aging 63: 2501-2520 (2003). 
 General introduction  
  31 
23. P. Diot, P. F. Dequin, B. Rivoire, et al. Aerosols and anti- infectious agents. J Aerosol 
Med 14: 55-64 (2001). 
24. E. De Clercq. Antiviral drugs in current clinical use. J Clin Virol 30: 115-133 (2004). 
25. H. Dimich-Ward, M. L. Wymer, and M. Chan-Yeung. Respiratory health survey of 
respiratory therapists. Chest 126: 1048-1053 (2004). 
26. J. Lewis and R. A. Veldhuizen. Sur factant: current and potential therapeutic 
application in infants and adults. J Aerosol Med 9: 143-154 (1996). 
27. A. M. Cantin, D. E. Woods, D. Cloutier, et al. Leukocyte elastase inhibition therapy in 
cystic fibrosis: role of glycosylation on the distribution of alpha-1-proteinase inhibitor 
in blood versus lung. J Aerosol Med 15: 141-148 (2002). 
28. J. E. Gadek. Consensus on surfactant and inhaled nitric oxide for ARDS. J Aerosol 
Med 9: 155-162 (1996). 
29. C. Vogelmeier and R. Buhl. Therapy of lung diseases with antiproteases. Pneumologie 
48: 57-62 (1994). 
30. T. Quattrin. Inhaled insulin: recent advances in the therapy of Type 1 and 2 diabetes. 
Expert Opin Pharmacother 5: 2597-2604 (2004). 
31. Pfizer/Nektar Therapeutics. Insulin inhalation. Pfizer/Nektar Therapeutics: HMR 
4006. Drugs R D 5: 166-170 (2004). 
32. Y. Qi, G. Zhao, D. Liu, et al. Delivery of therapeutic levels of heparin and low-
molecular-weight heparin through a pulmonary route. Proc Natl Acad Sci U S A 101: 
9867-9872 (2004). 
33. G. J. Burkart, G. C. Smaldone, M. A. Eldon, et al. Lung deposition and 
pharmacokinetics of cyclosporine after aerosolization in lung transplant patients. 
Pharm Res 20: 252-256 (2003). 
34. J. Kropp, M. Wencker, A. Hotze, et al. Inhalation of [123I]alpha1-protease inhibitor: 
toward a new therapeutic concept of alpha1-protease inhibitor deficiency? J Nucl Med 
42: 744-751 (2001). 
35. M. L. Ellett. Alpha 1-antitrypsin deficiency. Gastroenterol Nurs 14: 138-141 (1991). 
36. H. K. Chan, A. R. Clark, J. C. Feeley, et al. Physical stability of salmon calcitonin 
spray-dried powders for inhalation. J Pharm Sci 93: 792-804 (2004). 
37. D. Kohler. Aerosols for systemic treatment. Lung 168: 677-684 (1990). 
38. C. Bosquillon, V. Preat, and R. Vanbever. Pulmonary delivery of growth hormone  
using dry powders and visualization of its local fate in rats. J Control Release 96: 233-
244 (2004). 
39. J. Y. Zheng, M. Y. Fulu, D. Y. Lee, et al. Pulmonary peptide delivery: effect of taste-
masking excipients on leuprolide suspension metered-dose inhalers. Pharm Dev 
Technol 6: 521-530 (2001). 
40. A. Adjei, D. Sundberg, J. Miller, et al. Bioavailability of leuprolide acetate following 
nasal and inhalation delivery to rats and healthy humans. Pharm Res 9: 244-249 
(1992). 
41. E. R. Weibel. Morphology of the human lung, Springer-Verlag, Berlin, 1963. 
42. R. Ferlinz. Pneumologie in Praxis und Klinik, Thieme Verlag, Stuttgart, 1994. 
43. C. Mobley and G. Hochhaus. Methods used to assess pulmonary deposition and 
absorption of drugs. DDT 6: (2001). 
44. D. A. Groneberg, M. Nickolaus, J. Springer, et al. Localization of the peptide 
transporter PEPT2 in the lung: implications for pulmonary oligopeptide uptake. Am J 
Pathol 158: 707-714 (2001). 
45. W. Schoedel, H. Slama, and E. Hansen. Time-dependent behaviour of lung alveolar 
surfactant film. Pflugers Arch 322: 336-346 (1971). 
 Chapter 1  
   32 
46. J. Vadolas, R. Williamson, and P. A. Ioannou. Gene therapy for inherited lung 
disorders: An insight into pulmonary defence. Pulm Pharmacol Therapeutics 15: 61-
72 (2002). 
47. M. Gumbleton. Caveolae as potential macromolecule trafficking compartments within 
alveolar epithelium. Adv Drug Deliv Rev 49: 281-300 (2001). 
48. M. Gumbleton, A. J. Hollins, Y. Omidi, et al. Targeting caveolae for vesicular drug 
transport. J Control Release 87: 139-151 (2003). 
49. D. P. McIntosh, X. Y. Tan, P. Oh, et al. Targeting endothelium and its dynamic 
caveolae for tissue-specific transcytosis in vivo: A pathway to overcome cell barriers 
to drug and gene delivery. Proc Natl Acad Sci USA 99: 1996-2001 (2002). 
50. S. M. Danilov, V. D. Gavrilyuk, F. E. Franke, et al. Lung uptake of antibodies to 
endothelial antigens: key determinants of vascular immunotargeting. Am J Physiol 
Lung Cell Mol Physiol 280: 1335-1347 (2001). 
51. S. Li, Y. Tan, E. Viroonchatapan, et al. Targeted gene delivery to pulmonary 
endothelium by anti-PECAM antibody. Am J Physiol Lung Cell Mol Physiol 278: 504-
511 (2000). 
52. D. Lechardeur, A. S. Verkman, and G. L. Lukacs. Intracellular routing of plasmid 
DNA during non-viral gene transfer. Adv Drug Deliv Rev 57: 755-767 (2005). 
53. T. Thepen, G. Kraal, and P. G. Holt. The role of alveolar macrophages in regulation of 
lung inflammation. Ann N Y Acad Sci 725: 200-206 (1994). 
54. S. Ferrari, U. Griesenbach, D. M. Geddes, et al. Immunological hurdles to lung gene 
therapy. Clin Exp Immunol 132: 1-8 (2003). 
55. R. Dhand. New frontiers in aerosol delivery during mechanical ventilation. Respir 
Care 49: 666-677 (2004). 
56. S. Pedersen. Inhalers and nebulizers: which to choose and why. Respir Med 90: 69-77 
(1996). 
57. P. P. Le Brun, A. H. de Boer, H. G. Heijerman, et al. A review of the technical aspects 
of drug nebulization. Pharm World Sci 22: 75-81 (2000). 
58. S. P. Newman. Dry powder inhalers for optimal drug delivery. Expert Opin Biol Ther 
4: 23-33 (2004). 
59. D. T. Loffert, D. Ikle, and H. S. Nelson. A comparison of commercial jet nebulizers. 
Chest 106: 1788-1792 (1994). 
60. A. H. Kendrick, E. C. Smith, and R. S. Wilson. Selecting and using nebuliser 
equipment. Thorax 52: 92-101 (1997). 
61. PARI GmbH. Product information, www.pari.com (2004). 
62. Nebu-Tec GmbH. Optineb Product information, www.nebu-tec.de (2004). 
63. Aerogen Technologie. Review and performance report for the Aerogen professional 
nebulizer system, www.aerogen.com (2002). 
64. R. Dhand. Nebulizers that use a vibrating mesh or plate with multiple apertures to 
generate aerosol. Respir Care 47: 1406-1416 (2002). 
65. G. Einberg and S. Holmberg. Characteristics of particles and their behaviour in 
ventilation air. Int J Ventilation 2: 45-54 (2003). 
66. T. B. Martonen and I. M. Katz. Deposition patterns of aerosolized drugs within human 
lungs: effects of ventilatory parameters. Pharm Res 10: 871-878 (1993). 
67. J. Fiegel, C. Ehrhardt, U. F. Schaefer, et al. Large porous particle impingement on 
lung epithelial cell monolayers--toward improved particle characterization in the lung. 
Pharm Res 20: 788-796 (2003). 
68. K. Koushik and U. B. Kompella. Preparation of large porous deslorelin-PLGA 
microparticles with reduced residual solvent and cellular uptake using a supercritical 
carbon dioxide process. Pharm Res 21: 524-235 (2004). 
 General introduction  
  33 
69. P. P. Le Brun, A. H. de Boer, D. Gjaltema, et al. Inhalation of tobramycin in cystic 
fibrosis. Part 1: the choice of a nebulizer. Int J Pharm 189: 205-214 (1999). 
70. T. Friedmann and R. Roblin. Gene therapy for human genetic disease? Science 175: 
949-955 (1972). 
71. E. Freese. Prospects of gene therapy. Science 175: 1024-1025 (1972). 
72. R. M. Blaese, K. W. Culver, A. D. Miller, et al. T lymphocyte-directed gene therapy 
for ADA- SCID: initial trial results after 4 years. Science 270: 475-480 (1995). 
73. http://www.wiley.com/legacy/wileychim/genmed/clinical/ (2005). 
74. T. Friedmann. Overcoming the obstacles to gene therapy. Sci Am 276: 96-101 (1997). 
75. D. M. Prazeres, G. A. Monteiro, G. N. Ferreira, et al. Purification of plasmids for gene 
therapy and DNA vaccination. Biotechnol Annu Rev 7: 1-30 (2001). 
76. C. Toniatti, H. Bujard, R. Cortese, et al. Gene therapy progress and prospects: 
transcription regulatory systems. Gene Ther 11: 649-657 (2004). 
77. M. Nishikawa, Y. Takakura, and M. Hashida. Theoretical considerations involving the 
pharmacokinetics of plasmid DNA. Adv Drug Deliv Rev 57: 675-88 (2005). 
78. A. Rolland. Gene medicines: The end of the beginning? Adv Drug Deliv Rev 57: 669-
673 (2005). 
79. D. Luo and W. M. Saltzman. Synthetic DNA delivery systems. Nature Biotechnology 
18: 33-37 (2000). 
80. T. Friedmann. Clinical gene therapy: lessons from the ether dome. Mol Ther 10: 205-
206 (2004). 
81. Z. L. Xu, H. Mizuguchi, F. Sakurai, et al. Approaches to improving the kinetics of 
adenovirus-delivered genes and gene products. Adv Drug Deliv Rev 57: 781-802 
(2005). 
82. T. Friedmann. Stanfield Rogers: insights into virus vectors and failure of an early gene 
therapy model. Mol Ther 4: 285-288 (2001). 
83. C. M. Wiethoff and C. R. Middaugh. Barriers to nonviral gene delivery. J Pharm Sci 
92: 2003-217 (2003). 
84. A. J. Comerota, R. C. Throm, K. A. Miller, et al. Naked plasmid DNA encoding 
fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower 
extremity ischemia: preliminary results of a phase I trial. J Vasc Surg 35: 930-936 
(2002). 
85. R. Morishita, M. Aoki, N. Hashiya, et al. Safety evaluation of clinical gene therapy 
using hepatocyte growth factor to treat peripheral arterial disease. Hypertension 44: 
203-209 (2004). 
86. A. Matsuki, S. Yamamoto, H. Nakagami, et al. No influence of tumor growth by 
intramuscular injection of hepatocyte growth factor plasmid DNA: safety evaluation 
of therapeutic angiogenesis gene therapy in mice. Biochem Biophys Res Commun 315: 
59-65 (2004). 
87. M. G. Svahn, K. E. Lundin, R. Ge, et al. Adding functional entities to plasmids. J 
Gene Med 6 Suppl 1: S36-44 (2004). 
88. W. Li, F. Nicol, and F. C. Szoka, Jr. GALA: a designed synthetic pH-responsive 
amphipathic peptide with applications in drug and gene delivery. Adv Drug Deliv Rev 
56: 967-985 (2004). 
89. Y. Yamashita, M. Shimada, R. Minagawa, et al. Muscle-targeted interleukin-12 gene 
therapy of orthotopic hepatocellular carcinoma in mice using in vivo 
electrosonoporation. Mol Cancer Ther 3: 1177-1182 (2004). 
90. Genetronics Biomedical. Bleomycin - electrical pulse delivery: electroporation 
therapy, MedPulser-bleomycin-Genetronics. Drugs R D 5: 293-296 (2004). 
 Chapter 1  
   34 
91. S. Mehier-Humbert and R. H. Guy. Physical methods for gene transfer: Improving the 
kinetics of gene delivery into cells. Adv Drug Deliv Rev 57: 733-753 (2005). 
92. C. Trimble, C. T. Lin, C. F. Hung, et al. Comparison of the CD8+ T cell responses and 
antitumor effects generated by DNA vaccine administered through gene gun, 
biojector, and syringe. Vaccine 21: 4036-4042 (2003). 
93. M. Koeping-Hoeggard, K. M. Varum, M. Issa, et al. Improved chitosan-mediated 
gene delivery based on easily dissociated chitosan polyplexes of highly defined 
chitosan oligomers. Gene Ther 11: 1441-1452 (2004). 
94. F. Chellat, A. Grandjean-Laquerriere, R. Le Naour, et al. Metalloproteinase and 
cytokine production by THP-1 macrophages following exposure to chitosan-DNA 
nanoparticles. Biomaterials 26: 961-970 (2005). 
95. J. Panyam and V. Labhasetwar. Biodegradable nanoparticles for drug and gene 
delivery to cells and tissue. Adv Drug Deliv Rev 55: 329-247 (2003). 
96. S. Madhusudan, A. Tamir, N. Bates, et al. A multicenter Phase I gene therapy clinical 
trial involving intraperitoneal administration of E1A-lipid complex in patients with 
recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene. Clin Cancer 
Res 10: 2986-2996 (2004). 
97. I. Tranchant, B. Thompson, C. Nicolazzi, et al. Physicochemical optimisation of 
plasmid delivery by cationic lipids. J Gene Med 6 Suppl 1: S24-35 (2004). 
98. N. S. Templeton. Cationic liposome-mediated gene delivery in vivo. Biosci Rep 22: 
283-295 (2002). 
99. E. Wagner. Strategies to improve DNA polyplexes for in vivo gene transfer: will 
"artificial viruses" be the answer? Pharm Res 21: 8-14 (2004). 
100. R. Kircheis, L. Wightman, and E. Wagner. Design and gene delivery activity of 
modified polyethylenimines. Adv Drug Deliv Rev 53: 341-358 (2001). 
101. G. F. Lemkine and B. A. Demeneix. Polyethylenimines for in vivo gene delivery. 
Curr Opin Mol Ther 3: 178-182 (2001). 
102. O. Boussif, F. Lezualcho, M. A. Zanta, et al. A versatile vector for gene and 
oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl 
Acad Sci U S A 92: 7297-7301 (1995). 
103. A. Gautam, C. L. Densmore, S. Melton, et al. Aerosol delivery of PEI-p53 complexes 
inhibits B16-F10 lung metastases through regulation of angiogenesis. Cancer Gene 
Ther 9: 28-36 (2002). 
104. A. Gautam, J. C. Waldrep, C. L. Densmore, et al. Growth inhibition of established 
B16-F10 lung metastases by sequential aerosol delivery of p53 gene and 9-
nitrocamptothecin. Gene Ther 9: 353-357 (2002). 
105. S. F. Jia, L. L. Worth, C. L. Densmore, et al. Aerosol gene therapy with PEI: IL-12 
eradicates osteosarcoma lung metastases. Clin Cancer Res 9: 3462-3468 (2003). 
106. S. F. Jia, L. L. Worth, C. L. Densmore, et al. Eradication of osteosarcoma lung 
metastases following intranasal interleukin-12 gene therapy using a nonviral 
polyethylenimine vector. Can Gene Ther 9: 260-266 (2002). 
107. J. W. Wiseman, C. A. Goddard, D. McLelland, et al. A comparison of linear and 
branched polyethylenimine (PEI) with DCChol/DOPE liposomes for gene delivery to 
epithelial cells in vitro and in vivo. Gene Ther 10: 1654-1662 (2003). 
108. A. C. Hirko, D. D. Buethe, E. M. Meyer, et al. Plasmid delivery in the rat brain. Biosci 
Rep 22: 297-308 (2002). 
109. A. Johansson, G. Nowak, C. Moller, et al. Non-viral delivery of the porphobilinogen 
deaminase cDNA into a mouse model of acute intermittent porphyria. Mol Genet 
Metab 82: 20-26 (2004). 
 General introduction  
  35 
110. Y. K. Oh, J. S. Park, M. J. Kang, et al. Enhanced adjuvanticity of interleukin-2 
plasmid DNA administered in polyethylenimine complexes. Vaccine 21: 2837-2843 
(2003). 
111. A. N. Uduehi, U. Stammberger, B. Kubisa, et al. Effects of linear polyethylenimine 
and polyethylenimine/DNA on lung function after airway instillation to rat lungs. Mol 
Ther 4: 52-57 (2001). 
112. S. Ferrari, A. Pettenazzo, N. Garbati, et al. Polyethylenimine shows properties of 
interest for cystic fibrosis gene therapy. Biochim Biophys Acta 1447: 219-225 (1999). 
113. F. Vernejoul, P. Faure, N. Benali, et al. Antitumor effect of in vivo somatostatin 
receptor subtype 2 gene transfer in primary and metastatic pancreatic cancer models. 
Cancer Res 62: 6124-6131 (2002). 
114. M. Ogris, S. Brunner, S. Schuller, et al. PEGylated DNA/transferrin-PEI complexes: 
reduced interaction with blood components, extended circulation in blood and 
potential for systemic gene delivery. Gene Ther 6: 595-605 (1999). 
115. L. Shi, G. P. Tang, S. J. Gao, et al. Repeated intrathecal administration of plasmid 
DNA complexed with polyethylene glycol-grafted polyethylenimine led to prolonged 
transgene expression in the spinal cord. Gene Ther 10: 1179-1788 (2003). 
116. C. Rudolph, U. Schillinger, C. Plank, et al. Nonviral gene delivery to the lung with 
copolymer-protected and transferrin-modified polyethylenimine. Biochim Biophys 
Acta 1573: 75-83 (2002). 
117. A. Kichler, M. Chillon, C. Leborgne, et al. Intranasal gene delivery with a 
polyethylenimine-PEG conjugate. J Control Release 81: 379-388 (2002). 
118. I. J. Hildebrandt, M. Iyer, E. Wagner, et al. Optical imaging of transferrin targeted 
PEI/DNA complexes in living subjects. Gene Ther 10: 758-764 (2003). 
119. R. Kircheis, T. Blessing, S. Brunner, et al. Tumor targeting with surface-shielded 
ligand-polycation DNA complexes. J Control Release 72: 165-170 (2001). 
120. M. Ogris, G. Walker, T. Blessing, et al. Tumor-targeted gene therapy: strategies for 
the preparation of ligand-polyethylene glycol-polyethylenimine/DNA complexes. J 
Control Release 91: 173-181 (2003). 
121. K. Morimoto, M. Nishikawa, S. Kawakami, et al. Molecular weight-dependent gene 
transfection activity of unmodified and galactosylated polyethyleneimine on hepatoma 
cells and mouse liver. Mol Ther 7: 254-261 (2003). 
122. S. H. Pun, N. C. Bellocq, A. Liu, et al. Cyclodextrin-modified polyethylenimine 
polymers for gene delivery. Bioconjug Chem 15: 831-840 (2004). 
123. D. Fischer, A. v. Harpe, and T. Kissel. Polyethylenimine: Polymer Structure 
Influences the Physicochemical and Biological Effects of Plasmid/PEI Complexes. 
Biomaterials 195-211 (2000). 
124. E. Kleemann, L. A. Dailey, H. G. Abdelhady, et al. Modified polyethylenimines as 
non-viral gene delivery systems for aerosol gene therapy: Investigations of the 
complex structure and stability during air-jet and ultrasonic nebulization. J Control 
Release 100: 437-450 (2004). 
125. M. Ruponen, P. Honkakoski, S. Ronkko, et al. Extracellular and intracellular barriers 
in non-viral gene delivery. J Control Release 93: 213-217 (2003). 
126. J. P. Behr. The proton sponge: A trick to enter cells the viruses did not exploit. Chimia 
51: 34-36 (1997). 
127. W. T. Godbey, K. K. Wu, and A. G. Mikos. Tracking the intracellular path of 
poly(ethylenimine)/DNA complexes for gene delivery. Proc Natl Acad Sci USA 96: 
5177-5181 (1999). 
 Chapter 1  
   36 
128. T. Bieber, W. Meissner, S. Kostin, et al. Intracellular route and transcriptional 
competence of polyethylenimine-DNA complexes. J Control Release 82: 441-54 
(2002). 
129. M. Brisson and L. Huang. Liposomes: conquering the nuclear barrier. Curr Opin Mol 
Ther 1: 140-6 (1999). 
130. J. Suh, D. Wirtz, and J. Hanes. Efficient active transport of gene nanocarriers to the 
cell nucleus. Proc Natl Acad Sci U S A 100: 3878-3882 (2003). 
131. S. Brunner, E. Furtbauer, T. Sauer, et al. Overcoming the nuclear barrier: Cell cylce 
independent nonviral gene transfer with linear polyethylenimine or electroporation. 
Mol Ther 5: 80-86 (2002). 
132. T. R. Flotte and B. L. Laube. Gene therapy in cystic  fibrosis. Chest 120: 124S-131S 
(2001). 
133. T. R. Flotte, P. L. Zeitlin, T. C. Reynolds, et al. Phase I trial of intranasal and 
endobronchial administration of a recombinant adeno-associated virus serotype 2 
(rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study. Hum 
Gene Ther 14: 1079-1088 (2003). 
134. D. K. Meyerholz, B. Grubor, J. M. Gallup, et al. Adenovirus-mediated gene therapy 
enhances parainfluenza virus 3 infection in neonatal lambs. J Clin Microbiol 42: 4780-
4787 (2004). 
135. M. F. Tosi, A. van Heeckeren, T. W. Ferkol, et al. Effect of Pseudomonas- induced 
chronic lung inflammation on specific cytotoxic T-cell responses to adenoviral vectors 
in mice. Gene Ther 11: 1427-1433 (2004). 
136. D. Duan, Y. Yue, Z. Yan, et al. Endosomal processing limits gene transfer to 
polarized airway epithelia by adeno-associated virus. J Clin Invest 105: 1573-1587 
(2000). 
137. C. L. Halbert and A. D. Miller. AAV-mediated gene transfer to mouse lungs. Methods 
Mol Biol 246: 201-212 (2004). 
138. A. C. Fischer, S. E. Beck, C. I. Smith, et al. Successful transgene expression with 
serial doses of aerosolized rAAV2 vectors in rhesus macaques. Mol Ther 8: 918-926 
(2003). 
139. T. R. Flotte. Gene therapy progress and prospects: recombinant adeno-associated virus 
(rAAV) vectors. Gene Ther 11: 805-810 (2004). 
140. Y. Yonemitsu, C. Kitson, S. Ferrari, et al. Efficient gene transfer to airway epithelium 
using recombinant Sendai virus. Nat Biotechnol 18: 970-973 (2000). 
141. S. Ferrari, U. Griesenbach, R. Farley, et al. Recombinant Sendai virus mediates CFTR 
gene transfer to airway epithelium both ex vivo and in vivo. Thorax 58: 19-20 (2003). 
142. S. Ferrari, U. Griesenbach, T. Shiraki-Iida, et al. A defective nontransmissible 
recombinant Sendai virus mediates efficient gene transfer to airway epithelium in 
vivo. Gene Ther 11: 1659-1664 (2004). 
143. L. Bao, V. Jaligam, X. Y. Zhang, et al. Stable transgene expression in tumors and 
metastases after transduction with lentiviral vectors based on human 
immunodeficiency virus type 1. Hum Gene Ther 15: 445-456 (2004). 
144. E. Copreni, M. Penzo, S. Carrabino, et al. Lentivirus-mediated gene transfer to the 
respiratory epithelium: a promising approach to gene therapy of cystic fibrosis. Gene 
Ther 11 Suppl 1: S67-75 (2004). 
145. N. J. Caplen, E. W. F. W. Alton, P. G. Middleton, et al. Liposome-mediated CFTR 
gene-transfer to the nasal epithelium of patients with cystic-fibrosis. Nature Medicine 
1: 39-46 (1995). 
 General introduction  
  37 
146. S. C. Hyde, K. W. Southern, U. Gileadi, et al. Repeat administration of 
DNA/liposomes to the nasal epithelium of patients with cystic fibrosis. Gene Ther 7: 
1156-1165 (2000). 
147. D. R. Gill, K. W. Southern, K. A. Mofford, et al. A placebo-controlled study of 
liposome-mediated gene transfer to the nasal epithelium of patients with cystic 
fibrosis. Gene Ther 4: 199-209 (1997). 
148. D. J. Porteous, J. R. Dorin, G. McLachlan, et al. Evidence for safety and efficacy of 
DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of 
patients with cystic fibrosis. Gene Ther 4: 210-218 (1997). 
149. P. G. Noone, K. W. Hohneker, Z. Q. Zhou, et al. Safety and biological efficacy of a 
lipid-CFTR complex for gene transfer in the nasal epithelium of adult patients with 
cystic fibrosis. Mol Ther 1: 105-114 (2000). 
150. J. Zabner, B. W. Ramsey, D. P. Meeker, et al. Repeat administration of an adenovirus 
vector encoding CFTR to the nasal epithelium of patients with cystic fibrosis. J Invest 
Med 44: A319-A319 (1996). 
151. E. W. F. W. Alton, M. Stern, R. Farley, et al. Cationic lipid-mediated CFTR gene 
transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-
controlled trial. Lancet 353: 947-954 (1999). 
152. F. E. Ruiz, J. P. Clancy, M. A. Perricone, et al. A clinical inflammatory syndrome 
attributable to aerosolized lipid-DNA administration in cystic fibrosis. Hum Gene 
Ther 12: 751-761 (2001). 
153. M. Brzoska, K. Langer, C. Coester, et al. Incorporation of biodegradable nanoparticles 
into human airway epithelium cells- in vitro study of the suitability as a vehicle for 
drug or gene delivery in pulmonary diseases. Biochem Biophys Res Commun 318: 
562-570 (2004). 
154. L. Hyndman, J. L. Lemoine, L. Huang, et al. HIV-1 Tat protein transduction domain 
peptide facilitates gene transfer in combination with cationic liposomes. J Control 
Release 99: 435-444 (2004). 
155. C. Rudolph, C. Plank, J. Lausier, et al. Oligomers of the arginine-rich motif of the 
HIV-1 TAT protein are capable of transferring plasmid DNA into cells. J Biol Chem 
278: 11411-11418 (2003). 
156. J. S. Wadia, R. V. Stan, and S. F. Dowdy. Transducible TAT-HA fusogenic peptide 
enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat 
Medicine 10: 310 - 315 (2004). 
157. V. P. Torchilin, T. S. Levchenko, R. Rammohan, et al. Cell transfection in vitro and in 
vivo with non-toxic TAT peptide- liposome-DNA complexes. Proc Natl Acad Sci U S 
A 100: 1972–1977 (2003). 
158. T. Ferkol, A. Pellicena-Palle, E. Eckman, et al. Immunologic responses to gene 
transfer into mice via the polymeric immunoglobulin receptor. Gene Ther 3: 669-678 
(1996). 
159. A. G. Ziady, T. Ferkol, D. V. Dawson, et al. Chain length of the polylysine in 
receptor-targeted gene transfer complexes affects duration of reporter gene expression 
both in vitro and in vivo. J Biol Chem 274: 4908-4916 (1999). 
160. A. G. Ziady, T. J. Kelley, E. Milliken, et al. Functional evidence of CFTR gene 
transfer in nasal epithelium of cystic fibrosis mice in vivo following luminal 
application of DNA complexes targeted to the serpin-enzyme complex receptor. Mol 
Ther 5: 413-419 (2002). 
161. A. G. Ziady, C. R. Gedeon, T. Miller, et al. Transfection of airway epithelium by 
stable PEGylated poly-L-lysine DNA nanoparticles in vivo. Mol Ther 8: 936-947 
(2003). 
 Chapter 1  
   38 
162. C. L. Densmore. Polyethyleneimine-based gene therapy by inhalation. Expert Opin 
Biol Ther 3: 1083-1092 (2003). 
163. A. Gautam, C. J. Waldrep, and C. L. Densmore. Delivery systems for pulmonary gene 
therapy. Am J Respir Med 1: 35-46 (2002). 
164. C. M. Rudolph, R.H.; Rosenecker, J. Jet nebulization of PEI/DNA polyplexes: 
physical stability and in vitro gene delivery efficiency. J Gene Med 4: 66-74 (2002). 
165. D. Goula, C. Benoist, S. Mantero, et al. Polyethylenimine-based intravenous delivery 
of transgenes to mouse lung. Gene Ther 5: 1291-1295 (1998). 
166. D. Goula, N. Becker, G. F. Lemkine, et al. Rapid crossing of the pulmonary 
endothelial barrier by polyethylenimine/DNA complexes. Gene Ther 7: 499-504 
(2000). 
167. L. Wightman, R. Kircheis, V. Rossler, et al. Different behaviour of branched and 
linear polyethylenimine for gene delivery in vitro and in vivo. J Gene Med 3: 362-372 
(2001). 
168. P. Chollet, M. C. Favrot, A. Hurbin, et al. Side-effects of a systemic injection of linear 
polyethylenimine-DNA complexes. J Gene Med 4: 84-91 (2002). 
169. F. M. Orson, B. M. Kinsey, B. S. Bhogal, et al. Targeted delivery of expression 
plasmids to the lung via macroaggregated polyethylenimine-albumin conjugates. 
Methods Mol Med 75: 575-590 (2003). 
170. F. M. Orson, B. M. Kinsey, P. J. Hua, et al. Genetic immunization with lung-targeting 
macroaggregated polyethyleneimine-albumin conjugates elicits combined systemic 
and mucosal immune responses. J Immunol 164: 6313-6321 (2000). 
171. F. M. Orson, L. Song, A. Gautam, et al. Gene delivery to the lung using 
protein/polyethylenimine/plasmid complexes. Gene Ther 9: 463-471 (2002). 
172. N. Ernst, S. Ulrichskötter, W. A. Schmalix, et al. Interaction of liposomal and 
polycationic transfection complexes with pulmonary surfactant. J Gene Med 1: 331-
340 (1999). 
173. L. A. Dailey, E. Kleemann, T. Merdan, et al. Modified Polyethylenimines as Non 
Viral Gene Delivery Systems for Aerosol Therapy: Effects of Nebulization on Cellular 
Uptake and Transfection Efficiency. J Control Release 100: 425-436 (2004). 
174. A. Bragonzi, G. Dina, A. Villa, et al. Biodistribution and transgene expression with 
nonviral cationic vector/DNA complexes in the lung. Gene Ther 7: 1753-1760 (2000). 
175. S. Ferrari, E. Moro, A. Pettenazzo, et al. ExGen 500 is an efficient vector for gene 
delivery to lung epithelial cells in vitro and in vivo. Gene Ther 4: 1100-1106 (1997). 
176. C. Rudolph, J. Lausier, S. Naundorf, et al. In vivo gene delivery to the lung using 
polyethylenimine and fractured polyamidoamine dendrimers. J Gene Med 2: 269-278 
(2000). 
177. N. V. Koshkina, I. Y. Agoulnik, S. L. Melton, et al. Biodistribution and 
pharmacokinetics of aerosol and intravenously administered DNA-polyethyleneimine 
complexes: optimization of pulmonary delivery and retention. Mol Ther 8: 249-254 
(2003). 
178. C. L. Densmore, F. M. Orson, B. Xu, et al. Aerosol delivery of robust 
polyethylenimine-DNA complexes for gene therapy and genetic immunization. Mol 
Ther 1: 180-188 (2000). 
179. A. Gautam, C. L. Densmore, B. Xu, et al. Enhanced gene expression in mouse lung 
after PEI-DNA aerosol delivery. Mol Ther 2: 63-70 (2000). 
180. A. Gautam, C. L. Densmore, and J. C. Waldrep. Inhibition of experimental lung 
metastasis by aerosol delivery of PEI-p53 complexes. Mol Ther 2: 318-323 (2000). 
 General introduction  
  39 
181. A. Gautam, C. L. Densmore, S. Melton, et al. Aerosol delivery of PEI-p53 complexes 
inhibits B16-F10 lung metastases through regulation of angiogenesis. Cancer Gene 
Ther 9: 28-36 (2002). 
182. A. Gautam, C. L. Densmore, and J. C. Waldrep. Pulmonary cytokine responses 
associated with PEI-DNA aerosol gene therapy. Gene Ther 8: 254-257 (2001). 
183. E. Kleemann, N. Jekel, L. A. Dailey, et al. Enhanced gene expression in mice using 
polyplexes of low-molecular weight poly (ethylene imine) for pulmonary gene 
therapy. J Gene Med submited: (2005). 
184. G. Sessa and G. Weissmann. Phospholipid spherules (liposomes) as a model for 
biological membranes. J Lipid Res 9: 310-318 (1968). 
185. G. Gregoriadis and B. E. Ryman. Lysosomal localization of enzyme-containing 
liposomes injected into rats. Biochem J 128: 142P-143P (1972). 
186. G. J. R. Charrois and T. M. Allen. Drug release rate influences the pharmacokinetics, 
biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin 
formulations in murine breast cancer. Biochim Biophys Acta Biomem 1663: 167-177 
(2004). 
187. C. E. Swenson, L. E. Bolcsak, G. Batist, et al. Pharmacokinetics of doxorubicin 
administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) 
compared with conventional doxorubicin when given in combination with 
cyclophosphamide in patients with metastatic breast cancer. Anticancer Drugs 14: 
239-246 (2003). 
188. K. Mross, B. Niemann, U. Massing, et al. Pharmacokinetics of liposomal doxorubicin 
(TLC-D99 ; Myocet) in patients with solid tumors: an open- label, single-dose study. 
Canc Chemother Pharmacol 54: 514-524 (2004). 
189. S. Faivre, H. Alsabe, L. Djafari, et al. Locoregional effects of pegylated liposomal 
doxorubicin (Caelyx (R)) in irradiated area: a phase I-II study in patients with 
recurrent squamous cell carcinoma of the head and neck. Europ J Cancer 40: 1517-
1521 (2004). 
190. D. D. Lasic. Novel applications of liposomes. Trends Biotechnol 16: 307-321 (1998). 
191. A. Sharma and U. S. Sharma. Liposomes in drug delivery: progress and limitation. Int  
J of Pharm 154: 123-140 (1997). 
192. M. Anderson and A. Omri. The effect of different lipid components on the in vitro 
stability and release kinetics of liposome formulations. Drug Deliv 11: 33-39 (2004). 
193. Y. Barenholz. Liposome application: problems  and prospects. Curr Opin Coll 
Interface Sci 6: 66-77 (2001). 
194. K. M. G. Taylor and R. M. Morris. Thermal-analysis of phase-transition behaviour in 
liposomes. Thermochim Acta 248: 289-301 (1995). 
195. V. P. Torchilin and V. Weissig. Liposomes - A practical approach, Oxford University 
Press, Oxford, 2003. 
196. D. D. Lasic and D. Needham. The Stealth Liposomes: A Prototypical Biomaterial. 
Chem Rev 95: 2601-2627 (1995). 
197. T. Ishida, H. Harashima, and H. Kiwada. Liposome clearance. Biosci Rep 22: 197-224 
(2002). 
198. M. J. Fonseca, J. C. Jagtenberg, H. J. Haisma, et al. Liposome-mediated targeting of 
enzymes to cancer cells for site-specific activation of prodrugs: comparison with the 
corresponding antibody-enzyme conjugate. Pharm Res 20: 423-428 (2003). 
199. T. Hamaguchi, Y. Matsumura, Y. Nakanishi, et al. Antitumor effect of MCC-465, 
pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody 
GAH, in colorectal cancer xenografts. Cancer Science 95: 608-613 (2004). 
 Chapter 1  
   40 
200. R. M. Abra, R. B. Bankert, F. Chen, et al. The next generation of liposome delivery 
systems: recent experience with tumor-targeted, sterically-stabilized 
immunoliposomes and active-loading gradients. J Liposome Res 12: 1-3 (2002). 
201. R. Abu-Dahab, U. F. Schäfer, and C. M. Lehr. Lectin-functionalized liposomes for 
pulmonary drug delivery: effect of nebulization on stability and bioadhesion. Eur J 
Pharm Sci 14: 37-46 (2001). 
202. A. Gabizon, H. Shmeeda, A. T. Horowitz, et al. Tumor cell targeting of liposome-
entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv Drug 
Deliv Rev 56: 1177-1192 (2004). 
203. P. Holig, M. Bach, T. Volkel, et al. Novel RGD lipopeptides for the targeting of 
liposomes to integrin-expressing endothelial and melanoma cells. Protein Eng Des Sel 
17: 433-441 (2004). 
204. http://www.unizh.ch/onkwww/lipos.htm. (2005). 
205. R. L. Juliano and H. N. McCullough. Controlled delivery of an antitumor drug: 
localized action of liposome encapsulated cytosine arabinoside administered via the 
respiratory system. J Pharmacol Exp Ther 214: 381-387 (1980). 
206. S. G. Woolfrey, G. Taylor, I. W. Kellaway, et al. Pulmonary Absorption of Liposome-
Encapsulated 6-Carboxyflurescein. J Control Release 5: 203-209 (1988). 
207. D. A. Thomas, M. A. Myers, B. Wichert, et al. Acute effects of liposome aerosol 
inhalation on pulmonary function in healthy human volunteers. Chest 99: 1268-1270 
(1991). 
208. M. A. Myers, D. A. Thomas, L. Straub, et al. Pulmonary effects of chronic exposure 
to liposome aerosols in mice. Exp Lung Res 19: 1-19 (1993). 
209. A. Pettenazzo, A. Jobe, M. Ikegami, et al. Clearance of phosphatidylcholine and 
cholesterol from liposomes, liposomes loaded with metaproterenol, and rabbit 
surfactant from adult rabbit lungs. Am Rev Respir Dis 139: 752-758 (1989). 
210. R. N. Niven, T. M. Carvajal, and H. Schreier. Nebulization of liposomes III - The 
effects of operating conditions and local environment. Pharm Res 9: 515-520 (1992). 
211. R. N. Niven and H. Schreier. Nebulization of lLiposomes I - Effects of lipid 
compositon. Pharm Res 7: 1127-1133 (1990). 
212. R. W. Niven, M. Speer, and H. Schreier. Nebulization of liposomes II - The effects of 
size and modeling of solute release profiles. Pharm Res 8: 217-221 (1991). 
213. H. Schreier. Liposome Aerosols. J of Lip Res 2: 145-184 (1992). 
214. B. V. Wichert, R. J. Gonzalez-Rothi, L. E. Straub, et al. Amikacin liposomes: 
characterization, aerosolization, and in vitro activity against Mycobacterium avium-
intracellulare in alveolar macrophages. Int J Pharm 78: 227-235 (1992). 
215. Y. Darwis and I. W. Kellaway. Nebulisation of rehydrated freeze-dried 
beclomethasone dipropionate liposomes. Int J Pharm 215: 113-121 (2001). 
216. T. R. Desai, R. E. Hancock, and W. H. Finlay. A facile method of delivery of 
liposomes by nebulization. J Control Release 84: 69-78 (2002). 
217. R. J. Gonzalez-Rothi, S. Suarez, G. Hochhaus, et al. Pulmonary targeting of liposomal 
triamcinolone acetonide phosphate. Pharm Res 13: 1699-1703 (1996). 
218. S. Suarez, R. Gonzalez-Rothi, H. Schreier, et al. Effect of dose and release rate on 
pulmonary targeting of liposomal triamcinolone acetonide phosphate. Pharm Res 15: 
461-465 (1998). 
219. O. R. Hung, S. C. Whynot, J. R. Varvel, et al. Pharmacokinetics of inhaled liposome-
encapsulated fentanyl. Anesthesiology 83: 277-284 (1994). 
220. C. Khanna, J. C. Waldrep, P. M. Anderson, et al. Nebulized interleukin 2 liposomes: 
Aerosol charakteristics and biodistribution. J Pharm Pharmacol 49: 960-971 (1997). 
 General introduction  
  41 
221. R. M. Ten, P. M. Anderson, N. N. Zein, et al. Interleukin-2 liposomes for primary 
immune deficiency using the aerosol route. Int Immunopharm 2: 333-334 (2001). 
222. M. P. Lambros, D. W. A. Bourne, S. A. Abbas, et al. Disposition of Aerosolized 
Liposomal Amphotericin B. J of Pharm Sci 86: 1066-1069 (1997). 
223. T. L. Yaksh, J. C. Provencher, M. L. Rathbun, et al. Safety assessment of encapsulated 
morphine delivered epidurally in a sustained-release multivesicular liposome 
preparation in dogs. Drug Deliv 7: 27-36 (2000). 
224. P. A. Bridges and K. M. G. Taylor. An investigation of some of the factors influencing 
the jet nebulization of liposomes. Int J Pharm 204: 69-79 (2000). 
225. K. K. M. Leung, P. A. Bridges, and K. M. G. Taylor. The stability of liposomes to 
ultrasonic nebulization. Int J Pharm 145: 95-102 (1996). 
226. P. A. Bridges and K. M. G. Tayler. Nebulisers for the generation of liposomal 
aerosols. Int J Pharm 173: 117-125 (1998). 
227. P. A. Bridges and K. M. G. Taylor. The effect of freeze-drying on the stability of 
liposomes to jet nebulization. J Pharm and Pharmacol 53: 393-398 (2001). 
228. O. R. Hung, E. M. Sellers, H. L. Kaplan, et al. Phase IB clinical trial of aerosolized 
liposome encapsulated fentanyl (AeroLEF (TM). Clinical Pharmacol Therapeutics 
75: P4-P4 (2004). 
229. M. Saari, M. T. Vidgren, M. O. Koskinen, et al. Pulmonary distribution and clearance 
of two beclomethasone liposome formulations in healthy volunteers. Int J Pharm 181: 
1-9 (1999). 
230. E. J. Ruijgrok, A. G. Vulto, and E. W. M. van Etten. Aerosol delivery of amphotericin 
B desoxycholate (fungizone) and liposomal amphotericin B (AmBisome): Aerosol 
characteristics and in-vivo amphotericin B deposition in rats. J Pharm and Pharmacol 
52: 619-627 (2000). 
231. D. Fischer, T. Bieber, Y. Li, et al. A novel non-viral vector for DNA delivery based 
on low molecular weight, branched polyethylenimine: effect of molecular weight on 
transfection efficiency and cytotoxicity. Pharm Res 16: 1273-1279 (1999). 
232. H. Petersen, M. F. Fechner, A. L. Martin, et al. Polyethylenimine-graft-poly(ethylene 
glycol) copolymers: Influence of copolymer block structure on DNA complexation 
and biological activities as gene delivery system. Bioconjug Chem 13: 845-854 
(2002). 
 
Chapter 2 
Modified polyethylenimines as non-viral gene delivery systems for 
aerosol gene therapy: Investigations of the complex structure and 
stability during air-jet and ultrasonic nebulization 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Journal of Controlled Release, December 2004 
 Chapter 2  
 43 
ABSTRACT  
Polyelectrolyte complexes between plasmid DNA and polyethylenimine (PEI) are 
promising non-viral delivery systems for pulmonary inhalation gene therapy and thus require 
sufficient stability during nebulization. The structure and stability of four different PEI/DNA 
polyplexes, namely branched (BPEI), linear (linPEI), poly(ethylene glycol)-grafted-PEI 
(PEGPEI), biodegradable PEI (bioPEI) with DNA, were investigated. Using atomic force 
microscopy the morphology of DNA and polyplexes before and after both air-jet and 
ultrasonic nebulization was characterized. The influence of nebulization on the physico-
chemical properties, particle size and zeta potential, was studied. Efficient DNA condensation 
to spherical particles was achieved with BPEI (90 nm) and PEGPEI (110 nm). By contrast, 
incomplete DNA condensations, seen as flower structures were observed with linPEI (110 
nm) and bioPEI (105 nm). Air-jet nebulization altered the polyplex structure to a greater 
extent than ultrasonic nebulization and resulted mainly in smaller and non-spherical particles 
(30-200 nm). Ultrasonic nebulization did not change the spherical structure or particle size of 
the polyplexes. In particular, the shape and size of the PEGPEI polyplexes did not change. We 
conclude that ultrasonic nebulization is a milder aerosolization method for gene delivery 
systems based on PEI. Additionally, PEGPEI/DNA polyplexes seem to be more stable than 
their counterparts, which may be advantageous in pulmonary inhalation gene therapy. 
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INTRODUCTION 
Pulmonary gene therapy holds great promise for the treatment of many incurable lung 
diseases, such as cystic fibrosis, asthma or lung cancer [1, 2]. A number of delivery systems 
to target the peripheral lung tissues have been investigated, for example viral vectors 
including retro- or adeno-viruses, as well as non-viral gene delivery systems which include 
cationic polymers, cationic lipids or liposomes and peptides [3-7]. Polyethylenimine (PEI) has 
been proven to be a promising cationic polymeric delivery system, which complexes DNA by 
electrostatic interactions and can transfect cells under in vitro, as well as in vivo conditions  
[8-10].  
Different application methods for gene therapy to the lung have been investigated, such 
as intravenous, intratracheal or even nasal administration [7, 11, 12]. Aerosol inhalation 
represents a non-invasive route for gene transport into the lung. Nebulization, in particular, 
can target gene carriers to the peripheral regions of the respiratory tract. A problem associated 
with gene delivery by aerosol inhalation of naked DNA, viruses or liposomes is their marked 
loss in transfection efficiency due to the nebulization process [5, 13]. Successful transfection 
of lung tissue after the aerosol application of PEI/DNA using an air-jet nebulizer was reported 
recently in mice, showing that PEI/DNA complexes are resistant to nebulizer- induced 
reduction of transfection efficiency [14, 15]. However, to our knowledge, structural 
investigations of aerosolized PEI/DNA complexes have not yet been reported in the literature. 
Air-jet and ultrasonic nebulizations are the two predominant methods utilized 
therapeutically to aerosolize drug solutions. Air-jet nebulizers operate with compressed air, 
transporting liquid through nozzles creating small aerosol droplets, whereas ultrasonic 
nebulizers use the piezoelectric effect to generate high-frequency acoustic energy which 
generates aerosol droplets by cavitation. Both types of nebulizers offer various advantages 
and disadvantages. Air-jet nebulization can affect gene carrier systems as a result of the high 
shear forces applied during nebulization. Ultrasonic energy is notorious for altering or 
damaging some aerosolized drug substances [16, 17]. Furthermore, ultrasonic nebulizers are 
usually more expensive and have not yet been investigated for the aerosolization of gene 
delivery systems based on cationic polymers. To date only air-jet nebulizers have been used 
in inhalative gene therapy studies [5, 13, 18]. A significant disadvantage of air-jet nebulizers 
is the lower output, which results in a prolonged exposure time of the DNA to shear forces. 
In this study we prepared complexes consisting of plasmid DNA and four different PEI-
derivatives (polyplexes): A branched form, a linear form, a poly(ethylene) glycol-grafted and 
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a biodegradable PEI. The polymer-DNA complexes were nebulized with commercially 
available air-jet and ultrasonic nebulizers and the polyplex stabilities before and after 
nebulization were evaluated. Atomic force microscopy (AFM) was used to characterize the 
morphology of these gene delivery systems. AFM is a comparatively new technique for 
studying events involving DNA, such as condensation or degradation, and has recently been 
used to visualize the morphology of gene delivery systems [19, 20]. The AFM technique 
allows polyplex structures to be investigated under liquid conditions, which are more relevant 
to the physiological milieu, in contrast to electron microscopy studies, which frequently 
require fixation and sample preparation prone to artefacts. Furthermore, we used AFM to 
study the effect of jet and ultrasonic nebulization on the structure of naked DNA and 
compared this to the PEI/DNA complexes. We also investigated physico-chemical properties 
of the four PEI modifications regarding their ability to condense DNA, the complex size, zeta-
potential, and their stability against DNase digestion, parameters which are important for 
efficient gene expression in vitro and in vivo [21-25]. 
Further investigations of the polyplexes were performed, mainly to prove the biological 
activity after nebulization. The transfection efficiency and cellular association in primary 
alveolar cells (AEC), A549 cells, and primary bronchial cells (BEC) was studied [26]. 
METHODS AND MATERIALS 
Materials 
Branched polyethylenimine (BPEI) with a molecular weight (MW) of 25 kDa was 
purchased from Sigma-Aldrich (Seelze, Germany). Plasmid DNA pBR322 (4 MDa, 4363 bp) 
was purchased for the AFM experiments from Sigma-Aldrich (Poole, Dorset, UK). For all 
other studies the plasmid DNA pgl3CMV-Luc (4.4 MDa, 4800 bp) was propagated in E. coli 
and purified using a Maxi Prep kit from Promega (Mannheim, Germany). DNase 1 for the 
DNase digestion study was purchased from Boehringer Mannheim (Mannheim, Germany).  
Synthesis  
Linear polyethylenimine (linPEI) with MW of 22 kDa was synthesized as previously 
reported [8]. The poly(ethylene glycol)-grafted-polyethylenimine (PEGPEI) and the 
biodegradable PEI (bioPEI) were synthesized as previously described [27, 28]. Briefly, PEG-
PEI (45 kDa) was obtained by activating PEG-monomethyl ether (5 kDa) with a 
hexamethylene diisocyanate. The coupling of PEG to the amino groups of BPEI was carried 
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out in anhydrous chloroform at 60 °C, which led to a PEI copolymer containing 10 PEG 2000 
Da molecules per molecule PEI. BioPEI (8 kDa) was synthesized by linking 4 molecules low 
molecular weight PEI (1.2 kDa) blocks to 3 molecules oligo(L- lactic acid-co-succinic acid) (1 
kDa).  
Polyplex formation 
All polyplexes consisting of DNA and PEI were prepared in isotonic glucose solution at 
pH 7. The DNA concentration in the resulting complex solution was 1.5 µg/ml for the AFM 
investigations and 20 µg/ml for all other experiments. An optimal nitrogen-phosphorous ratio 
(N/P) of 10 for BPEI/DNA complexes has been previously described for intrapulmonary in 
vivo transfection [5, 15]. Therefore, the complexes of branched and linear PEI were 
formulated at N/P 10. It was reported, that modifications of  PEI, like PEG-grafted or 
biodegradable PEIs, lead to a decrease in complex charges and significant less cytotoxicity than 
BPEI after applying them at high concentration to mouse fibroblasts [28, 29]. Transfection 
experiments for further studies in mind, an higher N/P ratio of 30 for PEGPEI and bioPEI was 
chosen to improve the cellular uptake and endosomal escape. The appropriate amount of 
polymer was added to the solution of plasmid, mixed by vigorous pipetting, and incubated for 
10 minutes at room temperature.  
DNA condensation 
The efficiency of DNA condensation by the PEIs was examined using a fluorescence 
quenching method [30]. The fluorescence of ethidium bromide, a DNA-intercalating agent, is 
enhanced upon binding to DNA and quenched when displaced by higher affinity compounds. 
Briefly, complex preparation and the subsequent addition of ethidium bromide were carried 
out in isotonic glucose solution at pH 7. Increasing amounts of PEI were added to 0.4 µg 
plasmid to reach final N/P ratios of 0.5, 1, 1.5, 2, 3 and 10 for the BPEI and linPEI complexes 
and 0.5, 1, 1.5, 2, 3, 4, 6 and 30 for the PEGPEI and bioPEI complexes. The resulting 200 µl 
polyplex were incubated for 10 minutes prior to the addition of 300 µl of a 0.3 µg/ml 
ethidium bromide solution. The mixture was analyzed with a Perkin-Elmer LS 50 B 
fluorescence reader using an excitation wavelength of 518 nm (15 nm slit and 515 nm 
emission filter), and emission wavelength of 605 nm (20 nm slit). Relative fluorescence of the 
samples is reported as the sample values in relation to the fluorescence obtained in the 
absence of PEI (= 100 %). Data are presented as a mean of three measurements (± SD) and 
the values were fitted to a Bolzmann sigmoidal function using Microcal Origin® v 7.0. 
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Nebulization  
PEI/DNA polyplexes were aerosolized using the air-jet nebulizer Pari LC® star (Pari, 
Starnberg, Germany) operated with the Pari Boy® compressor and the ultrasonic nebulizer 
Optineb® (Nebutec, Elsenfeld, Germany) operated with a frequency of 2.4 MHz and 12 l/min 
air flow rate. The filling volumes of the nebulizer were 4 ml and the nebulization to residual 
volume was performed in approximately 10-20 minutes. The nebulized samples were 
collected by aerosol deposition on a glass plate and subsequent collection in 1.5 ml Eppendorf 
tubes. All nebulizations for the investigations conducted were repeated twice. 
Atomic force microscopy 
Images of DNA and the PEI/DNA polyplexes were obtained using a Nanoscope IIIa 
Multimode Atomic Force Microscope (Veeco, Santa Barbara, CA, USA), operating in tapping 
mode in a liquid environment. All imaging was carried out at a scan speed of approximately 3 
Hz with a 256 x 256 or 512 x 512 pixel resolutions. Silicon nitride oxide-sharpened 
cantilevers were selected, operating at resonance frequencies of approximately 10 kHz. The 
experiments were repeated twice to ensure reproducibility. A sample volume of 40 µl was 
placed onto a 1 cm2 disk of freshly cleaved mica. Initially, non-nebulized and nebulized 
plasmid samples were imaged in absence of polymer. 10 mM nickel chloride was added to the 
plasmid solution to facilitate immobilization of the plasmid at the mica surface. The freshly 
prepared non-nebulized as well as the polyplexes 10 minutes after ultrasonic and air-jet 
aerosolization were imaged. To determine the mean particle size from these images, the 
diameters at about half-height of at least 30 polyplexes were analyzed.  
Dynamic light scattering 
Particle sizes of non-nebulized and nebulized PEI/DNA polyplexes were measured using 
a Zetasizer 3000 HS (Malvern Instruments, Worcester, UK). The instrument was calibrated 
with Nanospheres Size Standards (polymer microspheres in water, 220 nm +/- 6 nm) from 
Duke Scientific (Palo Alto, CA). The scattered light was detected at a 90° angle through a 400 
µm pinhole. Measurements were performed at 25°C with count rates between 50 and 300 
kCps in 5 runs of 60 sec duration each and analyzed in CONTIN mode. The size 
measurements of each non-nebulized and nebulized PEI/DNA were repeated twice with a 
newly prepared sample.  
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Laser Doppler anemometry  
The zeta-potential measurements of DNA, as well as that of non-nebulized and nebulized 
PEI/DNA complexes, were carried out in the standard capillary electrophoresis cell of a 
Zetasizer 3000 HS (Malvern Instruments, Worcester, UK). The measurements were 
performed at 25 °C with automatic duration. The average values were calculated in three 
independent measurements (five runs each) of the plasmid DNA and all PEI/DNA polyplexes. 
DNase digestion 
Protection of DNA by the four different PEI modifications against DNase was examined 
in a DNase digestion experiment as published previously [31]. Polyplexes were formed as 
described above. The reaction mixture for the DNase digestion study contained 30 µl 
digestion buffer, 0.25 units DNase I and either 0.5 µg DNA or PEI/DNA polyplexes including 
0.5 µg DNA. The reaction was carried out for 30 minutes at 37 °C and was then stopped by 
the addition of 5 µl stop solution. The digestion buffer for this experiment contained 0.1 M 
sodium acetate, 5 mM magnesium sulphate and was titrated to pH 8.0. The DNase stop 
solution contained equal volumes of 0.5 M EDTA, 2 M NaOH and 0.5 M NaCl. To separate 
the DNA from the polymer, 0.2 mg dextran sulphate per 1 µg DNA were added to the 
polyplexes. This experiment was performed three times and one representative gel was 
chosen to present the results. 
Agarose gel electrophoresis 
The electrophoresis gels contained 1 % agarose and 2 µg ethidium bromide. The gel 
electrophoresis was run in TBE buffer at pH 8 for 1.5 hours at a voltage of 80 V. To visualize 
the DNA, the fluorescence of intercalated ethidium bromide was detected using a 
transilluminometer (Biometra, Göttingen, Germany). The experiments were performed at 
least three times. 
Statistics 
Statistical calculations were carried out with SPSS 9.0 for Windows (SPSS GmbH, 
Munich, Germany). The results are reported as mean ± standard deviation (SD) and, in the 
case of AFM size measurements, the size range is also provided. Nonparametric statistical 
tests were performed using the Mann-Whitney-Test. Comparisons for analyzing 
hydrodynamic diameters measured by PCS and zeta-potential were performed using unpaired 
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Student’s t-tests. In the case of multiple testing, the Bonferroni correction was applied [32]. 
Probability values P<0.05 were considered to be significant. 
RESULTS AND DISCUSSION 
DNA condensation 
The nitrogen to phosphorous (N/P) ratio between PEI and DNA has been shown to 
critically affect lung tissue transfection [5, 33]. To quantify DNA condensation at different 
N/P ratios, we utilized the ability of PEI to quench DNA/ethidium bromide fluorescence. If 
DNA is condensed by the cationic polymer, ethidium bromide can no longer intercalate and 
fluorescence intensity decreases measurably. In Figure 1, the relative fluorescence is 
presented as a function of the N/P ratio. The comparison of the curves inflection points (point 
on a curve at which the sign of the concavity changes) give evidence about the interactions 
between polymer and DNA.  
The relative fluorescence of all polyplexes decreased with increasing N/P ratios, due to 
increased DNA condensation. Unmodified BPEI condenses DNA at low N/P ratios efficiently 
(inflection point at N/P = 1.58 ± 0.19) and ratios > N/P 6 exhibit a maximum ethidium 
bromide exclusion with a residual fluorescence of approximately 6 %. The curve obtained 
with linPEI shows that efficient DNA condensation also commences at relatively low N/P 
ratios, the inflection point was observed at N/P = 1.63 ± 0.17. However, the maximum extent 
of DNA condensation is lower than that of BPEI; at N/P ratio > 4 a residual fluorescence of 
12 % was observed. It is worth noting, that the linPEI/DNA at N/P = 0.5 showed a higher 
fluorescence (120 %) than the DNA alone. This is probably due to the configuration of DNA 
in the polyplexes (c. f. AFM results), which might even enhance ethidium bromide 
intercalation at low N/P ratios as compared to the free plasmid alone. It is conceivable that at 
low N/P ratios (< 1.5) in the linPEI/DNA polyplexes the plasmid strands are presented in 
wide loops, which makes an ethidium bromide intercalation easier as compared to supercoiled 
DNA. With an N/P ratio increase the DNA will be more incorporated in the polyplexes, 
however, not completely seen as residual fluorescence of 12 %. In contrast, both PEGPEI and 
bioPEI did not exhibit complete DNA condensation until much higher N/P ratios were 
attained. The inflection point in the quenching curve of the PEGPEI polyplexes was reached 
at the N/P ratio of 3.26 ± 0.22 and that of bioPEI polyplexes at 3.73 ± 0.26. At N/P 30, the 
ratio we used in all PEGPEI/DNA experiments, a complete quenching of ethidium bromide 
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fluorescence could be observed. The lowest extent of DNA condensation among all four PEIs 
was shown by bioPEI with a residual fluorescence of 15 % at N/P 30.  
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Figure 1. DNA condensation of the PEIs by increasing the N/P ratio measured as ethidium 
bromide quenching. Relative fluorescence of 100 % represents the fluorescence of DNA 
alone, while 0 % represents the residual fluorescence of ethidium bromide. 
 
The four different derivatives of PEI exhibited highly variable effects with respect to 
DNA condensation. The fluorescence quenching assay suggests that unmodified PEIs (BPEI 
and linPEI) condense DNA at lower N/P ratios. At higher N/P ratios BPEI and PEGPEI in 
particular, exhibit a high extent of DNA condensation, whereas linPEI and bioPEI were not 
able to fully condense plasmid DNA.  
Atomic force microscopy 
Atomic force microscopy (AFM) in liquid media was used to study the morphology of 
DNA and PEI/DNA polyplexes, as well as to examine the influence of aerosolization on these 
structures. AFM is well suited for studying the morphology and size of polymer-DNA 
complexes in an aqueous environment [20]. However, it should be noted this technique 
examines individual polyplexes and only a fraction of the PEI/DNA complexes can be 
investigated. To document the prevalent polyplex morphology we selected one representative 
image. Furthermore, we measured the particle sizes of 30-50 polyplexes from different 
images (Table 1). 
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Table 1. Particle sizes of the non-nebulized and nebulized PEI/DNA were measured by using 
AFM and DLS. The size obtained from AFM images were measured by using the commercial 
available Digital Instruments section analyzer software. The values are given in nm ± SD 
(n=30). The mean hydrodynamic diameter (HD) and the polydispersity index (PDI) measured 
by using DLS were determined from 3 samples and repeating the measurement 5 times. The 
hydrodynamic diameters are given as z-average in nm ± SD. The significant  differences in 
particle size and in polydispersity between the non-nebulized and nebulized complexes are 
marked with an asterisk (p<0.05). 
method polyplexe BPEI/DNA linPEI/DNA PEGPEI/DNA bioPEI/DNA 
 non-nebulized 
mean 78.2 ± 15.6 64.5 ± 13.7 97.1 ± 19.5 79.3 ± 18.9 
range 58.6 - 128.0 48.8 - 94.5 64.5 - 138.2 48.5 - 133.4 
HD 90.6 ± 13.4 110.9 ± 18.7 109.7 ± 7.3 105.0 ± 11.2 
AFM 
 
DLS 
PDI 0.49 ± 0.11 0.50 ± 0.06 0.60 ± 0.05 0.51 ± 0.15 
 air-jet nebulized 
mean 33.1 ± 29.5* 27.7 ± 19.1* 133.5 ± 80.0* 181.1 ± 89.2* AFM 
range 10.7 – 134.0 9.3 – 93.0 29.3 - 263.7 23.1 - 348.8 
HD 109.2 ± 11.4 166.2 ± 40.0* 209.6 ± 21.6* 147.8 ± 72.5 DLS 
PDI 0.53 ± 0.05* 0.64 ± 0.26* 0.87 ± 0.13* 0.56 ± 0.12 
 ultrasonic nebulized 
mean 209.5 ± 118.2* 121.9 ± 71.9* 87.8 ± 34.1 55.6 ± 20.7* 
range 70.3 - 459.6 60.6 - 251.9 36.7 - 162.7 25.7 - 94.0 
HD 109.0 ± 14.2 145.4 ± 8.6* 123.2 ± 13.6 110.4 ± 14.3 
AFM 
 
DLS 
PDI 0.53 ± 0.09 0.46 ± 0.1 0.61 ± 0.08 0.5 ± 0.08 
 
To evaluate the differences between uncondensed and condensed DNA we first imaged 
uncomplexed DNA (Figure 2). Non-nebulized plasmid DNA (Figure 2A) showed a relaxed, 
open loop structure with little twisting of the strands. The open loop structures and 
supercoiled forms are characteristic morphologies for uncondensed plasmids [19, 34]. After 
air-jet nebulization (Figure 2B), the plasmid is still relaxed, but many of the circular strands 
are fragmented. This DNA fragmentation may be explained by strong shear forces generated 
during this process. DNA fragmentation resulting from air-jet nebulization has also been 
reported before using gel electrophoresis [18]. Ultrasonic nebulization (Figure 2C) led not 
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only to the formation of DNA fragments, but also to the appearance of aggregated structures 
(blue arrows).  
 
Figure 2. AFM images of DNA alone (scan sizes 1 µm x 1 µm, z-ranges 5 nm): A = non-
nebulized, B = after air-jet nebulization, C = after ultrasonic nebulization. The DNA was 
solved in water and imaged on mica surface before and after the aerosolization processes. 
The addition of 10 mM nickel chloride solution to both the non-nebulized and air-jet 
nebulized DNA was necessary to encourage attraction at the mica surface. The blue arrows 
distinguish plasmid aggregates. 
 
Representative AFM images of non-nebulized PEI/DNA polyplexes are shown in the 
Images A, D, G and J of Figure 3. The complexes of BPEI and DNA (Figure 3A) are highly 
condensed, forming spherical particles with sizes of approximately 80 nm. Condensates of 
linPEI/DNA displayed open loops of DNA outside the polyplex core (Figure 3D). This 
morphology is also known as a “flower structure” and indicates incomplete DNA 
condensation. The linPEI/DNA polyplex cores had a mean size of approximately 65 nm. 
PEGPEI/DNA polyplexes (Figure 3G) are fully condensed particles with a size of 
approximately 100 nm. Most of the bioPEI/DNA polyplexes (Figure 3J) are not fully 
condensed and plasmid loops outside the actual particle were observed. The morphology of 
the bioPEI/DNA polyplexes varied, and in addition to spherical particles often flower 
structures or rod like structures were noted. The AFM images suggest differing interactions 
between plasmid DNA and the PEI modifications leading to polyplex structures as outlined in 
Scheme 1.  
 
 
A     B      C 
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Figure 3. AFM images of PEI/DNA polyplexes (scan sizes 1 µm x 1 µm; z-ranges 10 - 50 nm). 
The polyplexes were formulated in isotonic glucose solution and imaged after the incubation 
time of ten minutes. Images were also taken immediately after the nebulization processes. The 
blue arrow distinguishes single particles in the polyplex agglomerate. 
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Scheme 1. Schematic representation of the four polyethylenimine modifications and their 
condensation with plasmid DNA. 
 
 
 
AFM images showed that only BPEI and PEGPEI form highly condensed spherical 
particles with plasmid DNA, which was confirmed by the high extent of DNA condensation 
seen for BPEI and PEGPEI in the ethidium bromide exclusion assay. Due to the branched 
structure of both PEGPEI and BPEI these molecules have a higher density of protonable 
amino groups than the linear PEI form or the bioPEI (see synthesis). A higher density of 
amino groups enables better interaction with phosphate groups of the DNA and thus might 
explain the better DNA condensation of BPEI and PEGPEI compare to linPEI and bioPEI. 
Incomplete DNA condensation with non-nebulized linear PEI was also observed by Dunlap et 
al. using AFM [20]. Complexes of DNA and linear PEI seem to be excellent non-viral 
transfection reagents under in vitro conditions, as well as in vivo gene transfer experiments, 
even surpassing the efficiency of BPEI [8, 11, 35, 36]  This discrepancy might be evidence 
supporting the argument that efficient transfection does not require spherical particles. 
Furthermore, it seems to be important that the degree of condensation is not too strong to 
hinder the release of DNA from the complex inside the cell nucleus.  
 Chapter 2  
 55 
Figures 3B and C show AFM images of nebulized BPEI/DNA polyplexes. After air-jet 
nebulization (Figure 3B) smaller particles with sizes of approximately 33 nm (Table 1) and 
occasionally aggregates (not shown in the image) were observed, whereas after ultrasonic 
nebulization (Figure 3C) spherical particles and aggregates ranging from 70 nm to 460 nm 
were found. Within these aggregates single polyplexes can be distinguished (blue arrows in 
Figure 3C) therefore we assume these are agglomerates. Images of air-jet nebulized 
linPEI/DNA (Figure 3E) showed disrupted polyplexes as well as some spherical particles 
(small image). In contrast, the ultrasonic nebulization of linPEI/DNA (Figure 3F) led mainly 
to the formation of polyplexes and aggregates in a size range of 60-250 nm. After air-jet 
nebulization of PEGPEI/DNA (Figure 3H) we observed spherical, as well as rod- like particles 
and occasionally aggregates, with sizes ranging from 30 nm to 264 nm. A representative 
image of the ultrasonic nebulized PEGPEI/DNA polyplexes (Figure 3I) shows mainly 
spherical particles which have a size of 90 nm, similar to the non-nebulized PEGPEI/DNA 
polyplexes. Air-jet nebulization of bioPEI/DNA (Figure 3K) increased the amount of smaller 
particles. Ultrasonic nebulization of bioPEI/DNA (Figure 3L) seemed to have promoted a 
complete condensation of DNA resulting in condensed spherical particles with sizes ranging 
from 26 to 94 nm. In both images (Figure 3 K, L) free polymer can be seen probably due to 
the high N/P ratio of 30.  
Due to high N/P ratios, polyplex suspensions can contained free polymer, in addition to 
polymer which is bound to the plasmid via electrostatic interactions. During the nebulization 
smaller polyplexes can be obtained either through rearrangement of the polyplexes/polymer 
or through fragmentation. Supercoiled plasmid has a size of 10 nm [37] and PEI alone 
approximately 5 nm. The smallest polyplexes we obtained after air-jet nebulization were 10 to 30 
nm. Therefore we conclude both could be possible some polyplexes were disrupted and some 
could be still intact. Transfection of lung epithelial cells was successfully achieved after 
polyplex nebulization, suggesting that they retained their biological activity [26].  
In all cases, the AFM investigations indicated that ultrasonic nebulization influenced the 
polyplex structure to a lesser extent than air-jet nebulization, because the images of 
polyplexes exposed to ultrasonic nebulization displayed primarily spherical particles and 
aggregates. In case of linPEI and bioPEI we assume that cavitation induced interactions 
between the uncondensed amino groups and the DNA, thus leading to the formation of 
condensed, spherical particles and aggregates.   
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Gel electrophoresis 
Agarose gel electrophoresis was used to determine whether the strands or disrupted 
particles observed in the AFM images of nebulized polyplexes consisted of uncomplexed 
DNA. We expected only a small amount of DNA fragments and, therefore, we used 10 times 
concentrated solutions. The gel in Figure 4 shows the polyplexes: non-nebulized in lane 4-7, 
air-jet nebulized lane 8-11 and ultrasonic nebulized lane 12-15. A part of the plasmid in lane 
4-6 was retained at the application point due to incomplete separation from the polymer by 
dextran sulphate. The gel demonstrated that in all cases of nebulized polyplexes, DNA 
fragments were generated to a higher (air-jet) or lower (ultrasonic) extent. Due to solvent 
evaporation during nebulization, concentration changes could not be determined in a 
quantitative manner. Nevertheless DNA fragmentation was observed using both nebulization 
techniques. Thus gel electrophoresis of the polyplexes confirms the finding of DNA 
fragmentation seen in some AFM images, especially those of air-jet nebulization. In case of 
naked DNA aerosolization, it could be shown here and in the AFM images, that the formation 
of DNA fragments during air-jet nebulization is more pronounced than during ultrasonic 
nebulization. Both gel electrophoresis and AFM confirm unexpectedly that ultrasonic energy 
does not alter or damage plasmid DNA and polyplexes severely in contrast to other ultrasonic 
aerosolized drug substances [16, 17]. 
 
 
Figure 4. Agarose gel of non-nebulized and nebulized DNA and PEI/DNA: lane 1-3 showing 
DNA: non-nebulized (1), air-jet nebulized (2), ultrasonic nebulized (3); lane 4-7 showing non-
nebulized polyplexes: BPEI (4), linPEI (5), PEGPEI (6), bioPEI (7); lane 8-11 showing air-
jet nebulized polyplexes: BPEI (8), linPEI (9), PEGPEI (10), bioPEI (11); lane 12-15 
showing ultrasonic nebulized polyplexes: BPEI (12), linPEI (13), PEGPEI (14), bioPEI (15). 
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Dynamic light scattering 
In addition to the polyplex sizes determined from AFM images, the mean hydrodynamic 
diameters (HD) and the polydispersity index (PDI) of the non-nebulized and nebulized 
polyplexes was measured using DLS (Table 1 at page 51) to validate these results with an 
independent method. In the case of non-nebulized polyplexes, we observed that the smallest 
particles were formed between BPEI and DNA with mean hydrodynamic diameters of 
approximately 91 nm. The linPEI/DNA exhibited a particle size of 111 nm. Polyplexes 
consisting of DNA and PEGPEI (110 nm), or bioPEI (105 nm), yielded similar hydrodynamic 
diameters. As demonstrated by DLS and AFM, BPEI was able to form the smallest particles 
with DNA probably because of the branched molecule structure. PEGPEI formed the largest 
complexes with DNA probably because of the high molecular weight of the PEGPEI 
molecule.  
After both air-jet, as well as ultrasonic nebulization, the hydrodynamic diameters of all 
investigated polyplexes increased. The differences of non-nebulized to air-jet nebulized 
polyplexes were higher than these of non-nebulized to ultrasonic nebulized polyplexes. The 
fact that particle sizes for the same complex measured by DLS were larger than those 
measured by AFM was particularly pronounced for the linPEI and the bioPEI polyplexes. 
This observation can be explained by the incomplete complexation process for linPEI and 
bioPEI, which let to a lower diffusivity and thus to a considerable increase in hydrodynamic 
diameter, as measured by DLS.  
To understand the differences in particle size measurements obtained by AFM and DLS 
the following considerations should be taken into account. The method of DLS is a reliable 
size analysis technique for spherical particles, which measures the diffusivity of the particles 
by means of the scattered light and calculates their corresponding diameter. The major 
advantage of this method as compared to AFM is that a large number of particles are 
measured and thus subjective  selection criteria cannot influence the results. Therefore, many 
studies have used DLS to investigate the particle size alteration to prove the polyplex stability 
[18, 38]. A considerable disadvantage of DLS is the fact that non-spherical particles show a 
lower diffusivity compare to spherical particles of the same volume equivalent diameter. This 
leads to a nominally larger diameter for non-spherical particles compared to spherical 
particles of the same volume equivalent diameter. Therefore, we think it is necessary to use 
both AFM and DLS to compensate the disadvantages of both methods and thus achieve more 
detailed information about the polyplex structure. In present study, both methods could 
demonstrate that air-jet nebulization alters the size of the PEI/DNA complexes to a greater 
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extent than ultrasonic nebulization. The images of air-jet nebulized polyplexes demonstrated 
that not only larger particles were formed, as the DLS measurements have shown, but that 
also many fragments were formed. Using CONTIN analyses for DLS data fitting we were not 
able to detect bimodal particle size distributions. However, in all cases the particle size 
polydispersity index increased after air-jet nebulization and it did not increase during 
ultrasonic nebulization. Thus the polydispersity increase after the air-jet nebulization 
supported the AFM results, which showed that particles with different particle sizes were 
formed.  
The size of the polyplexes has been reported to be an important factor in facilitating gene 
transfer in cells [22, 24, 38]. Beside this the lung describes a more complex system to deliver 
polyplexes to and into the cells. Substances which are transported into the respiratory tract 
undergo two major clearance processes, the mucociliary and the alveolar macrophage clearance. 
Particles larger than 5 µm will be deposit mainly in the upper airways and bronchioles, hence 
such particles can be removed by the beating cilia. Particles which have been deposit in the 
alveolar space can be cleared by alveolar macrophages. A particle diameter less than 0.26 µm 
prevents from macrophageal phagocytosis [39]. Furthermore, endocytotic processes occur to 
formations smaller than 0.2 µm [37] and it is known that polyplexes based on PEI will be uptake 
by endocytosis and be released into the cytoplasm by lysosomal rupture according to the proton 
sponge theory [21]. These considerations make clear, that PEI/DNA particles should have a size 
smaller than 0.2 µm to ensure the uptake by pulmonary epithelial cells and according to the sizes 
measured by AFM and PCS the majority of the investigated polyplexes are smaller. However, 
some aggregates were formed (air-jet nebulized PEGPEI/DNA and bioPEI/DNA; ultrasonic 
nebulized BPEI/DNA and linPEI/DNA) which can not be uptake by endocytosis and could be 
cleared due to macrophages activity.  
Laser Doppler anemometry 
Interactions between PEI/DNA polyplexes and cell surfaces are dependent upon the 
particle surface charge [21]. To estimate the surface charge of the PEI/DNA polyplexes, we 
measured their respective zeta-potentials. The results of the zeta-potential analysis for DNA 
alone and the PEI/DNA polyplexes are depicted in Figure 5. The zeta-potential of the plasmid 
changed from approximately -33 mV for the non-nebulized to -20 mV after both air-jet and 
ultrasonic nebulization. This observation implies that strong structural alterations occurred 
and thus confirm the AFM and gel electrophoresis results. 
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For all four non-nebulized PEI/DNA polyplexes a highly positive charge was observed. A 
slightly lower zeta-potential of 25 mV was seen with PEGPEI/DNA compared to 30 mV for 
the other three PEI/DNA polyplexes. In the case of polyplex aerosolization, no statistically 
significant alterations in zeta-potentials were found, although PEGPEI/DNA did show an 
increase in zeta-potential from 25 mV (non-nebulized) to 33 mV for the air-jet nebulized and 
to 28 mV for the ultrasonic nebulized polyplexes. The increase was, however, not significant 
and the reason for this slight zeta-potential increase might be due to structural changes of the 
nebulized complexes which decreased the shielding effect of the PEG groups. For all other 
complexes the change in zeta-potential was minimal. This implies that the transfection 
efficiency of the aerosolized complexes might be comparable to that of non-nebulized 
complexes.  
 
 
Figure 5. Zeta-potential measurements of non-nebulized and nebulized PEI/DNA polyplexes 
and naked DNA. For each PEI/DNA polyplex, three samples and five measurements for each 
sample were taken. The differences between the non-nebulized and nebulized polyplexes were 
not significant. Between non-nebulized and nebulized DNA the differences were significant at 
p<0.05. 
DNase digestion 
The ability of the gene carrier to protect DNA against enzymatic degradation by DNase I, 
which is located in the cytoplasm, can be demonstrated by DNase digestion studies [12, 30]. 
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Agarose gel electrophoresis was carried out after the digestion experiment (Figure 6). 
Untreated plasmid DNA (lane 1) can be differentiated in the supercoiled, open circular and 
linear form. During digestion, the DNase first unwinds the supercoiled DNA form and then 
cuts it into small DNA fragments of different lengths. The linear plasmid form was not 
present in the untreated DNA samples, but was formed due to the DNase digestion (lane 2). 
As low as 0.05 units DNase per one µg DNA caused DNA degradation to occur, as shown by 
the smear beneath the last band. Digestion with 0.5 units DNase (lane 3) led to a complete 
fragmentation and very short fragments were seen as a smear at the running front. Lanes 4 to 
7 display the DNA of non-digested polyplexes. Insufficient separation of BPEI and DNA 
(lane 4) was observed probably because dextran sulphate did not separate these strongly 
condensed complexes completely. The DNase digestion is shown in lane 8 to 11. In all cases 
of the PEI/DNA polyplexes no smear in the top lane was observed, which means DNA was 
not degraded by the DNase. In lane 10 (PEGPEI/DNA) the supercoiled DNA form decreased 
and the open circular as well as the linear form increased. Thus, the enzyme seemed to have 
an effect on these polyplexes, however DNA was not degraded. The linPEI and bioPEI have 
shown incomplete complexation and less protection against DNase would be conceivable. 
However, no fragmented DNA was found after the digestion. It is probably, that the DNase 
enzymes are sterically hindered by the polyplex core. It can be concluded, that all four 
investigated PEIs were able to protect the DNA against DNase digestion.  
 
Figure 6. DNase digestion: agarose gel showing DNA non-digested (1), digested for 15 
minutes with 0.05 Units (2) and 0.5 Units (3) DNase per 1 µg DNA; the four different 
complexes (in the order BPEI, linPEI, PEGPEI, bioPEI) non-digested (4-7), digested with 0.5 
Units DNase per 1 µg DNA for 30 minutes (8-11). 
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CONCLUSIONS 
PEGPEI was the only polymer of the four investigated PEIs, which was able to form 
spherical complexes that are stable during nebulization, particularly after ultrasonic 
nebulization. Furthermore, previous studies of Petersen et al. [27] have demonstrated superior 
transfection efficiency in vitro for PEGPEI modifications compare to BPEI. Due to these 
observations and the superior stability seen in this study, PEGPEI showed the most promising 
properties for pulmonary gene delivery. Methods like DLS and gel electrophoresis are often 
used to demonstrate the stability of gene carrier systems during nebulization. These methods 
are, of course, necessary; however, they cannot provide complete information about the 
polyplex structure. In the present study, AFM was used for the first time to investigate the 
morphology of PEI polyplexes before and after nebulization. The size of non-spherical 
particles, which may be generated during aerosolization, cannot be measured reliably by DLS 
alone. We could show that it is necessary to use independent imaging methods to obtain more 
information about polyplexes alterations generated during aerosolization. Polyplex 
morphology, particles size measurement and the polyplex stability studies have demonstrated 
a higher stability, in the meaning of fewer alterations, of all polyplexes during ultrasonic 
nebulization, as compared to air-jet nebulization. Therefore, we conclude that ultrasonic 
nebulization is a milder method to aerosolize gene delivery systems based on PEI. Studies of 
polyplex nebulization for gene therapy in the lung, which can be found in the current 
literature, were all undertaken using air-jet nebulizers [14, 15]. We believe that ultrasonic 
nebulization should not be neglected for polyplex aerosolization. Ultrasonic nebulization of 
PEGPEI/DNA polyplexes merits further investigations as delivery sys tem for pulmonary gene 
therapy [26]. 
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ABSTRACT 
Non-viral gene delivery using polyethyleneimine (PEI) as a carrier have previously been 
demonstrated to successfully mediate gene transfer to the mouse lung. The aim of this study 
was to elicit improved gene expression and decreased cytotoxicity for pulmonary gene 
therapy by replacing the commonly used carrier 25 kDa branched PEI (BPEI) by two PEI 
derivatives, low molecular weight PEI (LMWPEI) and poly(ethylene glycol)-graft-PEI 
(PEGPEI). Polyplexes, generated with different N/P ratios, were characterized by studying 
their structure, size and zeta-potential using atomic force microscopy, dynamic light 
scattering and laser Doppler anemometry respectively. Polymer and polyplex cytotoxicity was 
investigated using LDH and MTT assays. Polyplex transfection efficiencies studied in vitro 
on A549 and in vivo in the mouse lung were quantified via measurement of luciferase 
expression. Finally, by employing a modified fluorescence quenching assay, the polyplex 
stability was studied in an in vitro assay mimicking the alveolar lining layer. All polymers 
were shown to condense DNA to spherical particles of approximately 100 nm in size with 
positive zeta-potentials (+32 mV for BPEI, +17 mV for LMWPEI & PEGPEI polyplexes). 
LMWPEI demonstrated the lowest membrane damage and cell viability reduction, while 
BPEI was observed to be the most cytotoxic. Luciferase expression in vitro was 
approximately three times higher for PEGPEI/DNA when compared to BPEI/DNA. Although 
LMWPEI/DNA was shown to be less efficient in vitro, it caused the highest luciferase 
expression in the mouse lung after intratracheal instillation. The maximum efficiency was 
observed at N/P 8 for LMWPEI/DNA. Whilst PEGPEI polyplexes demonstrated the  highest 
stability in the alveolar lining layer, a significant ly higher transfection compared to naked 
DNA was not observed in the mouse lung.  In conclusion, LMWPEI combines low 
cytotoxicity with high transfection efficiency in lung under in vivo conditions, rendering it a 
promising strategy for pulmonary gene delivery. 
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INTRODUCTION 
Gene therapy is a relatively new approach for the treatment of lung disorders by 
replacement of defective genes or the introduction of new protein-based functions into 
pulmonary cells. Recently, gene therapy has been successfully implemented in the treatment 
of severe disorders, such as cystic fibrosis and tumors [1, 2]. However, several clinical trials 
using adenoviruses or adeno-associated viruses as gene carriers for the treatment of cystic 
fibrosis demonstrated a number of limitations for their clinical use. These include the lack of 
vector persistence in proliferating cells and immune responses, which inevitably precludes 
repeated administration. Clinical trials using cationic lipids as non-viral gene carriers have 
demonstrated that gene transfer to the upper airway epithelium is safe, but also transient and 
inefficient [3-5]. Thus, it is clear that more efficient and safe gene delivery systems are 
necessary to exploit gene therapy for the treatment of pulmonary diseases. 
A variety of non-viral gene carriers, including polycationic polymers, cationic lipids, 
nanoparticles, peptides, proteolipidic and bacterial vectors have been developed for 
administration of DNA to the airway epithelium [6-10]. Of these, the polycation 
polyethyleneimine (PEI) has shown potential for lung gene therapy. After the first reported 
use of PEI as a pulmonary gene delivery system, numerous improvements were achieved 
regarding the efficiency of this non-viral carrier [11]. Polymer-DNA-complexes (polyplexes) 
formed of plasmid DNA and linear PEI (22 kDa) have shown high transfection levels in the 
lung epithelium via the intravenous, as well as intratracheal route [12, 13]. However, systemic 
side effects, such as blood cell aggregation (intravenous route) and deterioration of the lung 
function (intratracheal route), highlighted the limits of  linear PEI in lung gene therapy [14, 
15]. Polyplexes of branched PEI (25 kDa) (BPEI) with DNA resulted in significantly higher 
levels of pulmonary transgene expression compared to linear PEI after inhalation [16]. 
Additionally,  minimal inflammatory effects and no immune response were recorded [17]. 
Furthermore, aerosol delivery of polyplexes containing BPEI and p53 DNA resulted in a 
significant reduction in the tumor burden and inhibition of lung metastasis in mouse models 
[18, 19]. Also, IL-12 transferred to the mouse lung using BPEI resulted in a therapeutic 
response of pulmonary osteosarcoma metastases [20].  
Recently, we synthesized a branched low molecular weight PEI (LMWPEI), with a 
molecular weight of 5 kDa [21]. In several cell types, polyplexes of LMWPEI displayed a 
significantly lower toxicity combined with a high transfection efficiency when compared to 
high molecular weight PEI [22]. Furthermore, the stability and transfection efficiency post-
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nebulization of polyplexes using the commercially available BPEI and a poly(ethylene glycol) 
-graft-PEI copolymer (PEGPEI) was shown to be dependant on polymer structure and 
composition [23, 24]. 
Consequently, the aim of this study was to compare different PEI derivatives, LMWPEI 
and PEGPEI, with the commercially available BPEI and assess their suitability for pulmonary 
gene therapy. This was achieved by studying various physico-chemical properties of the 
polyplexes, including their structure and dimensions by atomic force microscopy (AFM) and 
dynamic light scattering (DLS), as well as their charge by measuring the zeta-potential. The 
transfection efficiency and the cytotoxicity of the different polyplexes were studied in 
alveolar epithelial cells in vitro (A549). The stability in the alveolar compartment was 
addressed by in vitro studies in alveolar lining fluid (lavage) and natural lung surfactant 
(AlveofactÒ) in a fluorescence quenching assay. Finally, the transfection efficiencies in the 
mouse lung were investigated under in vivo conditions. 
METHODS AND MATERIALS 
Materials 
Branched polyethyleneimine (BPEI) with a molecular weight of 25 kDa was purchased 
from Sigma-Aldrich (Seelze, Germany). The plasmid DNA pGL3 carrying luciferase coding 
region under the promoter control of cytomegalovirus (CMV) was kindly provided by J. 
Hänze (Department of Molecular Biology, University of Giessen, Germany), was propagated 
in E.coli and purified by PlasmidFactory (Bielefeld, Germany). Standard quality control 
performed by the manufacturer resulted in the following data: supercoiled content 92 %, 
bacterial DNA and RNA not detectable by AGE, identity confirmed by restriction fragment 
length. Alveofact® was purchased from Boehringer-Ingelheim (Germany). Bronchial alveolar 
lining fluid was freshly obtained form C57BL/6 mice via intratracheally instillation 1 hour 
prior to use. For removal of the cells, the BALF was centrifuged at 300 g at 4°C, and the 
pellet was discarded. All other materials were of analytical grade. 
Synthesis  
The low molecular weight PEI (LMWPEI) was synthesised and extensively characterized 
as described by von Harpe et al. [25]. The synthesis was carried out in aqueous solution from 
aziridine using HCl as a catalyst. The resulting molecular weight was approximately 5 kDa 
[22]. Ppoly(ethylene glycol)-graft-polyethyleneimine (PEGPEI), was synthesized as 
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previously described [26]. Briefly, PEGPEI was obtained by activating PEG-monomethyl 
ether (5 kDa) with a hexamethylene diisocyanate. The coupling of PEG to the amino groups 
of BPEI was carried out in anhydrous chloroform at 60 °C, which led to a PEI copolymer 
containing 2 PEG 5 kDa molecules per molecule of BPEI. 
Polyplex Formation 
All polyplexes consisting of DNA and PEI were prepared in sterile isotonic glucose 
solution at pH 7.4. The preparation occurred in two steps. First, PEI solution was prepared by 
mixing the appropriate amount of PEI stock solution (2 mg/ml) with glucose. The DNA was 
gently mixed with the glucose solution to achieve a final DNA concentration of 2 µg/100 µl 
polyplex solution for the in vitro experiments and 26 µg/100 µl for in vivo experiments. Both 
solutions were then incubated for a period of ten minutes. In the second step, polymer 
solution was added rapidly to the DNA and mixed by vigorous pipetting. The resulting 
polyplexes were incubated for 10-20 minutes at room temperature prior to use. When various 
PEI nitrogen to DNA phosphate ratios (N/P) were investigated, the final volumes of 100 µl  
for in vitro transfection and 150 µl for in vivo transfection were kept constant. The 
concentration of PEI was adjusted to the amount of DNA in order to maintain N/P ratios of 6, 
8 and 10 for BPEI and LMWPEI and N/P ratios of 8, 10 and 20 for PEGPEI.  
Physico-chemical Properties 
To study the physico-chemical properties of the different polyplexes, investigations of 
structure, particle size and charge were performed. The polyplexes were prepared as described 
above. 
Structure and morphology of DNA and polyplexes at N/P 8 was investigated using 
atomic force microscopy (AFM). Images of DNA and the PEI/DNA polyplexes were obtained 
using a Nanoscope IIIa Multimode Atomic Force Microscope (Veeco, Santa Barbara, CA, 
USA), operating in tapping mode in a liquid environment. All imaging was carried out at a 
scan speed of approximately 3 Hz with a 512 x 512 pixel resolution. Silicon nitride oxide-
sharpened cantilevers were selected, operating at resonance frequencies of approximately 10 
kHz. A sample volume of 40 µl was placed onto a 1 cm2 disk of freshly cleaved mica. 10 mM 
nickel chloride was added to the naked DNA solution to facilitate immobilization of the 
plasmid at the mica surface. To determine the mean polyplex size from these images, the 
diameter at about half-height of 30-50 polyplexes were analyzed.  
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The hydrodynamic diameters of PEI/DNA polyplexes were measured by dynamic light 
scattering (DLS) using an Autosizer (Malvern Instruments, Worcester, UK). The scattered 
light was detected at a 90° angle through a 100 µm pinhole. Measurements were performed at 
25°C with count rates between 50 and 300 kCps in 5 runs of 60 sec duration each and 
analyzed in CONTIN mode. The z-average of the polyplexes hydrodynamic diameters and the 
corresponding standard deviations (SD) were calculated from three independent 
measurements with freshly prepared samples.  
The surface-charges of PEI/DNA and naked DNA were determined by measuring the 
zeta-potential using the method of laser Doppler anemometry (LDA). The zeta-potentials 
were measured in the standard capillary electrophoresis cell of a Zetasizer 3000 HS (Malvern 
Instruments, Worcester, UK). The measurements were performed in pure water at pH 7.4 at 
25 °C with automatic duration. The average values and the corresponding SD were calculated 
in three independent measurements, five runs each.  
In vitro transfection 
Human lung epithelial cell line (A549) was obtained from the German Collection of 
Microorganisms and Cell Cultures and was maintained according to the supplier’s 
specifications. To evaluate the gene expression in A549, the transfection experiments were 
carried out as previously described in detail [23]. Briefly, cells in passages 6-15 were seeded 
at a density of 25000 cells per well on 24-well cell culture plates 24 h prior to the transfection 
experiments. The polyplexes were prepared as described above and 100 µl solutions were 
added to each well containing 900 µl fresh medium and incubated for 4 hours. The medium 
was then replaced and the cells were allowed to grow for a further 44 hours. The luciferase 
expression and protein concentration was determined in the cell lysate. All experiments were 
performed in triplicate and data were expressed in ng luciferase per mg protein (± SD). 
Cytotoxicity 
The cytotoxicity of PEI/DNA polyplexes at different N/P ratios was investigated using 
both LDH and MTT assays on A549 cells. The polyplex formation and administration to cell 
cultures was performed as described above. Furthermore, the cytotoxicity of the polymers 
alone at increasing concentration was studied using the MTT assay. 
To evaluate the polyplexes membrane cytotoxicity, a lactate dehydrogenase (LDH) assay 
was performed using A549. The cells were cultured as described above and allowed to grow 
for 72 hours prior to the polyplex application. Four hours post application, the amount of 
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cytoplasmatic LDH released as a result of cell membrane damage was quantified using a LDH 
activity kinetic assay from Sigma Diagnostics (St. Louis, MO, USA) according to the 
manufacturer’s protocol. The assay is based upon the enzymatic reaction of pyruvate and 
NADH to lactate and NAD+ catalyzed by LDH. The reduction of NADH was 
spectrophotometrically determined at 340 nm (Ultrospec 1000, Pharmacia Biotech, Freiburg, 
Germany). Controls were performed using medium (no LDH release) and 0.1 % Triton X-100 
set as maximum LDH release (100 %). The results were presented as percentage cytotoxicity 
calculated by the released LDH * 100 % / total LDH. All samples were run in triplicate and 
the experiments were repeated twice. 
The MTT assay was performed using the previously reported method [27]. A549 cells 
were seeded in 96-well microtiter plates at a density of 4200 cells per well and allowed to 
grow for 72 hours prior to polyplex application. The three different polymers were mixed 
with medium to final concentrations of 0.001, 0.01, 0.1, 0.5 and 1.0 mg/ml and 100 µl of 
these were applied per well. When polyplexes cytotoxic ity was studied 100 µl of the medium 
were replaced with 83 µl fresh medium and 17 µl polyplexes to achieve the same conditions 
as used in the in vitro transfection experiments. After 4 hours incubation with polymers and 
polyplexes respectively, the medium was replaced by 200 µl fresh medium and 20 µl (3-(4,5-
dimethylthiatol-2-yl)-2,5-diphenyl tetrazolium bromide) (MTT, Sigma, Seelze). After 4 
hours, the unreacted dye was removed and 200 µl DMSO was added. The absorption was 
measured using the ELISA reader Titertek Plus MS 212 (ICN, Eschwege, Germany) at 570 
nm, with a background correction at 690 nm. The relative cell viability (%) was related to 
control wells containing cell culture medium without polymer or polyplexes and was 
calculated by: absorption test x 100 % / absorption control. Data are presented as a mean of 
six measurements (± SD). The values of the polymers were fitted to a Bolzmann sigmoidal 
function using Microcal Origin® v 7.0 (OriginLab, Northampton, USA) and IC50 was 
calculated. 
In vivo transfection 
The polyplexes were prepared as described above and 150 µl of PEI/DNA or naked DNA 
were instilled into the lung of C57BL/6 mice. The mice were purchased from Charles River 
Laboratories (Sulzfeld, Germany) aged 4-6 weeks, weighing 22-28 g. Prior to the application 
the animals were held for five days in the animal lab were they were fed regularly (Muskator 
GmbH, Düsseldorf, Germany). For in vivo transfection, the animals were lightly anesthetized 
with 0.06-0.08 µl mixture (1:1:3) of ketamine hydrochloride 100 mg/ml (Ketavet®, 
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Pharmacia, Erlangen, Germany), xylacine hydrochloride 2 % (Rompun®, Bayer, Leverkusen, 
Germany) and isotonic sodium chloride. For intratracheal instillation the mice were 
positioned in a vertical position and polyplexes were administered using a flexible needle (0.9 
x 25 mm). Forty-eight hours after instillation the mice were sacrificed. After washing the 
lungs with isotonic sodium chloride by catheterizing the arteria pulmonalis, the lungs were 
removed and weighed. Per one gram of lung tissue 2 µl reporter lysis buffer (Promega, 
Mannheim, Germany) were added, the lung was immediately homogenized and frozen at 
minus 20°C. After thawing, the samples were centrifuged for 20 minutes at 4 °C and the 
luciferase assay was performed as described in the in vitro experiments. The transfection 
efficiencies and the corresponding SD were calculated as the mean value of 6 experiments 
and presented as pg luciferase per mg lung tissue. The use of animals in this study was 
approved by the local ethics committee for animal experimentation and the experiments were 
carried out according to the guidelines of the German law of protection of animal life. 
Stability 
The effect of Alveofact® and bronchial alveolar lining fluid (BALF) upon the polyplex 
stability was evaluated using a reverse fluorescence quenching assay [28, 29]. The 
fluorescence of ethidium bromide (EtBr), a DNA-intercalating agent, is enhanced upon 
binding to DNA and quenched when displaced by higher affinity compounds.  
Polyplex preparation was carried out as described. The amount of DNA was increased to 
6 µg per 100 µl and condensed with the appropriate amount of polymer to achieve N/P ratios 
of eight. The polyplexes were placed in a 96-well plate and 50 µl EtBr (40 µg/ml) were 
added. Alveofact® was dissolved in isotonic glucose solution pH 7.4 and added to the 
polyplexes to achieve final concentrations of 0.002, 0.02, 0.2, 1.0, 2.0 µg/µl. When stability in 
BALF was tested 100 µl of freshly attained BALF instead of Alveofact® was added to the 
polyplexes. The fluorescence measurements were began immediately after the addition of 
Alveofact® and BALF respectively,  and were carried out over a period of 90 minutes at a 
temperature of 37°C (Fluorescence reader FL600, Micro plate Fluorescence BioTEK, 
Winooski, USA) using ?ex = 485 nm and  ?em = 590 nm. The fluorescence is reported relative 
to the value obtained with naked DNA and EtBr (= 100%), as the mean ± SD of five 
measurements. 
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Statistical analysis 
Statistical calculations were carried out using the software package GraphPad InStat 
v3.06 (GraphPad Software, Inc. San Diego, CA, USA). To identify statistically significant 
differences one-way ANOVA with Bonferroni’s post test analysis was performed. 
Differences were considered significant if P = 0.05 (*), P = 0.01 (**), P = 0.001 (***) and 
marked accordingly in the figures. 
RESULTS AND DISCUSSION 
The delivery of genes to the airways holds considerable promise for the treatment of lung 
diseases, such as cystic fibrosis, asthma, cancer and pulmonary hypertension. Non-viral gene 
delivery systems have been shown to be safe alternatives to viral vectors in pulmonary gene 
therapy [30, 31]. However, there are still several problems to overcome with these systems, 
such as the need for a higher transfection efficiency, repeated administration, cell specific 
targeting and lower toxicity. The polycation PEI has been shown to hold several advantages 
as a non-viral gene carrier to the lung, such as a higher efficiency compared to lipid carriers, 
superior stability against DNase, lung surfactant and nebulization [13, 24, 28, 31]. The aim of 
our study was to find a PEI modification that exhibits comparable or improved transfection 
efficiency and is less toxic than the commonly utilized BPEI. Furthermore, by implementing a 
range of methods to thoroughly characterize the polyplexes, an enhanced understanding of the 
polymer structure-response relationship should be elucidated. 
Physico-chemical properties 
Plasmid and polyplex (N/P 8) morphologies in an aqueous environment were determined 
by AFM and representative images are shown in Figure 1. Image A displays naked plasmid 
DNA in a predominantly open circular form, however, some twisting of the DNA strands can 
also be observed. Images B-D illustrate the BPEI, LMWPEI and PEGPEI polyplexes 
respectively on the nanoscale. No uncomplexed strands of DNA were detected. Hence, it can 
be assumed that at an N/P ratio of 8 all three polymers fully condensed the plasmid forming 
spherical particles as shown in the AFM micrographs.  
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Figure 1. In situ AFM images showing the structure of naked DNA in isotonic glucose 
solution (A) and polyplexes formed of DNA and BPEI (B), LMWPEI (C), PEGPEI (D) at an 
N/P ratio of 8. 
 
The particle sizes of PEI/DNA polyplexes were measured using DLS and AFM (Table 1). 
Both methods yielded the smallest particles sizes for polyplexes from BPEI and DNA. 
LMWPEI and PEGPEI formed the slightly larger polyplexes at all the investigated N/P ratios 
with particle diameters of ca. 100-140 nm. 
Size of the polyplexes has been reported to be an important factor in facilitating gene 
transfer in cells [32-34]. An additional complication of polyplex delivery to the lung stems 
from the fact that two major clearance processes are seen in lung tissue, namely mucociliary and 
alveolar macrophage clearance. While particles > 500 nm are usually removed from the lung by 
mucociliary clearance, those < 250 nm may escape phagocytosis of alveolar macrophages [35]. 
Also, endocytotic uptake of particles is clearly affected by their size and increases with 
decreasing diameters [36]. Polyplexes from PEI will be taken up by endocytosis and  
subsequently release DNA according to the proton sponge hypothesis [37]. These considerations 
suggest that the PEI/DNA polyplexes studied here may have to fulfill different size requirements 
under cell culture conditions and in vivo. 
To estimate the surface charge of the PEI/DNA polyplexes, we measured their zeta-
potentials using LDA. The results for naked DNA and PEI/DNA polyplexes at different N/P 
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ratios are shown in Table 1. Plasmid DNA had a highly negative zeta-potential of -33 mV. All 
polyplexes displayed positive zeta-potentials due to an excess of the polycation. The highest 
zeta-potential of approximately +32 mV was obtained for BPEI polyplexes. An increase in the  
N/P ratio did not affect upon the BPEI polyplex surface charge. Zeta-potentials of LMWPEI 
polyplexes were found to be significantly lower than these of BPEI polyplexes. Furthermore, 
a slight potential increase (from 15 to 22 mV) at higher N/P ratios was observed. Constant 
low zeta-potentials of approximately 17 mV were measured for all PEGPEI polyplexes.  
 
Table 1. Physico-chemical properties of the different polyplexes: Polyplex hydrodynamic 
diameters were measured using DLS and average values were determined from three 
measurements of five runs each. AFM was also used to make size measurements. The mean 
values were calculated from 30-50 polyplexes of different images. The zeta-potential mean 
values ± SD were determined in three independent measurements of five runs each using 
LDA.  
polyplexes particle sizes [nm] 
 
N/P ratio 
 DLS AFM 
zeta-potential 
[mV] 
BPEI 6 95.0 ± 6.7  32.9 ± 4.4 
BPEI 8 102.5 ± 10.0 87.3 ± 12.6 32.3 ± 6.2 
BPEI 10 90.6 ± 13.4  31.5 ± 4.5 
LMWPEI 6 105.2 ± 10.7  15.2 ± 3.9 
LMWPEI 8 138.4 ± 16.9 91.0 ± 39.9 18.7 ± 5.1 
LMWPEI 10 136.6 ± 8.9  21.7 ± 6.5 
PEGPEI 8 111.2 ± 5.7 115.1 ± 18.7 17.0 ± 1.9 
PEGPEI 10 120.2 ± 20.2  17.3 ± 2.2 
PEGPEI 20 104.7 ± 21.1  16.9 ± 2.3 
DNA    -32.7 ± 9.48 
 
The high zeta-potential of the BPEI polyplexes we observed here is in line with previous 
reports [37]. It was stated that at N/P ratios > 4, BPEI polyplexes have a zeta-potential 
between 30 and 35 mV, due to the complete DNA condensation and an excess of polymer. 
This excessive polymer covers the particle surface of the polyplexes and therefore, the zeta-
potential of BPEI/DNA does not further increase with the increasing N/P ratio. This, on the 
other hand, led us conclude that the LMWPEI polyplexes are less compact and the particle 
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surface is not completely covered by the polymer at N/P ratios of 6 and 8. We believe that the 
zeta-potential increase with the increasing N/P ratio, provides evidence for a reduction in 
DNA condensation compared to that observed with BPEI, due to its lower molecular weight 
[22]. The low charge of PEGPEI/DNA confirmed that PEG shields the polyplex surface, also 
at N/P ratios > 10 [38, 39]. 
In vitro transfection 
To evaluate the gene transfer efficiency of the three PEI modifications, polyplexes at 
differing N/P ratios were applied to A549 cells and luciferase gene expression was quantified 
after 48 hours (Figure 2). The data indicated that the transfection efficiency increases with 
increasing N/P ratio. This finding is consistent with previous reports [21, 39]. Among the 
different PEIs tested, PEGPEI was by far the most effective transfection agent. At N/P ratios 
of both 8 and 10, the efficiency of PEGPEI polyplexes (4.3 and 6.1 ng/mg respectively) was 
three times higher (P = 0.05) than observed with BPEI polyplexes (1.5 and 2.1 ng/mg 
respectively). At N/P 20 the transfection rate of PEGPEI polyplexes increased to 
approximately 52 ng/mg, which was 20 times higher than observed with the BPEI polyplexes 
at N/P 10 (P = 0.001). Whilst the transfection of LMWPEI polyplexes was the least efficient, 
its increase with an increasing N/P ratio was the highest and approximately 0.9 ng/mg was 
achieved using N/P 10. The transfection rate of naked DNA was negligible (0.0014 ng/mg) to 
the point of not being detectable in the diagram.  
Apart from the PEGPEI used in this study, other PEG-grafted PEI derivatives have been 
extensively investigated as potential candidates for non-viral gene delivery [39]. After 
screening these polymers as gene vectors for A549 cells, the PEGPEI selected here was found 
to be by far the most efficient carrier in lung epithelial cells. Furthermore, an N/P ratio of 20 
for PEG-grafted PEIs was shown to be highly efficient and less toxic than BPEI in mouse 
fibroblasts [39]. For this reason, we chose this N/P ratio for the experiments in this study, in 
addition to the N/P ratios of 8 and 10. 
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Figure 2. Transfection efficiency of PEI/DNA polyplexes at different N/P ratios in an 
epithelial cell culture model (A549). All results are the average ± SD of three independent 
experiments of three samples each. 
 
We have demonstrated a remarkable increase in the transfection efficiency of 
PEGPEI/DNA compared to BPEI/DNA polyplexes in A549 alveolar epithelial cells. In 
contrast, the transfection efficiencies of LMWPEI polyplexes in the A549 lung cells were 
shown to range below that of the commercially available BPEI. However, the efficiency of 
LMWPEI/DNA improved with increasing N/P ratio, probably due to the increased zeta-
potential. Similar results have been reported before and the gene expression of PEIs with a 
low molecular weight were described to range below that of high molecular weight PEIs 
when applied to numerous cell lines at N/P ratios < 10 [22, 27]. In this context, it was also 
assumed that in comparison to BPEI, the poor in vitro transfection, the low zeta-potential and 
the slightly larger size provide evidence for a reduction in the condensation between 
LMWPEI and DNA. 
Cytotoxicity 
The LDH assay was performed to test the cytotoxicity based upon membrane damage 
caused by polyplexes under transfection conditions, whereas the MTT assay was chosen to 
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study the cell viability over a wide range of polymer concentrations and under transfection 
conditions.  
To assess the cell membrane damage, polyplexes at different N/P ratios were applied to 
A549 cells over a period of four hours and then the extracellular LDH was quantified (Figure 
3). Naked DNA at a concentration of 2 µg/ml, the same concentration used in polyplex 
formulation, caused membrane damage as represented by a LDH release of 2.2% (P = 0.05 in 
comparison with medium control). No significant LDH release compared to the control cells 
and, therefore, no membrane toxicity was observed using polyplexes at N/P 6. Whilst the 
polyplexes of LMWPEI and PEGPEI did not show a significantly higher LDH release at an 
N/P ratio of 8, BPEI polyplexes led to an increasing LDH release of up to 4 %. At an N/P 
ratio of 10, BPEI/DNA caused the most sever membrane damage (5.2 % LDH release) when 
compared with LMWPEI/DNA (3.5 %) and PEGPEI/DNA (4 %). The highest cytotoxicity of 
approximately 6.5 % LDH release was observed for PEGPEI/DNA at N/P 20. When 
comparing polyplexes with naked DNA, we observed that only BPEI N/P 10 and PEGPEI 
N/P 20 led to significantly higher levels of membrane damage. Because the LDH release of 
these two polyplexes exceeded 5 %, they are considered to be cytotoxic [27]. 
 
Figure 3. The cell membrane damaging effect of naked DNA and PEI/DNA polyplexes at 
different N/P ratios was quantitated by the release of the cytosolic enzyme, LDH, from A549. 
Each value represents the mean ± SD of three determinations of three samples each. 
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Statistically significant differences from the medium control are denoted with one (P = 0.05), 
two (P = 0.01) or three (P = 0.001) asterisks. 
The metabolic and mitochondrial activity of polymer- or polyplex-treated cells was 
determined using the colorimetric MTT-assay [40]. As illustrated in Figure 4A, the toxicity of 
all polymers was concentration dependent. Whilst both BPEI and PEGPEI reduced the cell 
viability dramatically at polymer concentrations of 0.01 mg/ml (~ 25 % viability), LMWPEI 
showed less influence upon the cells (~ 75 % viability). Considering the IC50 values, BPEI 
0.071 mg/ml, PEGPEI 0.074 mg/ml and LMWPEI 0.26 mg/ml, it is clear that the metabolic 
activity reduction is far lower using LMWPEI compared to BPEI and PEGPEI.  
After four hours of polyplex application (Figure 4B) to A549, the cell viability decreased 
for BPEI/DNA, LMWPEI/DNA at N/P ratios 6-10 and PEGPEI/DNA at N/P ratios 8 and 10 
to approximately 85-75 %. Comparison of these polyplexes did not show significant 
differences in cell viability. Only PEGPEI polyplexes at an N/P ratio of 20 caused a strong 
reduction in the metabolic activity and the viability dropped to 65 %. Application of naked 
DNA alone resulted in a remaining cell viability of 95% ± 3.3 (data not shown).  
PEG-grafted PEI modifications have been shown to hold distinct advantages in lung gene 
therapy as they are involved in fewer interactions with proteins or cells, thus they tend to 
exhibit a lower toxicity, due to the shielding effect of PEG [41, 42]. Reduced interactions 
between the polyplexes and the cell surface can be observed as a decrease in the cell 
membrane damage [27]. The LDH assay data obtained here for PEGPEI in comparison to 
BPEI polyplexes suggested a decrease in cell membrane damage at N/P ratios of 8 and 10, 
respectively. This observation and the lower zeta-potential of PEGPEI/DNA confirmed the 
shielding effect of PEG [38, 39]. However, at an N/P ratio of 20, PEGPEI polyplexes 
significantly increased the LDH release, thus the cell membrane was aggravated to a 
significant extent. We assume that at an N/P ratio of 20, free, uncomplexed polymer is present 
in the solution and interaction between this free PEGPEI and the cell surface increased 
conspicuously. Furthermore, according to the reduced cell viability observed in the MTT 
assay, PEGPEI showed a similar cytotoxicity as that of BPEI. This reduction in the metabolic 
activity indicated, that after membrane interaction the polymer was incorporated in the cell 
plasma and damaged the mitochondria. Taken together, the PEGPEI polyplexes have, in 
comparison to BPEI polyplexes, a reduced cytotoxicity at N/P ratios of 8 and 10. This finding 
is in agreement with the low cytotoxicity of PEGPEI polyplexes previously reported [42, 43]. 
However, uncomplexed PEGPEI, which probably existed at the high N/P ratio of 20, led to 
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significant damage of lung epithelial cells. Therefore, PEGPEI advantages, such as polyplex 
surface shielding and low toxicity, can only be taken into account when N/P ratios = 10 are 
applied to lung epithelial cells. We assume that the PEGPEI/DNA interaction with the 
membrane is reduced, due to the PEG shielding [39], but once inside the cell the lysosomal 
release is highly efficient. This would explain the high gene expression in vitro combined 
with low zeta-potential and reduced membrane damage. 
 
 
 
Figure 4. Cytotoxic effects were determined by MTT assay and presented as the relative cell 
viability (mean ± SD of six determinations). Polymer solutions (A) of 0.001, 0.01, 0.1, 0.5, 
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and 1.0 mg/ml and polyplexes (B) BPEI/DNA, LMW/DNA N/P 6, 8, 10 and PEGPEI/DNA 
N/P 8, 10, 20 were applied to A549 over a period of four hours.  
 
Several studies performed in our laboratory have compared low and high molecular weight 
PEIs. Lower toxicity combined with a high transfection efficiency in differing cell lines was 
clearly demonstrated [22, 33]. Using human lung epithelial cells, lower toxicity, demonstrated 
by a reduction in membrane damage and favorable cell viability, was also observed for the 
LMWPEI utilized in this study. Therefore, it can be concluded, that in contrast to BPEI and 
PEGPEI, the interaction between the cell membrane and LMWPEI is reduced and, thus, the 
incorporation of the polyplexes into the cells and the mitochondrial damage are also reduced. 
The lower zeta-potentials of the LMWPEI polyplexes confirmed the in vitro results, i.e., the 
lower charge caused fewer interactions with the cell membranes, which in turn suppressed 
gene expression.  
In vivo transfection 
To determine the transfection efficiency of the PEI modifications in mice, polyplexes and 
DNA were delivered to the lung via an intrapulmonary route. In order to evaluate the 
transfection peak in the mouse lung, a time screening experiment (Figure 5) was carried out 
prior to the investigation of the various polyplexes. Luciferase concentrations were measured 
at 12, 24, 48, 72, 120 and 240 hours after LMWPEI/DNA N/P 6 instillation, with the highest 
transfection rate being observed at 48 hours post-administration. Therefore, all studies of the 
luciferase expression in the mouse lung were carried out 48 hours after the intrapulmonary 
administration. An equivalent incubation time for PEI/DNA treated mice via aerosol 
administration has been described before [31]. 
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Figure 5. Transfection efficiency of LMWPEI/DNA polyplexes N/P 6 in C57BL/6 mice lung 
12, 24, 48, 120, 240, 360 hours post-administration. Values are averages ± SD of three 
experiments. 
 
Figure 6 presents the luciferase expression of DNA and the different polyplexes in the 
mouse lung 48 hours after intrapulmonary application. When administering plasmid DNA in 
the absence of a carrier, a transfection efficiency of approximately 0.4 pg luciferase per mg 
lung tissue was obtained. Marginally more luciferase was produced when polyplexes of DNA 
with BPEI or LMWPEI N/P 6 and PEGPEI N/P 8, 10 and 20 were administered to the lungs 
of mice. Thus, these polyplexes did not cause a significant increase in the transfection 
efficiency when compared to naked DNA. A ten fold higher efficiency was obtained when 
BPEI polyplexes at N/P 8 were administered. The highest luciferase accumulation (8.2 
pg/mg) was observed for LMWPEI polyplexes at N/P 8. This enormous in vivo transfection 
efficiency significantly surpassed (P = 0.01) that of all other polyplexes investigated in this 
study. 
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Figure 6. Transfection efficiency of PEI/DNA polyplexes at different N/P ratios in C57BL/6 
mice lung. All results provided are mean ± SD of six experiments. Statistically significant 
differences from DNA are denoted with one (P = 0.05) or three (P = 0.001) asterisks. 
 
Whilst PEGPEI/DNA appears to be an outstanding transfection agent in cell culture, this 
behavior was not confirmed in the in vivo experiments. It was found that the transfection 
efficiency of the PEGPEI polyplexes was at the same level as DNA applied without a carrier, 
independent of the N/P ratios. Also, Kichler et al [42] reported a low transfection efficiency 
of PEGPEI polyplexes when compared to naked DNA after instillation to the mouse lung. 
However, our data are still to some extent encouraging since it has been reported that PAA 
dendrimers or lipid based carriers show a lower transfection efficiency than naked DNA [44, 
45].  
The transfection efficiencies of LMWPEI polyplexes in the A549 lung epithelial cells 
were shown to range below that of the commercially available BPEI. An efficacious gene 
expression in the mouse lung was achieved after LMWPEI/DNA was administered via an 
intrapulmonary route. In particular at the N/P ratio of 8, LMWPEI polyplexes seem to have 
better properties than BPEI and PEGPEI as a gene carrier to deliver the plasmid DNA into the 
nucleus of lung cells in living mice.  
To our knowledge, this significant transfection rate increase from the N/P ratio of 6 to 8 
and then the significant transfection decrease from the N/P ratio of 8 to 10 seen for BPEI and 
LMWPEI polyplexes were not demonstrated before. It was particularly surprising since 
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Gautam et al. reported the highest gene expression in the lung of aerosol-treated mice for 
BPEI polyplexes at a N/P ratio of 15 [46]. However, the conditions used in this study were 
different from ours, e.g. the reporter gene and the amount of polyplex used were different, as 
well as the route of administration. Similar conditions were used by Bragonzi et al. who 
condensed BPEI with DNA (50 µg per mouse of a CMV controlled plasmid), administered 
the polyplexes via the intrapulmonary route to C57BL/6 mice and compared the transfection 
efficiency using a range of N/P ratios [13]. They demonstrated a luciferase expression 
decrease when the N/P ratio increased from 5 to 10, which is comparable to our results here. 
We assume that the amount of free polymer for BPEI and LMWPEI polyplexes at an N/P 
ratio of 6 was still too low to enhance the endosomal escape by the proton sponge effect [37]. 
At an N/P ratio of 10, un-complexed BPEI and LMWPEI probably enhanced endosomal 
escape, but also increased the in vivo toxicity. Because, high toxicity was shown to reduce 
transfection efficiency in vivo but not in vitro [6], we assume that this is the case in the mouse 
lung at an N/P ratio of 10. The cytotoxicity studies in vitro had shown a slight increase in 
membrane and mitochondrial damage with an increasing N/P ratio, but did not affect the 
transfection efficiency of the A549 cells. We assume that under the complex conditions in the 
lung environment, at high N/P ratios free polymer can easier escape from the polyplexes and 
cause cell damage and thus led to the transfection efficiency drop when the N/P ratio was 
increased from 8 to 10. Also Goula et al. observed stronger side effects with an increasing 
N/P ratio after the intra venous administration of PEI/DNA polyplexes (125 µg plasmid per 
mouse) [12]. Taken together, utilizing BPEI and LMWPEI as carrier for pulmonary gene 
delivery an N/P ratio of eight is preferable.   
Stability 
It was reported, that components of the bronchial alveolar lining layer affect the 
transfection efficiency of pulmonary gene delivery systems [47].  In an attempt to identify if 
similar pattern can explain the differences observed between the in vitro and in vivo 
transfection efficiencies, stability studies in Alveofact® and BALF were carried out using the 
DNA intercalation agent, EtBr (Figure 7). If the PEI condenses DNA successfully, EtBr can 
no longer intercalate and fluorescence intensity decreases measurably. Conversely, increasing 
fluorescence signal indicates decreased DNA condensation and loosing of the complex 
structure [29].  
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Figure 7. Polyplex (N/P = 8) stability: A) Polyplexes were treated with increasing amounts of 
Alveofact ® for 90 minutes at 37°C. B) Polyplexes were treated at 37°C with freshly attained 
BALF. Values ± SD were determined in three independent measurements and depicted as a 
percentage  
 
When Alveofact® and BALF were not present, the polymers were able to condense the 
DNA (N/P 8) up to a residual fluorescence of approximately 8.5 % (BPEI and LMWPEI) and 
7 % (PEGPEI), respectively. Using increasing quantities of Alveofact®, the stability of the 
polyplexes (N/P 8) was investigated at 37°C for 1.5 hours (Figure 7A). For all three 
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polyplexes, slight increases in fluorescence were observed at 0.002 µg/µl. However, at higher 
Alveofact® concentrations, LMWPEI/DNA displayed a lower stability, with a relative 
fluorescence under these conditions of 17 % (1.0 µg/µl) and 17.9 % (2 µg/µl). Whilst the 
relative fluorescence for PEGPEI polyplexes was highest at 0.2 µg/µl (10.8 %), the DNA 
release did not increase at 1 and 2 µg/µl Alveofact® (10.8 % and 11.4 % relative 
fluorescence). A constant fluorescence increase up to 14.2 % was observed for BPEI/DNA. 
The kinetics of DNA liberation from the polyplexes in BALF (at 37°C) is presented in 
Figure 7B. All three polyplexes investigated showed similar increases in relative fluorescence 
over the observation period of 90 minutes. However, the fluorescence data obtained over a 
period of 60 minutes indicated that PEGPEI was superior, followed by BPEI and LMWPEI 
when considering the DNA condensation and encapsulation. 
In comparison to BPEI and LMWPEI, the PEGPEI polyplexes were most stable in the 
presence of a high concentration of Alveofact® and BALF. As mentioned before, the PEG 
chains prevent interactions between serum cells and proteins [38, 43]. A similar reduction in 
the interactions probably also protects the polyplexes and, thus, the DNA against proteins, 
proteolipids and enzymatic degradation in the BALF and Alveofact®. Therefore, a better 
stability of PEGPEI polyplexes in the lung environment can be assumed. As discussed above, 
LMWPEI is not as efficient in condensing DNA as BPEI. Due to the denser structure of 
amino groups in the BPEI molecule, the compaction ability is improved and this advance 
BPEI compare to LMWPEI in protecting the DNA. Interestingly, it was demonstrated, that 
strong condensation between DNA and its carrier can reduce the gene expression [48]. Also 
in our study higher stability was associated lower in vivo transfection efficiency. 
 
As a consequence, we expla in the discrepancy between in vitro and in vivo transfection 
efficiency as follows. Firstly, different conditions in vivo and in vitro should be taken into 
account. These include: i) the higher concentration of polyplexes in vivo, ii) the range of 
different salts, proteins, proteolipids and enzymes in the mouse lung, and iii) the number of 
different cell types present in the mouse lung (e.g. bronchial and alveolar epithelial cells, as 
well as macrophages) compared to the one single type of human alveolar epithelial cell in 
vitro. Furthermore, it has been reported that lung cells can function differently in vitro 
compared to in vivo. It was observed that forty-one percent of the proteins expressed in vivo 
were not detected in cell culture [47].  
Secondly, the superior transfection efficiency of LMWPEI polyplexes in the mouse lung 
was obvious and can be explained by interactions with lung surfactant, such as Alveofact®. 
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This destabilization of LMWPEI polyplexes suggests that transfection experiments under in 
vitro conditions are not predictive of experimental results in animals. Hence, other polyplex 
properties seem to be important for successful gene transfer in mice, rather than those 
anticipated from the in vitro experiments. A sufficiently high stability in the lung environment 
seems to be essential [1]; however, if the polymer-DNA interactions are too strong, 
intracellular DNA release may be compromised. For an improved in vivo gene transfer the 
polyplexes need to disassemble and release the DNA into the nuclear compartment, yet 
protect the DNA against degradation during the uptake process [4]. We assume that the DNA 
release from LMWPEI polyplexes is facilitated under in vivo conditions and, thus, has 
improved the gene expression in the mouse lung. Further investigations, e.g. lung histology 
studies after administration of labeled polyplexes, are necessary to confirm this hypothesis. 
Koeping-Hoeggård et al. studied a range of low molecular weight chitosan-DNA polyplexes 
and also observed differences between in vitro and in vivo transfection experiments. They 
reported a moderate efficiency in epithelial cells for the polyplexes with the highest 
transfection efficiency in the mouse lung, and, interestingly, a low stability in the presence of 
heparin [48].  
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CONCLUSION 
In summary, this study has demonstrated LMWPEI to be a non-viral gene carrier 
combining low cytotoxicity in lung epithelial cells with a high gene delivery in the mouse 
lung. To our knowledge, this paper is the first to describe the use of low molecular weight PEI 
for pulmonary gene delivery. In essence, we have shown that the use of LMWPEI in vivo 
achieves a significant improvement in gene expression when compared to the commercially 
available BPEI. PEGPEI was also investigated and was shown to be a stable, efficacious 
transfection agent with low membrane toxicity. However, only moderate gene expression was 
observed in vivo. In conclusion, we believe that LMWPEI holds great promise as a carrier 
system in lung gene therapy. Indeed, the fact that LMWPEI caused significant improvements 
in gene expression makes this polymer an extremely promising alternative to the commonly 
used BPEI in pulmonary gene therapy.  
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ABSTRACT 
The non-viral vector polyethylenimine (PEI) has been intensively characterized as DNA 
carrier for pulmonary gene therapy. In a previous study we compared the commonly used 
branched PEI (BPEI) with a low molecular weight  PEI (LMWPEI) and (polyethylene glycol)-
graft PEI (PEGPEI) for gene delivery to the mouse lung (Chapter 3). Here we studied these 
vectors in terms of DNA protection and safety of the polyplexes following intrapulmonary 
administration into mice. As LMWPEI/DNA displayed superior transgene expression and 
biocompatibility in the mouse lung, we investigated the distribution of fluorescence labeled 
polyplexes and the nebulization employing an electric micropump nebulizer. The DNase 
digestion study confirmed earlier findings in that the LMWPEI polyplexes display the lowest 
stability, followed by BPEI and PEGPEI. All parameters investigated to assess polyplex 
toxicity (cell counts, percentage of neutrophils and macrophages, protein and cytokine 
concentrations) showed a rang order of inflammation response: naked DNA ~ LMWPEI/DNA 
< BPEI/DNA < PEGPEI/DNA. LMWPEI polyplexes were distributed in the cells of both the 
bronchi and alveoli, whereas BPEI polyplexes were mainly deposited in the conducting 
airways. With a Green Fluorescing Protein (GFP) encoding plasmid, the transgene expression 
was located, thus confirming the findings of the distribution studies. The transfection 
efficiency of nebulized LMWPEI polyplexes was found to decrease by a factor of 50 
compared to the intratracheal instillation. Distribution studies showed an even but low level of 
polyplex deposition throughout the mouse lung, indicating, that further investigations are 
necessary to improve the efficiency of the nebulizer system. In conclusion, the excellent level 
of gene expression seen with LMWPEI/DNA administered via instillation can be explained 
by low levels of inflammation and enhanced distribution in the mouse lung. Thus LMWPEI 
holds great promise for safe and efficient gene delivery in the therapy of pulmonary diseases.  
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INTRODUCTION 
The lung holds promise for gene therapy since it is easily accessible through the airways, 
offers a large surface area for transfection and avoids risks of systemic side effects. 
Polyethylenimine (PEI) and various PEI modifications have been successfully studied gene 
transfer to lung tissue via direct intratracheal instillation [1-3], aerosolization [4, 5] and 
intravenous injection [6, 7]. Serious lung inflammation, evidenced by neutrophil infiltration 
and reduced arterial oxygen saturation, was observed when plasmid DNA (pDNA) with the 
commonly used 25 kDa branched PEI (BPEI) was administered intratracheally in the mouse 
lung [3]. By contrast, only mild lung inflammation was reported for pDNA and BPEI 
polyplexes administered via aerosol inhalation [8].  
Recently, we synthesized and characterized a branched low molecular weight PEI 
(LMWPEI) which displayed superior transgene expression in the mouse lung and low toxicity 
in vitro [9, 10]. Polyethylenglycol-grafted derivatives of PEI (PEGPEI) seem to be beneficial 
for gene therapy of the lung due to reduced interactions with proteins or cells and hence lower 
cytotoxicity [2, 11]. Previously, we reported superior transfection efficiency in lung epithelial 
cells using a PEGPEI, however, a tremendous transfection rate decrease when administered to 
the mouse lung [10]. Lung inflammation and cytokine release after pulmonary delivery of 
cationic lipid-DNA complexes was shown to decrease the level of transgene expression [12, 
13]. In an attempt to clarify whether lung inflammation could  explain the reduced transfection 
efficiency of the PEGPEI in the mouse lung, we report here the total cell numbers, the 
percentage of neutrophils and alveolar macrophages, and the protein, TNF-alpha and IL-2 
concentrations in the bronchial alveolar lavage fluid (BALF) of polyplex treated mice.  
Intra- and extracellular enzymes affect the transfection efficiency of gene delivery 
systems [14, 15]. In particularly, non-viral vectors protecting DNA against DNase 
degradation were shown to improve the transfection efficiency [16]. Polyplex stability in the 
extracellular lung environment was extensively studied previously [10]. In the present report, 
the effects of the intracellular enzyme DNase I on polyplexes stability of LMWPEI, BPEI and 
PEGPEI were characterised in DNase digestion studies employing atomic force microscopy 
(AFM). AFM is a comparatively new technique for studying events involving DNA, such as 
condensation or degradation, and has recently been used to visualize the morphology of gene 
delivery systems [17, 18]. 
Fluorescent markers and pDNA encoding the GFP were used to study both the 
distribution and the transgene expression of poly- and lipoplexes in the mouse lung [19-22]. 
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Distribution and gene expression of BPEI polyplexes were shown mainly in the bronchial 
region, whereas linear PEI (22 kDa) polyplexes transferred the pDNA mainly to alveolar cells 
[19]. Furthermore, improved transfection efficiency of linear PEI polyplexes, was attributed 
to the larger surface area available in the alveolar cells. Since high transfection efficiency was 
also obtained for LMWPEI [10], we employed doubled- labeled polyplexes and GFP to study 
polyplexes distribution in the mouse lung.  
To accomplish both non-toxic gene delivery systems in addition to improved lung 
distribution, we developed an inhalation system for the delivery of PEI/DNA polyplexes into 
the mouse airways. An electric micropump nebulizer, namely Aeroneb Pro®, was thought  to 
be advantageous for drug aerosolization, due to small aerosol droplet sizes, high output and 
virtually no residual volume. The aerosol leaves the nebulizer through a vibrating mesh, 
creating a fine mist. This process significantly reduces effects upon the drug molecule due to 
the low frequency, constant temperature and the absence of baffles [23, 24]. Furthermore, a 
previous study (Chapter 6) showed reduced effects upon the stability of liposomal 
formulations. Therefore, we employed the nebulizer Aeroneb Pro® for the application of 
polyplexes into the airways of mice. To our knowledge, this is the first study employing an 
electric micropump nebulizer for the application of pulmonary gene delivery systems. 
The aim of this study was to increase the understanding of efficacious and safe 
pulmonary gene delivery, the distribution in the mouse lung and the DNA protection offered 
by BPEI/DNA, LMWPEI/DNA and PEGPEI/DNA polyplexes. 
MATERIALS AND METHODS 
Polymers 
The 25 kDa branched polyethylenimine (BPEI) was a gift from BASF (Ludwigshafen, 
Germany). The 5 kDa low molecular weight PEI (LMWPEI) was synthesised and 
characterized as described previously [25-27]. The (polyethylene glycol)-graft PEIs 
(PEGPEI), were synthesized as previously described [28]. Briefly, PEGPEIs were obtained by 
activating PEG-monomethyl ether with a hexamethylene diisocyanate. The coupling of PEG 
to the amino groups of BPEI was carried out in anhydrous chloroform at 60 °C, which led to a 
the PEI copolymers: (PEG5k)2PEI containing 2 PEG 5 kDa molecules per molecule of BPEI 
and (PEG550)35PEI containing 35 550 Da molecules per molecule of BPEI. For the 
distribution studies BPEI and LMWPEI respectively were labeled using Oregon Greenâ 488 
carboxyl acid (Molecular probes, Leiden, the Netherlands) and labelling procedure was 
 LMWPEI enhanced pulmonary compatibilaty  
 96 
carried out as described in the manufacturers protocol. All other reagents were of analytical 
grade. 
Plasmids  
The plasmid pGL3 carrying the luciferase coding region under the promoter control of 
cytomegalovirus (CMV) was kindly provided by J. Hänze (Department of Molecular Biology, 
University of Giessen, Germany). The plasmid peGFP-N1 carrying the green fluorescence 
coding region under the promoter control of CMV was kindly provided by C. Rudolph 
(Department of Paediatrics, University of Munich, Germany). Both plasmids were propagated 
in E. coli and purified by PlasmidFactory (Bielefeld, Germany). Labeled DNA (pGL3-Alexa 
Fluorâ) was prepared as described in the manufacturers protocol for ARESâ DNA labeling kit 
(Molecular probes, Leiden, the Netherlands). Briefly, the amine-modified dUTP was 
incorporated in the pGL3 plasmid strand by a Nick translation, followed by the addition of the 
amine-reactive dye Alexa Fluorâ. Unreacted enzymes and dye were removed from the labeled 
plasmid using the QIAquick PCR purification kit (Qiagen, Hilden, Germany). 
Polymplex formation 
Polyplexes consisting of pDNA and a PEI modification  (BPEI, LMWPEI or PEGPEI) 
were prepared in sterile isotonic glucose solution at pH 7.4 as described recently [29]. Briefly, 
the polymer solution was added rapidly to the DNA and mixed by vigorous pipetting followed 
by 10-20 minutes incubation at room temperature prior to use. When various nitrogen (PEI) to 
phosphate (DNA) ratios (N/P) were investigated, the concentration of the PEI was adjusted to 
the quantity of DNA in order to maintain N/P ratios of 6, 8, 10 and 20. When the transfection 
efficiency of different PEI mixtures was studied, the concentrations, relating to the quantity of 
nitrogen, were for 1:1 mixtures: 50 % BPEI or LMWPEI + 50 % (PEG5k)2PEI; for 1:2 
mixtures 33.3 % BPEI or LMWPEI + 66.6 % (PEG5k)2PEI.  
Atomic Force Microscopy 
Images of DNA and the PEI/DNA polyplexes were obtained using a Nanoscope IIIa 
Multimode Atomic Force Microscope (Veeco, Santa Barbara, CA, USA), operating in tapping 
mode in a liquid environment. All imaging was carried out at a scan speed of approximately 3 
Hz with a 512 x 512 pixel resolution. Silicon nitride oxide-sharpened cantilevers were 
selected, operating at resonance frequencies of approximately 10 kHz. The experiments were 
repeated twice to ensure reproducibility. The samples for the DNase digestion studies 
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contained polyplexes (N/P 8) or DNA (1.5 µg/ml) and 0.75 units/ml DNase I (Boehringer, 
Mannheim, Germany)  in digestion buffer. The reaction was carried out over a period of 120 
minutes at 37 °C. At severeal times (0, 30, 60, 90, 120 min) samples of 40 µl were taken, 
placed onto a 1 cm2 disk of freshly cleaved mica and imaged immediately. Due to the fast 
degradation of naked DNA, its digestion was tracked at room temperature by in situ AFM 
imaging [18]. PBS buffer (1mM) containing 2 mM MgCl2 and 1 mM NiCl2 was added to the 
plasmid solution to facilitate immobilization of the plasmid at the mica surface. The digestion 
buffer for these experiments contained 0.1 M sodium acetate, 5 mM magnesium sulphate and 
was titrated to pH 8.0 [30].   
Animals 
C57BL/6 mice were purchased from Charles River Laboratories (Sulzfeld, Germany) 
aged 4-6 weeks, weighing 22-28 g. Prior to treatment the animals were acclimatized for five 
days. For polyplex application, the animals were lightly anesthetized with 0.06-0.08 µl 
mixture (1:1:3) of ketamine hydrochloride 100 mg/ml (Ketavet®, Pharmacia, Erlangen, 
Germany), xylacine hydrochloride 2 % (Rompun®, Bayer, Leverkusen, Germany) and 
isotonic sodium chloride. For intratracheally instillation or lung lavage the mice were 
positioned in a vertical position and intubated using a flexible needle (0.9 x 25 mm). The use 
of animals in this study was approved by the local ethics committee for animal 
experimentation and the experiments were carried out according to the guidelines of the 
German law of protection of animal life. 
Polyplex toxicity in the mouse lung 
Toxic effects of the polyplexes and pDNA, both containing 260 µg/ml DNA, in the 
mouse airways were studied similar to reports in the literature [8, 31]. Controls were 
performed using isotonic glucose solution at pH 7.4. Polyplexes of BPEI and LMWPEI at the 
N/P ratios 6, 8, 10 and polyplexes of (PEG5k)2PEI at the N/P ratios 8, 10 and 20 were 
prepared and applied to the mouse lung via intratracheally instillation as described above. 
Twenty-four hours post-administration mice were sacrificed and bronchial alveolar lavages 
were performed with ice cold phosphate buffered saline (PBS) pH 7.4 containing 5 mM 
EDTA according to the following protocol: Lungs were lavaged successively with 300 µl, 300 
µl, 400 µl, and 8 x 500 µl PBS to achieve a total volume of 5.0 ml. The first three lavages 
were pooled separately and centrifuged at 300g. The supernatant was collected and the cell 
pellet resuspended with cell medium. The remaining 4 ml were also centrifuged at 300g, the 
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supernatant discarded, the cell pellet resuspended in cell medium, and added to the cells from 
the first three lavages. Total cells in the bronchial alveolar lavage fluid (BALF) were counted 
in a Neubauer hemacytometer. Polymorph-nuclear leucocytes (PMN) recruitment and 
alveolar macrophages were assessed by preparing centrifuge smears and staining them with 
DiffÒ (Dade, Munich, Germany). The number of neutrophils and macrophages were 
expressed as the percent of the total number of cells. A quantification of total proteins in the 
BALF supernatant (~1 ml) was performed based on the Bradford method using a standard 
BCA Assay Kit from Bio-Rad Laboratories (Munich, Germany) according to the 
manufacturer’s protocol. Protein concentrations were calculated from a standard curve made 
from bovine serum albumin (BSA) in concentrations ranging from 0.2 to 2.0 mg/ml. The 
cytokine quantification was performed using mouse-specific immunoassay kits for tumour 
necrosis factor alpha (TNF-a) and interleukin 2 (IL-2) respectively (R&D systems Inc., 
Minneapolis, USA) according to the manufacturers protocol. The values of the toxicity 
studies were calculated as mean ± SD of three experiments.  
In vivo transfection 
In vivo transfection studies were carried out as described previously [10]. Briefly, 48 
hours after polyplex application the mice were sacrificed. Prior to removal and weighing, the 
lung was washed with isotonic sodium chloride by catheterizing the arteria pulmonalis. 
Homogenization was carried out in reporter lysis buffer, followed by freezing at -20°C. 
Luciferase assay was performed and the transfection efficiencies ± SD were calculated as the 
mean value of 5 experiments and presented as pg luciferase per mg lung tissue. 
Nebulization  
The nebulization system (Figure 1) consisted of the electronic micro-pump Aeroneb 
Pro®, operated at a frequency of 0.13 MHz (Aerogen, Stierlin, CA, USA), a lung ventilator 
for mice (MiniVent, HSE-Harvard, March-Hugstetten, Germany) and numerous pipes. The 
nebulizer was connected to the lung ventilator to both facilitate aerosol transport within the 
inspiration cycle into the mouse lung, and to ensure expiration air was removed from the 
nebulization system. The nebulizer was filled with 1 ml LMWPEI polyplex solution (N/P 8) 
containing 160 µg DNA, and the aerosolization to residual volume was performed in 
approximately 30-40 minutes with an inspiration volume of 250 µl per breath and a frequency 
of 100 min-1. 
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Aerosol droplets that were deposited in the recycling compartment were collected and re-
introduced into the nebulizer reservoir. This compartment was designed by cutting a 20 ml 
syringe down to 1 cm length and inserted in the Aeroneb Pro® body. The syringe tip was 
connected to a plastic pipe, which was closed with a clamp. On opening the clamp, the 
deposited aerosol was collected into an Eppendorf tube. All nebulizations were repeated four 
times. 
 
Figure 1: Schematic of the inhalation system for aerosol treatment of mice (not to scale). 
 
Distributions of the polyplexes in the mouse lung 
To evaluate polyplex distribution in the mouse lung, polyplexes at N/P 8 were formed 
between pDNA-Alexa Fluorâ and BPEI-Oregon Greenâ or LMWPEI-Oregon Greenâ. Four 
hours post-administration the mice were sacrificed and perfused with PBS and 4% 
paraformaldehyde (PFA) in PBS via the arteria pulmonalis. The lung was then removed, and 
fixated in 4% PFA for approximately 1 hour. Lung immersion in PBS at 4°C was performed 
overnight prior to embedding in Tissue-Tekâ (Sakura Finetek, Zoeterwoude, the Netherlands) 
and flash-freezing in liquid nitrogen [32]. Cryosections (50 µm) were cut, embedded in 
FluorSaveâ (Merck Biosciences, Darmstadt, Germany) and examined under a confocal laser 
scanning microscope (Axiovertä , Zeiss CLSM 501, Jena, Germany) equipped with a Ze iss 
Neofluor 63x/1.2 water immersion objective. Simultaneous scans for Alexa Fluorâ and 
polyplex solution 
vibrating mesh 
aerosol mist 
lung  
ventilator 
inspiration 
exspiration 
recycling 
compartment 
 LMWPEI enhanced pulmonary compatibilaty  
 100 
Oregon Greenâ were performed with excitation wavelengths of 543 nm (bypass filter: 560-
615 nm) and 488 nm (bypass filter: 505-550 nm plus transmission light) respectively. A 
gallery of optical slices (0.4 µm) was collected and xz, yz composites were processed using 
Zeiss LSM 510ä  software.  
To localize gene expression in the mouse lung, LMWPEI and BPEI polyplexes (N/P 8) 
were prepared using peGFP-N1 instead of pGL3. Forty-eight hours post-administration mice 
were sacrificed and their lungs were treated using the same procedure described above. The 
localization of the GFP was also examined under the confocal laser scanning microscope 
using an excitation wavelength of 488 nm (by pass filter: 505-550 nm) and transmission light 
to achieved cell membrane visualization. A gallery of optical slices (0.4 µm) was collected 
and xz, yz composites were processed using Zeiss LSM 510ä  software 
The distribution studies of both the double labeled polyplexes and the GFP were repeated 
twice to ensure reproducibility. Controls were performed with unlabeled pGL3 and polymer. 
Statistical analysis 
Statistical calculations were carried out using the software package GraphPad InStat 
v3.06 (GraphPad Software, Inc. San Diego, CA, USA). To identify statistically significant 
differences one-way ANOVA with Bonferroni’s post test analysis was performed. 
Differences were considered significant if P = 0.05 (*) and marked accordingly in the figures. 
RESULTS AND DISCUSSION 
DNase digestion 
The ability of a gene carrier to protect DNA against enzymatic degradation by DNase I, 
which is located in the cytoplasm, can be demonstrated by DNase digestion studies [11, 33]. 
In the present work we utilized, for the first time, AFM to track the effect of DNase I upon the 
structure of PEI polyplexes. These investigations are based upon the method of Abdelhady et 
al. [18]. 
Figure 2 depicts a control study of naked DNA that has been exposed to DNase I. This 
shows that DNA fragmentation begins at around 15 minutes (Figure 2B) after the DNase 
addition, with complete fragmentation having occurred within 30 minutes (Figure 2C). Figure 
3 shows images of LMWPEI, BPEI and (PEG5k)2PEI polyplexes at certain times of the 
DNase digestion. The images observed at 0 minutes demonstrate the morphology of the 
polyplexes prior to DNase application. All three polymers fully condensed the pDNA, 
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forming spherical particles. After the application of DNase I full DNA protection was 
observed for all three polyplexes within 30 minutes. The strongest influence of DNase upon 
the polyplex morphology was observed for LMWPEI/DNA, indicating the lowest level of 
DNA protection. During the first 30 minutes, LMWPEI polyplexes tended to form aggregates. 
As the experiment progressed, the polyplex size steadily decreased and after 120 minutes of 
DNase digestion, only fragments remained. This fragmentation indicates that the enzyme is 
able to access the plasmid at the polyplex surface sufficiently to allow the accumulation at the 
DNA helix, and thus complete strand breakage. Interestingly, the degradation appeared to 
decrease the size of the particles slowly until complete fragmentation. This observation 
supports the assumption of DNA being spherically distributed throughout the polyplex.  
In contrast to LMWPEI, BPEI and (PEG5k)2PEI seemed to be able to protect the DNA 
for longer periods as the particle morphologies remaining unchanged after 90 minutes. The 
images recorded at 120 minutes after DNase application show a gradual degradation of the 
polyplexes. These findings suggest that BPEI and (PEG5k)2PEI  are able to bind the plasmid 
DNA more strongly, thus forming more stable polyplexes. These higher stabilities are in 
agreement with the observation of our previous stability studies in lung lining fluid and 
surfactant  [10]. Taken together, protection of the DNA against lung intra- and extra-cellular 
enzymes can be ranked as follow: (PEG5k)2PEI  > BPEI > LMWPEI.  
Consequently, the results of all stability studies performed suggest that DNA release from 
the gene vector is an important step for effective gene expression and too strong binding 
between DNA and PEI can reduce the transfection rate. However, polyplex stability is just 
one of many prerequisite for an effective gene delivery [14]. 
 
 
Figure 2: DNase digestion of the naked DNA. The plasmid degradation was tracked by in situ 
AFM imaging [18]. The x and y scales are 100 nm  and z scale 5 nm. 
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Figure 3: DNase digestion: Polyplexes were exposed to the DNase I over a period of 120 
minutes at 37 °C. AFM images were taken at the time zero and then at every 30 minutes. The 
x and y scales are 1 µm and z scale 30-50 nm. 
 
Polyplex toxicity in the mouse lung 
Recently, the cytotoxicity of the polymers BPEI, LMWPEI and (PEG5k)2PEI and their 
complexes with pDNA were determined by measuring the metabolic activity and membrane 
damage of treated lung epithelial cells in vitro [10]. The cytotoxic effects were shown to 
increase in the order: LMWPEI < (PEG5k)2PEI < BPEI, and furthermore the toxicity was 
found to increase at higher polymer concentrations. To investigate the compatibility of these 
vectors for pulmonary gene delivery, the effects of the polyplexes in the mouse airways were 
characterised (Figure 4 & 5). Previous reports have demonstrated a correlation between 
toxicity in the mouse lung and decreased transfection efficiency [12, 13]. Here, we have 
investigated whether lung inflammation occurred after polyplex application, an effect that, if 
observed, would provide some explanations to the discrepancies noted in our previous studies 
[10]. 
     The total protein concentration in the lining fluid of the lung can be consulted to 
characterize general alterations of the natural composition of the fluid, because proteins 
detected include enzymes, cytokines as well as immunoglobulins or other extracellular 
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proteins. As such, a significant protein increase does not necessarily indicate an inflammation 
process - the results have to be considered together with the values obtained for cell counts 
and cytokine response. Increased levels of protein (Figure 4A) were observed in the BALF for 
all investigated polyplexes when compared with DNA or glucose control. The Increase was, 
however, not significant in case of LMWPEI and BPEI polyplexes at the N/P ratio of 6. 
Considering the N/P ratios and thus the polymer concentration, increasing quantities of 
protein were observed. Comparing the three PEIs investigated, the most significant alteration 
of the lining fluid was observed for (PEG5k)2PEI/DNA at all N/P ratios employed.  
The total number of cells and polymorph-nuclear leucocytes (PMNs) present in the 
BALF are two particularly reliable indicators of lung inflammation [12]. Both measurements 
mirrored the trends observed for protein concentration. Figures 4B demonstrate that an 
increasing N/P ratio led to an influx of cells. Comparing this with Figure 4C it becomes clear 
that the increase in cell numbers was primarily due to an increase in the number of PMN. 
Both the total cell counts and the PMN recruitment increased in the order LMW < BPEI < 
(PEG5k)2PEI. By contrast to PMN, the percentage of alveolar macrophages (Figure 4D) 
decreased with increasing cell counts. These observations suggest a shift in the relative 
cellular constitution of the mouse lung from a primarily macrophage-dominated environment 
to one that was dominated by neutrophils. Large numbers of neutrophils in the lung serve as a 
source of activated oxygen species and proteolytic enzymes such as neutrophil elastase [12]. 
Therefore, the significant PMN increases observed for DNA (33 ± 11 %), LMWPEI/DNA (36 
± 10 % to 39 ± 3 %), BPEI/DNA (36 ± 10 % to 66 ± 15 %) and (PEG5k)2PEI/DNA (70 ± 6 % 
to 90 ± 6 %) compared to glucose control (0 ± 1 % PMN) suggest that acute inflammatory 
damage had occurred in the mouse lung. Furthermore, the inflammation was increasingly 
severe as higher N/P ratios were applied, probably as a consequence of the polymer excess in 
the polyplex formulation. The decrease of alveolar macrophages with increasing cell counts 
can be explained by their function as phagocytic cells of the distal lung [34]. Thus, 
macrophages may have taken up quantities of the polyplexes and DNA followed by autolysis 
or apoptosis. The degree to which macrophages and neutrophils contributed to the pulmonary 
inflammation remains unknown. More investigations are necessary in order to further clarify 
this situation, such as time scale of cytokine infiltration, inhibition of neutrophil influx into 
the lung or cytokine and superoxid anion release from macrophages [12]. 
The cytokines TNF-a and IL-2 are mediators in acute pulmonary inflammation and their 
appearance in the BALF of mice were found to be highest 24 hours post-application of gene 
vectors [8, 12]. Neutrophil influx appeared to coincide with the appearance of TNF-a and IL-
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2, indicating that these mediators play a predominant role in the infiltration of PMN [12]. Our 
aim here was to investigate whether the PEI modifications also led to TNF-a and IL-2 
response, thus causing or aggravating lung inflammation. Similar to the investigated 
inflammation parameters above, the cytokine concentrations (Figure 5) increased with 
increasing N/P ratios. These observa tions support the assumption of stronger cytotoxic effects 
upon the mouse airways due to the polymer excess at high N/P ratios. TNF-a response 
(Figure 5A) was observed in all investigated samples, even in the glucose control. It is likely 
that the stress for the mouse during the instillation caused already a TNF-a response in the 
mouse lung. However, the level of the control was still too low to initiate acute lung 
inflammation, noted previously as 0 % neutrophil infiltration. Whilst the comparison of TNF-
a  levels between the different gene vectors did not indicate significant differences, the IL-2 
concentration increased in the rang order: LMWPEI < BPEI < (PEG5k)2PEI. The results of 
the IL-2 concentrations mirrored almost exactly the results of the PMN recruitment, thus  
PMN infiltration is probably mediated predominantly by IL-2. Additionally, the observed 
protein values (Figure 4A) suggest that its increase was caused mainly by IL-2. 
These toxicity data document  severe lung inflammation when gene vectors were 
administered at high concentration. The pDNA itself, in particular under the promoter of 
CMV, has previously been reported to cause toxic side effects in numerous cells [35]. 
Considering the different PEI vectors, it was clear that the toxic effects upon the mouse 
airways increased in the order: LMWPEI < BPEI < (PEG5k)2PEI. When comparing these 
results with our previous in vitro studies [10], the low toxicity of LMWPEI could be 
confirmed. Moreover, the results provide evidence for the hypothesis of decreased 
transfection efficiency in vivo due to severe lung inflammation. 
Taken together, the LMWPEI caused the highest transfection efficiency in the mouse 
lung because of its low toxicity, which is at N/P 6 & 8 as low as that of naked DNA. BPEI 
and in particular (PEG5k)2PEI caused more severe pulmonary inflammation, in turn reducing 
transfection efficiency in the mouse lung. 
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Figure 4: Polyplex toxicity in the mouse lung: Bronchial alveolar lavage fluids were obtained 
to determine A) the protein concentration, B) the total cell counts, C) the percentage of 
polymorph-nuclear leucocytes (PMN) and D) the percentage of alveolar macrophages. Data 
are presented as mean ± SD of 3 experiments in each group. 
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Figure 5: Polyplex toxicity in the mouse lung: Bronchial alveolar lavage fluids were obtained 
to determine the cytokines concentration A) TNF-a and B) IL-2. Data are presented as mean 
± SD of 3 experiments in each group. 
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Transfection efficiency in the mouse lung 
Since poor transfection efficiency in the mouse lung for the gene vector (PEG5k)2PEI 
was obtained [10], our aim was to improve the efficiency and safety of PEGPEI vectors. In 
order to evaluate if the amount of PEG in the gene vector played a predominant role, we 
employed several modifications as pulmonary gene delivery systems, such as (PEG550)35PEI, 
mixtures of BPEI with (PEG5k)2PEI and mixtures of LMWPEI with (PEG5k)2PEI. The gene 
expressions of these vectors were studied in the mouse lung after intrapulmonary instillation, 
and compared to the previously studied BPEI, LMWPEI and (PEG5k)2PEI (Figure 6). All 
polyplexes were prepared at an N/P ratio of 8 since we had obtained the highest gene 
expression at this ratio [10].  
When administering pDNA in the absence of a carrier, a transfection efficiency of 
approximately 0.4 pg luciferase per mg lung tissue was observed. Marginally more luciferase 
was produced when polyplexes of DNA with (PEG5k)2PEI or (PEG5k)2PEI /BPEI mixtures 
were administered. Hence, these polyplexes did not cause any significant improvement in 
transgene expression. By contrast, significantly increased transfection efficiency was obtained 
when polyplexes of BPEI, LMWPEI, (PEG550)35PEI or mixtures of LMWPEI with 
(PEG5k)2PEI were administered. The improvement observed for (PEG550)35PEI suggested 
that higher grafting of BPEI with low molecular weight PEGs improved the transfection 
efficiency, whereas lower grafting with high molecular weight PEGs decreased the 
transfection rate in the mouse lung. These findings are in agreement with previous  studies [2]. 
They observed decreasing transfection efficiency in the mouse lung with increasing molecular 
weight of the PEG copolymer. Furthermore, gene expression at the level of naked plasmid 
DNA was reported for gene delivery systems formed with PEGPEI copolymers [2, 11]. 
Therefore, our findings are encouraging and (PEG550)35PEI should be considered for further 
in vivo studies, such as a coupling to targeting structures. Our results here support the 
advantages of high grafting with low molecular weight PEGs for an improved gene transfer to 
the lung. Furthermore it is worth noting that (PEG550)35PEI is the PEGPEI with the lowest 
toxicity synthesised in our laboratory [28, 36].  
Mixing LMWPEI with (PEG5k)2PEI led to an improved gene expression when compared 
with (PEG5k)2PEI alone. However, the high level of LMWPEI transfection was not achieved. 
Since (PEG5k)2PEI has been demonstrated to be more toxic than LMWPEI, this polymer 
composition is not worth studying further. Although Ogris et al. favour mixtures of PEGPEI 
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copolymers with unmodified PEI [37, 38], our results do not confirm the advantages of 
PEI/PEGPEI mixtures when applied to the mouse airways. 
 
DNA BP
EI
LM
WP
EI
(PE
G5k
)2PE
I
(PE
G55
0)35
PEI
BPE
I/(PE
G5k
)2PE
I (1:
1)
BPE
I/(PE
G5k
)2PE
I (1:
2)
LM
WP
EI/(P
EG5
k)2P
EI (
1:1)
LM
WP
EI/(P
EG5
k)2P
EI (1
:2)
0
1
2
3
4
5
6
7
8
9
10
11
12
*
*
*
*
 
lu
ci
fe
ra
se
 p
g/
m
g 
lu
ng
 ti
ss
ue
*
 
Figure 6: In vivo transfection efficiencies of several polyplexes at an N/P ratio of 8. From left 
to right: pDNA alone, BPEI, LMWPEI, (PEG5k)2PEI, (PEG550)35PEI, BPEI mixed with 
(PEG5k)2PEI (1:1) and (1:2), LMWPEI mixed with (PEG5k)2PEI (1:1) and (1:2). The in vivo 
results are presented as mean ± SD of 3-6 experiments, with statistically significant 
differences from DNA being highlighted with an asterisk (P = 0.05). 
 
Inhalation device development 
One of the most important aspects in the development of an inhalation system is the 
choice of the nebulizer itself. As discussed in the introduction to this thesis, the Aeroneb Pro® 
holds several key advantages when compared to other common air-jet and ultrasonic 
nebulizers. Furthermore, the high cost of plasmid DNA make the low residual volume 
displayed by the Aeroneb Pro® an important feature.  
Unlike humans, mice are compulsive nose-breathing animals and aerosol delivery to the 
deeper compartment of the lung is severely impaired by the physiologic function of their 
nose. Only particles of diameters < 1 µm can be efficiently inhaled and deposited in the 
deeper airways of the mouse lung [39]. Since the mass median aerodynamic diameter 
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(MMAD) of the aerosol generated by Aeroneb Pro® was found to be 4 µm (Chapter 6), the 
majority of the aerosol would be deposited in the mouse nose. In order to bypass the nasal 
passage and acquire the applied dose, we have developed a new inhalation system for mice 
(Figure 1, page 99). In this system was the animal anaesthetized and intratracheally intubated. 
Constant deep breathing was achieved by employing a lung ventilator. 
As the Aeroneb Pro® was designed for humans, it has a high output of approximately 400 
µl per minute. While humans have a tidal volume of approximately 500 ml, the lung capacity 
of a mouse is approximately 0.3 ml. Thus the output of the Aeroneb Pro® is much too high for 
the mouse, and the majority of the generated aerosol deposit underneath the nebulizer mesh. 
Therefore, we have developed an “aerosol recycling compartment” which allows the 
deposited aerosol droplets to be collected by opening a clamp. These can subsequently be 
added back into the nebulizer reservoir.  
The lung ventilator was employed to ensure uniform deep breathing, thus increasing 
deposition in the respiratory airways of the anaesthetized mouse. Results obtained from the 
first runs of the new nebulizer system indicated that short pipes are important to reduce the 
total volume between the mouse and ventilator, because a large volume caused blending of 
the inspiration and expiration air stream.  
The new system was validated by aerosolizing 99m technetium labeled isotonic sodium 
chloride solution over a period of 30 minutes into the anaesthe tized intubated mouse. By 
measuring the total counts/sec of the whole mouse lung, the aerosol deposition in the airways 
could be determined. In these experiments (n=4) we observed an aerosol deposition of 
approximately 10 µl/min (data not shown). Therefore, we calculated for the polyplex 
aerosolization that a nebulization period of 25 minutes would lead to the deposition of 40 µg 
DNA in the lung, as this was the quantity used during the intratracheal instillation. In the 
following transfection experiments mice were treated with polyplex solutions employing the 
new nebulizer system over a 30-40 minute time period, to ensure enough polyplex deposition.  
Transfection efficiency of nebulized polyplexes 
As we have previously seen and discussed (chapter 3), LMWPEI/DNA triggers enormous 
luciferase accumulation in the lung of mice (8.2 pg/mg) [10] and further reveals high 
biocompatibility. As such, we have attempted to further develop this gene vector for 
inhalation therapy. The luciferase expression of LMWPEI polyplexes in the mouse lung was 
measured post-administration via the new inhalation system (Figure 7). Unfortunately, the 
transfection efficiency in the mouse lung after the nebulization decreased dramatically and 
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ranged below the level of DNA. This finding is particularly disappointing since we had 
observed no alterations post-nebulization of LMWPEI/DNA in vitro. In terms of particle size 
(dynamic light scattering), structure (atomic force microscopy) and in vitro transfection 
(A549), the aerosolized LMWPEI polyplexes were found to be unspoiled (data not shown). 
Due to the polyplex stability observed in these in vitro experiments, we had hypothesized that 
the transfection efficiency in the mouse lung after aerosol administration should be 
comparable to that of instillation. Interestingly, many reports of the group of Densmore et al. 
documented successful gene delivery by inhalation [5, 31]. In these studies varies types of 
genes, complexed with BPEI, were expressed at high levels in the lungs of mice upon aerosol 
administration. Their experimental setup was based on a whole animal body nebulization 
chamber, which even resulted in the inhibition of tumour growth when plasmid DNA coding 
for protein p53 or cytokine IL-12 was applied with BPEI (N/P 10) [40-42]. On the other hand 
a recent report of Rudolph et al. highlighted the difficulties involved in aerosol delivery to the 
mouse lung [4]. In their experimental setup also a whole body nebulization chamber was 
utilized and large quantities of DNA (250 µg per mouse) were necessary to achieve even 
slight levels of gene expression. By interposing a spacer with silica gel between the nebulizer 
and the mouse chamber, the transfection efficiency could be increased significantly. The silica 
gel triggered the evaporation of water from the aerosol passing the spacer and thus reduced 
the droplet size. Consequently, utilizing such a silica-covered spacer in the setup of our 
nebulizer model may increase the transfection efficiency of LMWPEI polyplexes.  
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Figure 7: In vivo transfection efficiencies of pDNA and LMWPEI polyplexes post-instillation 
versus post-inhalation. The in vivo results are presented as mean ± SD of 5 experiments, with 
statistically significant differences from DNA being highlighted with an asterisk (P = 0.05). 
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It is likely that gene delivery via inhalation leads to an even distribution in the bronchial 
and alveolar regions, whilst instillation leads to the “flooding” of only a proportion of lung 
bifurcations. It was demonstrated previously, that the gene expression of numerous PEI/DNA 
complexes in primary alveolar epithelial cells ranged four magnitudes below that of primary 
bronchial epithelial cells [43]. Hence, we assume a pronounced alveolar distribution in the 
mouse lung could have reduced the transfection efficiency of the nebulized LMWPEI 
polyplexes. Therefore, we investigated both the distribution of double labeled polyplexes in 
the mouse lung and the expression of GFP after the application of LMWPEI/peGFP-N1 via 
both the instillation and the inhalation route. 
Distributions of the polyplexes in the mouse lung 
Our main objective was to find out whether the distribution of polyplexes within the 
mouse lung altered the effectivity of transgene expression. The pDNA was labeled with Alexa 
Fluorâ and subsequently complexed with the Oregon Greenâ labeled BPEI or LMWPEI. 
These polyplexes were administered to the mouse lung via instillation or inhalation (only 
LMWPEI/DNA). In order to evaluate the location of the polyplexes in the lung, cryosections 
were imaged by confocal laser scanning microscopy. Representative images are depicted in 
Figure 8, and co- localisation of the plasmid DNA (red) with the polymer (green) appeared 
yellow. Whilst aerosol administration (Figure 8C & E) resulted in a uniform fluorescent 
polyplex distribution throughout the entire lung, the polyplex instillation resulted in a mixture 
of non-fluorescing (images not shown) and fluorescing regions, as can be seen in Figures 8A, 
B, D & E. This observation might be the result of a “pooling” of polyplex solution in certain 
lung bifurcations, whilst other areas were not reached by the polyplexes during the instillation 
process. In contrast, the nebulization seems to promote a constant distribution throughout the 
entire conducting and respiratory airways. This proposed “pooling” effect observed during 
instillation of the gene vectors was also observed by others, and might cause additional stress 
to the mouse thus further aggravating lung inflammation [12]. 
Double labeled BPEI polyplexes (Figure 8A & D) were mainly localized in the bronchial 
epithelia and endothelia cells. The consideration of the bronchial tree clarifies that the 
polyplexes first passes the bronchial cells before reaching the respiratory tract. Due the highly 
positive surface of BPEI/DNA [10], it is likely, that these adhere rapidly to the cilia of the 
bronchi, and then undergo endocytosis into the bronchial epithelial cells. Our results concur 
with previous reports concerning the highly efficient gene transfer mechanism of BPEI to the 
bronchial cells when targeting the mouse lung [19, 20].  
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Unlike BPEI, LMWPEI polyplexes were equally distributed in bronchi and alveoli 
(Figure 8B & E). Furthermore, similar to BPEI/DNA, a significant distribution was observed 
in the endothelial cells. Interestingly, LMWPEI and DNA were often not co-located, which 
suggest a separation of polymer and DNA. Indeed, the images (Figure 8B & E) suggest that 
DNA was internalized into the nucleus, while LMPEI remained in the cytoplasm. We assume 
that LMWPEI polyplexes were released into the cytoplasm via endosomal swelling and 
rupture [44], followed by the release of DNA from the polyplexes. Hence it seems that the 
DNA alone passed into the nuclear core through pores, while the polymer remained in the 
cytoplasm. This finding supports our assumption that the enhanced DNA release from 
LMWPEI polyplexes is advantageous in pulmonary gene delivery [10]. Localization of DNA 
alone in the nucleus was also observed for the nebulized LMWPEI polyplexes (Figure 8C & 
F), albeit to a far lower extent.  
 
 
Figure 8: Distribution of double labeled fluorescent polyplexes in the mouse lung 4 hours 
post-administration via instillation of BPEI/DNA (A&D) or LMWPEI/DNA (B&E) and via 
nebulization of LMWPEI/DNA (C&F). Alexa Flour®-DNA is shown in red, Oregon Green®-
polymer is green and the co-localization of both results in the appearance of yellow. DNA and 
polymer were found to be localized in bronchial epithelia cells (be), alveolar epithelia (ae) 
cells and lung endothelia cells (e).  
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Images recorded after the administration of GFP encoding plasmid complexed with BPEI 
and LMWPEI respectively, (Figure 9) confirmed the findings seen for the polyplex 
distribution. The application of BPEI and LMWPEI polyplexes via instillation resulted in the 
expression of GFP in some lung bifurcations and in others not (data not shown). In the case of 
BPEI polyplexes (Figure 9A & D), the majority of GFP was produced in the bronchial cells. 
Interestingly, the few alveolar cells that were found to express GFP were type II cells. Both 
nebulized (Figure 9B & E) and instilled (Figure 9C & F) LMWPEI polyplexes caused GFP 
expression in the bronchial and alveolar epithelial cells, as well as in the endothelial cells. The 
extent of GFP expression was reduced in the case of the nebulized LMWPEI/DNA, but 
evenly distributed throughout the lung. These data suggest uniform, but low efficient gene 
delivery by aerosolized polyplexes and confirm the findings of the distribution studies with 
double-labeled polyplexes. 
Interestingly, localization of the polyplexes in both endothelial and epithelial cells was 
demonstrated for intravenous injection but not for intrapulmonary application. Goula et al. 
reported that linear PEI (22 kDa) polyplexes, when delivered intravenously, rapidly cross the 
endothelial barrier and transfect the pulmonary tissue, resulting in transgene expression in 
alveolar and bronchial epithelial as well as endothelia cells [7, 22]. Our observations suggest 
that such movements also took place when polyplexes were delivery into the airways. Uyechi 
et al. observed similar distributions for lipoplexes on administration to mice airways [21]. 
Consequently, LMWPEI polyplexes are conceivably useful tools for the creation of 
therapeutic gene delivery systems for different lung diseases [45]. For example, lung 
metastases could be a targeted because of the different cell population being attacked by 
cancer cells. 
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Figure 9: Cryosections of polyplex treated mouse lungs, illustrating the GFP expression 
determined 48 hours after the intratracheal application of BPEI/DNA (A&D) and 
LMWPEI/DNA (B&E) as well as LMWPEI/DNA post-application via the new nebulizer 
system (C&F). GFP was found to be localized in bronchial epithelia cells (be), alveolar 
epithelia cells (ae) and lung endothelia cells (e). 
 
 
Taken together, the results presented here in suggest, that the high transfection efficiency 
of LMWPEI/DNA can be explained by their low toxicity and additionally due to their gene 
expression in both conducting and respiratory airways. In contrast, the nebulization of 
LMWPEI/DNA led to very low gene expression throughout the whole lung, due to the lower 
quantity of polyplexes deposited at the airway cells.  
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CONCLUSION 
In summary, we were able to gain new sights in pulmonary gene delivery. The conflicting 
results observed for in vivo and in vitro gene expression of LMWPEI and PEGPEI polyplexes 
were also further elucidated here.  
As a consequence of the DNase digestion and previous results, we postulate, that strong 
binding between DNA and polymer is an advantage in transferring genes safely into the cells. 
However this advantage does not necessarily increase the transfection efficiency in vivo. If 
gene vectors trigger toxic side effects and/or poor distribution in the targeted organ, the 
advantages observed in vitro could be nullified. 
Pulmonary inflammation and cytokine response in polyplex treated animals was low but 
detectable for DNA and LMWPEI/DNA, more pronounced for BPEI/DNA, and most severe 
for PEGPEI. The transfection efficiency of these gene vectors in vivo has been demonstrated 
to follow the rank order LMWPEI > BPEI > PEGPEI. Thus we conclude that lung 
inflammation by high concentrations of cytotoxic PEI-based gene vectors decrease the levels 
of gene expression in the mouse lung. As the DNA and gene vectors themselves were the 
underlying source of the toxicity, it is clear that strategies to increase the safety of plasmid 
DNA and PEIs would reduce any initial pulmonary inflammation. LMWPEI/DNA caused the 
same degree of lung inflammation as DNA, hence this vector could be a step in the right 
direction.  
With a view to achieving transient and stress free inhalation gene therapy, we have 
developed an aerosol inhalation system for mice. Unfortunately, this system failed to deliver 
sufficient doses of polyplexes into the mouse lung. Although a uniform distribution and gene 
expression throughout the conducting and respiratory airways was achieved, the amount of 
polyplexes reaching the lung cells was too little. Consequently, further studies are required to 
improve the nebulization efficiency of the inhalation system. Such studies may possibly 
include aerosol drying by silica gel, since this simple method has previously been 
demonstrated to optimize PEI-based gene delivery to the lung [4]. 
The location of the BPEI polyplexes and the  resulting transgene expression were detected 
primarily in the bronchial cells of the mouse lung. In contrast, LMWPEI polyplexes gave high 
signals in both the bronchial and alveolar cells. Therefore, LMWPEI may be useful for 
obtaining therapeutic gene transfer in diseases involving all lung cell types, such as lung 
metastases or pulmonary hypertension. 
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In conclusion, the data presented here underline both the high transfection capacity of 
LMWPEI polyplexes and the relative lack of toxicity associated with their use in the mouse 
lung. Taken together, these results strengthen arguments favouring the use of this vector to 
achieve safe and efficient pulmonary gene delivery in vivo.  
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ABSTRACT 
Gene therapy aimed at the respiratory epithelium holds therapeutic potential for diseases 
such as cystic fibrosis and lung cancer. Polyethylenimine (PEI) is commonly utilized for gene 
delivery to the airways. In this study, we describe a new modification of PEI, in which a 
protein transduction domain (TAT) was covalently coupled to 25 kDa branched PEI (BPEI) 
through a heterobifunctional polyethylenglycol (PEG) spacer resulting in a TAT-PEG-PEI 
conjugate. Improved plasmid DNA complexation and protection was observed for the 
polyplexes formed between plasmid DNA and TAT-PEG-PEI/DNA. These small polyplexes 
(~ 90 nm) evidenced significantly improved stability against polyanions, Alveofact®, 
bronchial alveolar lining fluid and DNase. In order to determine the polyplex toxicity in vitro, 
MTT assays were performed. In vivo investigations were also performed, with the mice 
bronchial alveolar lavage being tested for total cell counts, quantity of neutrophils and the 
total protein and TNF-alpha concentrations. All parameters suggested significantly lower 
levels of toxicity for TAT-PEG-PEI. Transfection efficiencies of both BPEI and TAT-PEG-
PEI polyplexes with DNA were studied under in vitro conditions (A549) and in the mouse 
lung after intratracheal instillation. While luciferase expression in A549 cells was 
significantly lower for TAT-PEG-PEI/DNA (0.2 ng/mg protein) than for BPEI/DNA (2 
ng/mg), higher transfection efficiencies for TAT-PEG-PEI/DNA were detected in the mouse 
lung. Confocal laser scanning microscopy studies demonstrated that transgene expression was 
distributed through bronchial and alveolar tissue. Thus, TAT-PEG-PEI represents a new 
approach to non-viral gene carriers for lung therapy, comprising protection for plasmid DNA, 
low toxicity and significantly enhanced transfection efficiency under in vivo cond itions.  
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INTRODUCTION 
Intensive efforts have been devoted to pulmonary gene medicine trying to address 
diseases such as cystic fibrosis and lung cancer [1, 2].  Of crucial importance in this context 
are vectors or carrier systems for genetic information among which non-viral vectors based on 
polyethylenimine (PEI), have shown some promise due to their stability under in vivo 
conditions and transfection efficiency after nebulization [3]. Polyethylenglycol-grafted 
derivatives of PEI (PEG-PEI) seem to be beneficial for gene therapy of the lung due to 
reduced interactions with proteins or cells and hence lower cytotoxicity [4, 5]. Polyplexes of 
DNA and branched 25 kDa PEI (BPEI) transfected preferably bronchial cells, a feature 
considered to be important in the treatment of cystic fibrosis and lung cancer [6, 7]. Normally 
different sub-populations of lung cells are involved in pulmonary diseases. Thus, vectors 
transfecting both bronchial as well as alveolar tissue would be of general interest. 
To improve the transfection efficiency of non-viral carriers, new strategies were put 
forward to enhance cellular uptake of PEI based polyplexes, amongst which peptides 
enhancing cell adhesion and internalization reached a prominent position [8]. Peptide 
sequences, also designated as protein transduction domains (PTD) or membrane 
translocalization signals, were identified as potentially useful labels for intracellular delivery 
of proteins, oligonucleotides, plasmid DNA (pDNA) and colloidal carrier systems [9]. 
Peptides derived from the TAT protein sequence of human immune deficiency virus (HIV) 
have been reported to show unusual translocation abilities by direct crossing biological 
membranes due to its strong cell surface adherence, independent from receptors and 
temperature [10]. Recently, however, several reports have cha llenged this view, suggesting a 
cell uptake via endocytic pathways for liposomal [11] and for cationic polymer based TAT 
conjugates [12]. Chloroquin influencing adsorptive endocytosis, [13] as well as fluid-phase 
macropinocytosis [14, 15], a receptor- and caveolar-/clathrin- independent specialized form of 
endocytosis, have recently been suggested as part of the translocation mechanism. In this 
context, cell fixation techniques need to be taken into account to avoid misinterpretation of 
cell uptake studies due to artefacts [16]. 
Apart from the uptake mechanism, sequence and the structure of the PTD have been the 
subjects of intensive investigations. Basis amino acid sequences seems to play an important 
role in translocation, as demonstrated for arginine [17] or guanidine rich peptides [18, 19]. 
Higher molecular weight peptide sequences consisting of multimers enhanced only the in 
vitro transfection of PEI/DNA polyplexes, but failed in increasing the in vivo expression in 
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the mouse lung [20]. Recently, polymerisation of HIV-TAT peptides resulted in high 
molecular weight polycations which displayed elevated DNA complexation and transfection 
efficiency in vitro [13].  
Peptides derived from the TAT protein sequence of HIV type 1 have been utilized to 
deliver nanoparticles into cells. Particularly, TAT conjugates have been employed in cationic 
gene delivery vehicles, either with [21] or without [20, 22] covalent attachment to the carrier. 
Consequently, TAT peptide in combination with a PEG-PEI copolymer could be a promising 
candidate as gene delivery vehicle intended for pulmonary administration. 
Here we report the synthesis and characterization of polymer conjugates in which a 
oligopeptide sequence derived from HIV-1 TAT modified by a C-terminal cysteine residue is 
covalently coupled to BPEI using a hetero-bifunctional linker based upon PEG. The aim of 
this study was to combine the favorable characteristics of PEG-grafted BPEI with the HIV-
TAT oligopeptide to yield a vector capable of mediating gene transfection after local 
administration to the airways. Furthermore, an ideal vector in the treatment of pulmonary 
diseases such as lung cancer would be able to mediate gene transfer to both bronchial and 
alveolar epithelial cell combined with lower toxicity than BPEI. The PEG linker is intended to 
reduce unwanted interactions of the polpylex with protein, cell or other components of the 
airways, thereby providing enhanced polyplex stability and lowered toxicity. Coupling of the 
oligopeptide to the cationic BPEI should help to overcome restrictions of pure oligopeptide 
based polyplexes, such as low plasmid complexation ability [23, 24] or the decrease of their 
potential biological effects due to interaction with the complexed DNA [25]. The PEG linker, 
additionally, provides a steric shielding of the cationic BPEI core from the oligopeptide 
sequence and, thereby, facilitates the coupling reaction of the two cationic moieties. In the 
resulting TAT-PEG-PEI conjugate, the TAT sequence is separated from the  BPEI core by the 
hydrophilic PEG, thus enabling the presentation of the TAT oligopeptide moieties on the 
surface of TAT-PEG-PEI/DNA polyplexes [26].  
MATERIALS AND METHODS 
Materials 
The synthetic decapeptide sequence GRKKKRRQRC was synthesized by Bachem 
(Bubendorf, Switzerland), a-vinyl sulfone-? -N-hydroxysuccinimide ester poly(ethylene 
glycol) (NHS-PEG-VS) was purchased from Nektar Therapeutics (Huntsville, USA). The 25 
kDa branched polyethylenimine (BPEI) was a gift from BASF (Ludwigshafen, Germany). 
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The plasmid pGL3 carrying luciferase coding region under the promoter control of 
cytomegalovirus (CMV) was kindly provided by J. Hänze (Department of Molecular Biology, 
University of Giessen, Germany) and was propagated in E. coli and purified by Plasmid 
Factory (Bielefeld, Germany). Herring testes DNA was obtained from Sigma (Seelze, 
Germany). The plasmid peGFP-N1 carrying green fluorescence coding region under the 
promoter control of cytomegalovirus (CMV-N1) was kindly provided by C. Rudolph 
(Department of Pediatrics, University of Munich, Germany), was propagated in E. coli and 
purified by Plasmid Factory (Bielefeld, Germany). The natural surfactant Alveofact® was 
purchased from Boehringer-Ingelheim (Germany). Bronchial alveolar lavage fluid (BALF) 
was freshly obtained form C57BL/6 mice via intra-tracheal instillation 1 hour prior to use. For 
removal of the cells, the BALF was centrifuged at 300 g at 4°C, and the pellet was discarded. 
All other reagents used were of analytical purity.  
Activation of BPEI 
19.2 mg (565 µmol) of bifunctional PEG (3.4 kDa), containing both an a-vinyl sulfone 
and an w-N-hydroxysuccinimide ester group, was weighed into a glass flask 4.293 µl of a 
BPEI solution (corresponding to 12.15 mg/0.486 µmol BPEI; 282.4 µmol total amines) in 
0.1M borate buffer at pH 5.5 were added and stirred. The activation reaction was carried out 
for 4 hours at room temperature, followed by pH adjustment to 7 with 1N chloride acid and 
additionally incubated for 2 hours at room temperature. 
Coupling of the oligopeptide onto activated PEG-PEI 
For coupling, 2.98 mg (2.26 µmol) of the oligopeptide TAT dissolved in 866 µl pure 
water were added to the activated PEG-PEI yielding a theoretical degree of substitution of 
approximately 1% based upon amine functions. The mixture was stirred for additional 2 hours 
at room temperature.  
Purification of TAT-PEG-PEI 
Removal of unreacted PEG and low molecular weight residues was performed with an 
ultrafiltration cell (Amicon, Bedford, USA) equipped with a 10 kDa molecular weight cut-off 
membrane (Millipore, Bedford, USA) and 0.1 M borate buffer at pH 7.5 as eluent. 
Amine concentration of the conjugate was determined by a recently described copper 
assay [27]. 
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Polyplex formation 
The polyplexes consisting of plasmid DNA and either BPEI or TAT-PEG-PEI, were 
prepared in sterile isotonic glucose solution at pH 7.4 as described recently [28]. Briefly, the 
polymer solution was added rapidly to the DNA and mixed by vigorous pipetting followed by 
10-20 minutes incubation at room temperature prior to use. When various polymer nitrogen to 
DNA phosphate ratios (N/P) were investigated, the concentration of the  BPEI or TAT-PEG-
PEI solution was adjusted to the amount of DNA (20 µg/ml polyplex solution for the in vitro 
experiments and 260 µg/ml for in vivo experiments) in order to maintain N/P ratios between 
0.5 and 10.  
Ethidium bromide exclusion assay 
DNA condensation was measured by quenching of ethidium bromide (EtBr) fluorescence 
as described earlier [29]. Briefly, quadruplicates of 8 µg of herring testes DNA were 
complexed with increasing amounts of BPEI or TAT-PEG-PEI in 96-well plates in 60 mM 
Tris buffer at pH 7.4. After 10 min incubation time, 20 µl EtBr solution (0.1 mg/ml) were 
added. The fluorescence was measured on a Perkin Elmer LS 50 B fluorescence plate reader 
(Perkin Elmer, Rodgau, Germany) at ?ex = 518 nm and ?em = 605 nm. Results are given as 
relative fluorescence (rel. F) and the value of 100% is attributed to the fluorescence of DNA 
with ethidium bromide (rel. F = F sample/F DNA solution).  
Physico-chemical properties 
To study the physico-chemical properties of the polyplexes, investigations of particle 
charge, size and aggregation tendency were performed. The surface-charges were determined 
by measuring the zeta-potential in the standard capillary electrophoresis cell of a Zetasizer 
3000 HS (Malvern Instruments, Worchester, U.K.). The measurements were performed in 
isotonic glucose solution at pH 7.4 at 25 °C with automatic duration. The average values and 
the corresponding SD were calculated in three independent measurements, five runs each.  
For dynamic light scattering, polyplexes were prepared in a total volume of 50 µl with 
isotonic glucose or sodium chloride solution at pH 7.4. Polyplex size measurements were 
carried out with a Nanosizer Lo-C from Malvern Instruments (Worchester, U.K.) at 25 °C 
(HeNe laser, 633 nm). For data analysis, the viscosity (0.8905 mPa s) and refractive index 
(1.333) of pure water at 25 °C were used. Results are given as mean values of three runs of 
120 sec duration each. 
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Polyplex stability in heparin, bronchial alveolar lavage fluid and surfactant 
Increasing amounts of heparin in 10 µl pure water were added to 100 µl polyplex 
solution, yielding heparin concentrations of 0.1 to 2.0 IU per µg DNA, and incubated for 10 
minutes. 25 µl of this mixture was applied to a 1% agarose gel containing EtBr. Gels were run 
for 60 minutes at 70 V, prior to the scanning with a transilluminometer (Biometra, Göttingen, 
Germany).  
The effect of surfactant (Alveofact®) and bronchial alveolar lavage fluid (BALF) upon 
the polyplex stability was evaluated using a reverse fluorescence quenching assay [30, 31]. 
For polyp lex preparation, the amount of DNA was increased to 60 µg/ml and condensed with 
the appropriate amount of BPEI and TAT-PEG-PEI respectively, to achieve an N/P ratio of 
eight. Hundred µl of the polyplex solution were placed in 96-well plate and 50 µl EtBr (40 
µg/ml) were added. Alveofact® was dissolved in isotonic glucose solution pH 7.4 and added 
to the polyplexes to achieve final concentrations of 0.002, 0.02, 0.2, 1.0, 2.0 µg/µl. When 
stability in BALF was tested 100 µl of freshly attained BALF instead of Alveofact® was 
added to the polyplexes. The fluorescence measurement (Fluorescence reader FL600, Micro 
plate Fluorescence BioTEK, Winooski, USA) was started immediately after BALF or 
Alveofact® addition and carried out over a period of 90 minutes at 37°C using ?ex = 485 nm 
and ?em = 590 nm. The fluorescence is reported relative to the value obtained with naked 
DNA and EtBr (= 100%), as mean ± SD of five measurements. 
DNase stability assay 
Polyplexes were prepared at N/P 6 in isotonic glucose using 5 µg of DNA in a total 
volume of 25 µl, as previously described [32]. Aliquots of 5 µl corresponding to 1 µg of DNA 
were incubated with 0.01, 0.1, 1, 2.5 and 5 international units (I.U.) of DNase I in 1 µl 
digestion buffer (0.1 M sodium acetate, 5 mM MgSO4 pH 7.4) for 15 minutes at 37 °C. To 
stop the DNase digestion, 6 µl termination buffer (equal volumes of 0.5 M EDTA, 2 M NaOH 
and 0.5 M NaCl) were added, followed by 2 µl of a heparin solution containing 1000 I.U. per 
ml. To separate the polymer form DNA, the resulting mixtures were applied to a 1 % agarose 
gel and electrophoresed at 70 V for 1 hour. The resulting gel was visualized and photographed 
with a transilluminometer (Biometra, Göttingen, Germany). 
In vitro transfection 
Human lung epithelial cell line (A549) was obtained from the German Collection of 
Microorganisms and Cell Cultures and was maintained according to the supplier’s 
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specifications. To evaluate the gene expression in A549, the transfection experiments were 
carried out as previously described in detail [28]. Briefly, cells in passages 8-15 were seeded 
at a density of 25 000 cells per well on 24-well cell culture plates, 24 h prior to the 
transfection experiments. The polyplexes were prepared as described above and 100 µl 
solutions were added to each well containing 900 µl fresh medium and incubated for 4 hours. 
The medium was replaced and the cells were allowed to grow for a further 44 hours. The 
luciferase expression (luciferase assay reagent, Promega, Mannheim, Germany) and protein 
concentration (see below) were determined in the cell lysate. All experiments were performed 
in triplicate and data were expressed in ng luciferase per mg protein (± SD).  
In vivo transfection 
To study the luciferase expression in the mouse lung 150 µl polyplexes or DNA alone 
were instilled into the lung of C57BL/6 mice. The mice were purchased from Charles River 
Laboratories (Sulzfeld, Germany) aged 4-6 weeks, weighing 22-28 g. Prior to the treatment, 
the animals were hold for five days in the animal lab were they were fed regularly (Muskator 
GmbH, Düsseldorf, Germany). For intratracheal instillation, the mouse was lightly 
anesthetized with 0.06-0.08 µl mixture (1:1:3) of ketamine hydrochloride 100 mg/ml 
(Ketavet®, Pharmacia, Erlangen, Germany), Xylacine hydrochloride 2 % (Rompun®, Bayer, 
Leverkusen, Germany) and isotonic sodium chloride. Then the mouse was positioned in a 
vertical position and polyplexes were administered using a flexible needle (0.9 x 25 mm). 
Forty-eight hours after instillation the animal was sacrificed using an overdose of anesthesia. 
The mouse lung was washed with isotonic sodium chloride by catheterizing the arteria 
pulmonalis, and then the lung was removed and weighed. Per one gram of lung tissue 2 µl of 
ice cold reporter lysis buffer (Promega, Mannheim, Germany) was added, the lung was 
immediately homogenized and frozen at -20°C. After thawing, the samples were centrifuged 
for 20 minutes at 4 °C and luciferase assay was performed as described in the in vitro 
experiments. The transfection efficiencies and the corresponding SD were calculated as the 
mean value of 5 experiments and presented as pg luciferase per mg lung tissue. The use of 
animals in this study was approval by the local ethics committee for animal experimentation 
and the experiments were carried out according to the guidelines of the German law of 
protection of animal life. 
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Cytotoxic effects of polymers on lung epithelial cells  
To evaluate the toxicity of BPEI and TAT-PEG-PEI, MTT assays were performed as 
previously reported [31, 33]. A549 cells were seeded in 96-well microtiter plates at a density 
of 4200 cells per well and allowed to grow for 72 hours prior to the application of the polymer 
solution (final concentrations: 0.001, 0.01, 0.1, 0.5 and 1.0 mg/ml in cell media). After 4 
hours of incubation, the medium was replaced with 200 µl fresh medium and 20 µl (3-(4,5-
dimethylthiatol-2-yl)-2,5-diphenyl tetrazolium bromide) (MTT, Sigma, Seelze). After 4 
hours, the unreacted dye was removed and 200 µl DMSO was added. The absorption was 
measured using the ELISA reader Titertek Plus MS 212 (ICN, Eschwege, Germany) at 570 
nm, with a background correction at 690 nm. The relative cell viability (%) was related to 
control wells containing cell culture medium without polymer and was calculated by: 
absorption test x 100 % / absorption control. Data are presented as a mean of six 
measurements (± SD). The values of the polymers were fitted to a Bolzmann sigmoidal 
function using Microcal Origin® v 7.0 (OriginLab, Northampton, USA) and IC50 was 
calculated. 
Polyplex toxicity in the mouse lung 
Toxic effects of the polyplexes at an N/P ratio of 10 and of the naked DNA in the mouse 
airways were studied based upon the experiments of Gautam et al. [34, 35]. Controls were 
performed using isotonic glucose solution at pH 7.4. Animals were treated as described for in 
vivo transfection. Twenty-four hours post-administration mice were sacrificed and lavages of 
the bronchial alveolar lining fluid (BALF) were performed with ice cold phosphate buffered 
saline (PBS) pH 7.4 containing 5 mM EDTA according to the following protocol: Lungs were 
lavaged successively with 300 µl, 300 µl, 400 µl, and 8 x 500 µl PBS to achieve a total 
volume of 5.0 ml. The first three lavages were pooled separately and centrifuged at 300g. The 
supernatant was collected and the cell pellet resuspended with cell medium. The remaining 4 
ml were also centrifuged at 300g, the supernatant discarded, the cell pellet resuspended in cell 
medium, and added to the cells from the first three lavages. Total cells in the BALF were 
counted in a Neubauer hemacytometer. Polymorph-nuclear leucocytes (PMN) recruitment 
was assessed by preparing centrifuge smears and staining them with DiffQuickÒ (Dade, 
Munich, Germany) according to the manufacturer’s protocol. A quantification of total 
proteins in the BALF supernatant (1 ml) was performed based on the Bradford method using 
a standard BCA Assay Kit from Bio-Rad Laboratories (Munich, Germany) according to the 
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manufacturer’s protocol. Protein concentrations were calculated from a standard curve made 
from bovine serum albumin (BSA) in concentrations ranging from 0.2 to 2.0 mg/ml. tumor 
necrosis factor alpha (TNF-a) quantification was performed using mouse-specific 
immunoassay kits for TNF-a (R&D systems Inc., Minneapolis, USA) according to the 
manufacturers protocol. The values of the toxicity studies were calculated as mean ± SD of 
three experiments. 
Distributions of the polyplexes in the mouse lung 
Labeled DNA (pGL3-Alexa Fluorâ) was prepared as described in the manufacturer’s 
protocol for ARESâ DNA labeling kit (Molecular probes, Leiden, the Netherlands). Briefly, 
the amine-modified dUTP was incorporated in the pGL3 plasmid strand by a Nick translation, 
followed by the addition of the amine-reactive dye Alexa Fluorâ. Unreacted enzyme and dye, 
respectively, were removed from the plasmid DNA using the QIAquick PCR purification kit 
(Qiagen, Hilden, Germany). TAT-PEG-PEI was labeled using Oregon Greenâ 488 carboxyl 
acid (Molecular Probes, Leiden, the Netherlands) and labeling procedure was carried out as 
described in the manufacturer‘s protocol. 
To evaluated polyplex distribution in the mouse lung, polyplexes at N/P ratio of 10 were 
formed between pGL3-Alexa Fluorâ and TAT-PEG-PEI-Oregon Greenâ and applied to the 
mouse lung as described above. Four hours post-administration the mouse was sacrificed, and 
then perfused with PBS and then with 4% paraformaldehyde (PFA) in PBS via the arteria 
pulmonalis. The lung was removed and fixation in 4% PFA was performed for 1 hour. Lung 
immersion in PBS at 4°C was performed overnight prior to embedding in Tissue-Tekâ 
(Sakura Finetek, Zoeterwoude, the Netherlands) and flash-freezing in liquid nitrogen. 
Cryosections (50 µm) of the mouse lung were cut and embedded in FluorSaveâ (Merck 
Biosciences, Darmstadt, Germany). The distribution of the double labeled polyplexes was 
examined under a confocal laser scanning microscope (Axiovertä , Zeiss CLSM 501, Jena, 
Germany) equipped with a Zeiss Neofluor 63x/1.2 water immersion objective. Simultaneous 
scans for Alexa Fluorâ and Oregon Greenâ were carried out with an excitation wavelengths 
of 543 nm (by pass filter: 560-615 nm) and 488 nm (by pass filter: 505-550 nm and 
transmission light) respectively. A gallery of optical slices (0.4 µm) was collected and xz, yz 
composites were processed using Zeiss LSM 510ä  software.  
To localize the expression of green fluorescence protein (GFP) in the mouse lung, TAT-
PEG-PEI polyplexes (N/P 10) were prepared using pDNA encouding GFP instead of 
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luciferase, and administered to the mouse lung as described above. Forty-eight hours post-
application the mice were sacrificed and their lungs were treated in the same procedure as 
described for the distribution studies of double labeled polyplexes. The localization of the 
GFP was also examined under the confocal laser scanning microscope as described above. 
Scans for the GFP was carried out with an excitation wavelengths of 488 nm (by pass filter: 
505-550 nm) and 1 % transmission light to visualize the cell membranes and nuclei. A ga llery 
of optical slices (0.4 µm) was collected and xz, yz composites were processed using Zeiss 
LSM 510ä  software 
The distribution studies of both the double labeled polyplexes and the GFP were repeated 
twice to ensure reproducibility. Controls were performed with unlabeled pDNA and TAT-
PEG-PEI at an N/P ratio of 10. 
Statistical analysis 
Statistical calculations were carried out using the software package GraphPad InStat 
v3.06 (GraphPad Software, Inc. San Diego, CA, USA). To identify statistically significant 
differences one-way ANOVA with Bonferroni’s post test analysis was performed. 
Differences were considered significant if P = 0.05 (*) and marked accordingly in the figures. 
RESULTS AND DISCUSSION 
TAT-PEG-PEI conjugate synthesis 
The TAT-PEG-PEI conjugate is composed of a BPEI core, a 3.4 kDa PEG linker and an 
oligopeptide sequence. The two-step reaction was performed as shown in Scheme 1. 
Bifunctional NHS-PEG-VS was used to activate BPEI via the primary amine reactive w-N-
hydroxysuccinimide ester moiety at pH 5.5, thus avoiding the conjugation and cross- linking 
of the a-vinyl sulfone groups to the amine functions of BPEI, which occurs at higher pH [36]. 
1H-NMR was used to confirm that the vinyl sulfone protons remained intact (data not shown). 
Additionally, the competing hydrolysis reaction of the N-hydroxysuccinimide ester is 
suppressed at acidic pH [37]. Reaction was carried out for 4h at pH 5.5, after adjusting the pH 
to 7; the solution was stirred for additional 2 hours to allow hydrolysis of eventually 
unreacted reagent.  
The vinyl sulfone group has been reported to selectively react with sulfhydryl groups at 
neutral pH [38]. Thus, after activation of the BPEI core, the oligo-peptide containing a 
cysteine moiety at the C terminus was coupled to the a-vinyl sulfone group at pH 7. The 
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composition of the conjugates was calculated by assuming that NHS-PEG-VS completely 
coupled to BPEI (containing 581 amine functions) and that the oligopeptide TAT coupled to 
80% of the PEG blocks (only 80% of PEG blocks of NHS-PEG-VS were substituted with 
vinyl sulfone as indicated by the manufacturer). The degree of PEG substitution was 
calculated to be 2.0% for PEG and 0.8% for TAT of all amines present in BPEI.  
 
Scheme 1. Reaction scheme for the activation of BPEI with PEG vinyl sulfone followed by the 
addition of the oligopeptide TAT. 
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Ethidium bromide exclusion assay 
The quenching of ethidium bromide fluorescence was used to compare the DNA 
condensation ability of TAT-PEG-PEI versus BPEI. While free ethidium bromide shows only 
weak fluorescence, its fluorescence increases strongly when intercalated into DNA [29]. As 
shown in Figure 1, TAT-PEG-PEI displays an enhanced DNA condensation ability compared 
to the poor condensation of BPEI, both significantly improved at the N/P ratio of 3. The 
stronger DNA condensation ability may be attributed to the enhanced cationic charge density 
of the conjugate due to the cationic amino acids, which exceeds the loss of positive charges 
due to the coupling. Additionally, these results indicate that there is no significant steric 
hindrance from the PEG shielding, as it was observed for similar peptide-PEG-PEI conjugates 
[39]. Taken together, it can be assumed that the BPEI core as well as the oligopeptide plays a 
role in DNA compaction.  
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Figure 1. Ethidium bromide fluorescence quenching assay of the BPEI polyplexes and TAT-
PEG-PEI polyplexes respectively, formed with salmon testes DNA. Values are given as mean 
± SD (n = 4).  
 
Physico-chemical properties 
To determine the surface charge of the polyplexes their corresponding zeta-potentials 
were measured using laser Doppler anemometry. While naked DNA had a highly negative 
zeta-potential of -33 mV, the polyplexes displayed positive zeta-potentials due to an excess of 
the polycation. For TAT-PEG-PEI polyplexes at an N/P ratio of 8 a zeta-potential of 15 ± 3 
mV was observed, which increased to 20 ± 3 mV at an N/P ratio of 10. However, it was 
significantly lower than the zeta-potential observed for BPEI polyplexes, which displayed a 
potential of 32 mV for both N/P ratio 8 and 10. Investigations of TAT peptide oligomers and 
monomers, respectively, had shown that the complexation between TAT and pDNA leads to 
the formation of highly positive charged (~ 30-40 mV) particles [13, 20]. These observations 
suggest that the reduced positive zeta-potentials observed for the TAT-PEG-PEI/DNA was 
neither caused by BPEI or TAT alone. It is likely that both BPEI and TAT are involved in the 
DNA condensation process and, thus, BPEI as well as TAT and PEG might appear at the 
particle surface. Therefore, we assume that the PEG spacer in the TAT-PEG-PEI molecule 
contributed to surface shielding as it was described before for PEG-PEI copolymers [40, 41].  
The size of the resulting polyplexes between TAT-PEG-PEI and pDNA is shown in 
Figure 2. Depending on the preparation medium and its ionic strength, the polyplex sizes 
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ranged from 135 to 176 nm in isotonic sodium chloride and from 89 to 107 nm in isotonic 
glucose at pH 7.4. A decrease in the particle size was observed for TAT-PEG-PEI/DNA in 
glucose solution when the N/P ratio increased from 3 to 10, most likely due to the enhanced 
condensation of DNA. In sodium chloride solution, the dependency of the size from the N/P 
ratio was less pronounced. Generally, polyplexes prepared at N/P ratio of 3 displayed the 
largest size, and the polydispersity index pointed to some aggregation (data not shown). 
Generally, polyplexes prepared at low N/P ratios with neutral surface charges tend to 
aggregate. Additionally, also polyplexes prepared with excess of polymer, thus leading to 
particles with a net positive surface charges, display enhanced aggregation tendency in high 
ionic strength media [42]. To overcome both problems, a hydrophilic shielding component, 
such as PEG, is commonly introduced into the complexes to reduce aggregation [43]. It was 
recently shown that the PEG chains in PEG-PEI copolymers must have a minimum molecular 
weight of about 5 kDa to prevent complex aggregation [44]. In contrast, in the case of TAT-
PEG-PEI, a 3.4 kDa PEG chain seems to be enough for efficient aggregation prohibition, 
presumably due to the unique structure of the conjugate having two cationic moieties linked 
together with a PEG chain. As depicted in Figure 2B, the TAT-PEG-PEI polyplexes prepared 
in high ionic strength medium (150 mM NaCl) remained stable over a period of 20 minutes, 
whereas BPEI polyplexes prepared as a control showed a drastic increase in size due to 
aggregation (as confirmed by polydispersity index, data not shown).  
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Figure 2. Particle size: A) Hydrodynamic diameters of TAT-PEG-PEI polyplexes in different 
media. B) Comparison of TAT-PEG-PEI polyplexes to BPEI polyplexes in their tendency to 
form aggregates in high ionic strength medium (NaCl 150 mM at pH 7.4). 
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Zeta-potential and size of the polyplexes have been reported to be important factors in 
facilitating gene transfer in cells [45, 46]. Endocytotic uptake of particles increases with 
increasing zeta-potential, but also enhances toxic side effects due to unspecific interactions 
between the gene delivery systems and cell membranes. Therefore, efforts have been 
undertaken to shield the highly positive particle surface of BPEI polyplexes to produce gene 
carriers with lower cytotoxicity [40, 47]. The reduced zeta-potential and the absence of 
aggregate formation of TAT-PEG-PEI polyplexes indicate a certain particle surface shielding, 
providing an enhanced stability and lower cytotoxicity. Beside the complications of gene 
delivery to the lung cells, such as mucociliary clearance and phagocytosis by alveolar 
macrophages, endocytotic uptake of particles is clearly affected by their size and increases with 
decreasing diameters [48, 49]. The TAT-PEG-PEI polyplexes obtained here were small and 
stable at numerous N/P ratios in several media. Therefore, prevention of mucociliary and 
macrophage clearance can be assumed and endocytotic uptake by the epithelial cells is 
pronounced. 
Polyplex stability 
To investigate whether the enhanced condensation ability of TAT-PEG-PEI also 
enhances the protection of the complexed DNA against polyanion exchange and enzymatic 
degradation in the lung environment, the polyplexes stability were studied in the presence of 
heparin, Alveofact®, BALF and DNase I (Figure 3-5). 
The polyplexes (N/P 8) were challenged with increasing amounts of the model polyanion 
heparin (Figure 3). BPEI was able to protect pDNA against heparin exchange up to 0.2 IU 
heparin. An amount of 0.5 IU heparin resulted in a release of the DNA from the BPEI 
polyplexes. In contrast, TAT-PEG-PEI was able to complex pDNA up to 0.5 IU with only 
minor release. And 1.0 IU heparin was necessary to completely release the DNA from these 
polyplexes, indicating enhanced DNA condensation ability. 
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Figure 3. Polyplex stability in heparin: BPEI and TAT-PEG-PEI polyplexes (N/P 8) were 
challenged with increasing amounts of heparin (0.1, 0.2, 0.5, 1, 1.5, 2, IU heparin per 1 µg 
pDNA).  
 
Stability studies using Alveofact® and BALF were carried out with a reverse EtBr 
exclusion assay [31] (Figure 4). In the absence of Alveofact® and BALF both polycations 
were able to condense DNA up to a residual fluorescence of approximately 8 % (BPEI) and 5 
% (TAT-PEG-PEI), respectively. Addition of Alveofact® increased the residual fluorescence 
for both polyplexes in a concentration dependent manner. The relative fluorescence after the 
addition of 2 mg/ml Alveofact® indicated BPEI/DNA displayed a lower stability (14.1 %) 
compared to TAT-PEG-PEI polyplexes (11.8 %). The relative fluorescence of the polyplexes 
in BALF indicating DNA release from the  BPEI polyplexes increased in a linear fashion from 
8 % (0 min) up to 18.5 % relative fluorescence (90 min), while DNA liberation from the 
TAT-PEG-PEI polyplexes was negligible (1.4 % increase over the 90 min observation). 
Consequently, protection of DNA against extracellular pulmonary enzymes was more 
pronounced for TAT-PEG-PEI compared to BPEI. 
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Figure 4. BPEI and TAT-PEG-PEI polyplexes (N/P 8) were treated with increasing amount of 
Alveofact® (grey scale) and BALF (black scale), respectively. Values ± SD were determined 
in three independent measurements and depicted as percentage of max imum fluorescence 
(100 %: naked DNA). 
 
Representative image of the DNase digestion assay is shown in Figure 5. When TAT-
PEG-PEI polyplexes were incubated with increasing concentrations of DNase I over a period 
of 15 minutes, DNA digestion occurred at a concentration of 2.5 IU DNase I per 1 µg DNA. 
Further increase of DNase I concentration up to 5 IU led to the complete degradation of 
pDNA. In the case of BPEI polyplexes, DNA degradation was observed at a significantly 
lower enzyme concentration (0.1 IU DNase I per 1 µg DNA). The denser structure of the 
TAT-PEG-PEI complexes could explain these differences. The structure of DNA seems to be 
complexed more loosely in BPEI polyplexes and hence DNase I partially degraded the 
plasmid over a vast range of enzyme concentrations, whereas TAT-PEG-PEI provides a 
complete protection up to more than 1 IU DNase per 1 µg pDNA.  
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Figure 5. BPEI/DNA (lane 2-6) and TAT-PEG-PEI/DNA (lane 7-11) were challenged with 
increasing amounts of DNase I (0.01, 0.1, 1, 2.5 and 5 IU per 1 µg pDNA). Lane 1 shows 
free, undigested pDNA. 
 
Apart from the protection of pDNA against intracellular enzymes (e.g. endo/lysosome), 
also a sufficiently high stability of gene delivery systems in the extracellular environment of 
the lung seems to be essential for an efficient pulmonary gene delivery [1, 50]. Compared to 
BPEI, the stability of TAT-PEG-PEI polyplexes was significantly higher in the presence of 
high concentration of heparin, Alveofact®, BALF as well as DNase I. This improved stability 
profile of TAT-PEG-PEI/DNA against anion exchange, is indicative of increased 
complexation and condensation properties of TAT-PEG-PEI for pDNA. Similarly, Soundara 
Manickam et al. demonstrated also an improved DNA condensation utilizing a polymerized 
TAT peptide in comparison to TAT monomers [13]. PEGylation of PEI has been shown to 
prevent interactions between the polyplexes and serum cells, proteins or enzymes [4, 44]. The 
modification of BPEI with TAT-PEG may have contributed to the reduced zeta-potential and 
increased polyplex stability by steric shielding through mobile PEG chains.  
Transfection efficiency 
Plasmid DNA was complexed with BPEI or TAT-PEG-PEI at N/P ratios of 8 and 10 to 
examine the transfection efficiency in vitro (Figure 6A) and in the mouse lung (Figure 6B). 
While the transfection efficiency of TAT-PEG-PEI polyplexes in the lung epithelial cells 
A549 was shown to range far below that of BPEI, an efficacious gene expression in the 
mouse lung was achieved after administration by intratracheal instillation. At N/P ratio of 10, 
a significant improvement in gene expression mediated by the TAT-PEG-PEI carrier (12.6 pg 
luciferase/mg lung tissue) was observed in comparison to BPEI (2 pg luciferase/mg lung 
tissue).  
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Since efficient gene transfer of  non-covalently coupled TAT oligepeptides under in vitro 
was demonstrated in the literature [13, 20], we investigated whether TAT alone also mediates 
efficient gene expression in the mouse lung under in vivo conditions. Therefore, complexes 
between unmodified TAT peptide and pDNA were prepared and administered under the same 
conditions as the other polyplexes. The transfection efficiency in the mouse lung was 
negligible and ranged at background level (data not shown). This observation suggests that 
the oligopeptide alone is not sufficient to mediate transfection of lung cells under in vivo 
conditions. Numerous other studies also failed to support gene transfer by TAT oligopeptides 
(11- and 17 amino acid respectively) alone. Reduced stability of complexes and lower 
electrostatic interactions between the TAT and pDNA were put forward as explanation [22, 
51]. To overcome these problems, Soundara Manickam et al. used high molecular weight 
polymerisates of TAT to complex plasmids [13]. 
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Figure 6. Transfection efficiency of the polyplexes at N/P ratios of 8 & 10: A) luciferase 
expression in A549, B) luciferase expression in C57BL/6 mice lung. The in vivo results are 
provided as mean ± SD of five experiments and statistically significant differences from DNA 
are denoted with an asterisk (P = 0.05). 
 
To probe whether the covalent linkage between TAT and BPEI was essential for 
improved transfection efficiency of our TAT conjugate in the mouse lung, we prepared 
polyplexes between DNA and the TAT peptide fo llowed by the addition of BPEI (N/P 10), as 
described by Rudolph et al. [20]. We did not detect an improved transfection rate for 
TAT/PEI polyplexes (0.75 pg luciferase/mg lung tissue) compared with BPEI polyplexes (2 
pg luciferase/mg lung tissue), indicating that the PEG linker in the TAT-PEG-PEI conjugate 
is required to facilitate gene transfer in the mouse lung. Torchilin et al. studied the 
transfection and cell uptake of liposomes that were covalent liked to TAT oligopeptide and 
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postulated that the peptide increases the cell membrane permeability only if it is attached to 
the liposome membrane and accessible for cell surface interaction [52]. In contrast to our 
results, Rudolph et al. demonstrated that covalent linkage is not necessary to improve the 
efficiency of a TAT vector [20]. They obtained a 390-fold transfection rate increase when a 
mixture of BPEI with a TAT dimer was studied in vitro; however, no significant improvement 
could be detected in vivo. The different TAT structures used in our (GRKKKRRQRC) and 
Rudolph`s study (dimeric C(YGRKKRRQRRRG)2) might explain these conflicting results.  
The in vivo transfection results obtained with TAT-PEG-PEI polyplexes demonstrated 
unexpected differences of a ca. 600% higher transfection efficiency compared to BPEI which 
is not reflected in the in vitro experiments. Similar discrepancies were reported before for 
both TAT-DNA and chitosan-DNA polyplexes [51, 53]. The success or failure of a gene 
delivery system to mediate gene expression in the lung may be related to cell membrane 
specific differences and extracellular environment. Thus, the multidimensional tissue 
structure of the lung and extra-cellular protein/enzyme network reveal difficulties in 
extrapolation of in vitro results to successful gene delivery into the complex lung systems 
[54]. Furthermore, aggregated particles have been reported to increase transfection efficiency 
in cell culture, simply by sedimentation onto the cell surface [55]. As shown above, BPEI 
polyplexes formed aggregates in sodium chloride and these large aggregates easily sediment 
on the surface of cells in culture resulting in improved cell uptake. In contrast much less of 
the small and stable TAT-PEG-PEI polyplexes could reach the cell surfaces at the bottom of 
the well plates, resulting in lower in vitro gene expression compared to BPEI. 
A significant increase in transfection efficiency was observed for TAT-PEG-PEI 
polyplexes in comparison to TAT/PEI polyplexes under in vivo conditions, suggesting that 
covalent coupling of TAT to BPEI via PEG led to significant advantages in mediating 
efficient gene delivery into lung epithelial cells of mice. Recent studies also reported that in 
both, polyplexes and liposomes, consisting of pDNA and TAT, the peptide needs to be freely 
accessible for cell membrane interactions [13, 22, 56]. It is tempting to speculate that the PEG 
spacer between TAT and BPEI provides both, shielding of the highly cationic  BPEI surface 
charge and free, un-hindered interaction for TAT with the cell membrane. The high gene 
expression in vivo and the enhanced DNA condensation as well as the protection by TAT-
PEG-PEI led us to the conclusion, that TAT is involved in both, the DNA compactation 
process and the cell uptake. A schematic representation of the gene delivery system reflecting 
our results is depicted in scheme 2.  
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Scheme 2. Schematic pattern of the interactions between TAT-PEG-PEI and pDNA forming 
polyplexes, and the interaction of those with cell membranes. 
 
Toxicity 
The metabolic and mitochondrial activity of polymer treated cells was determined using 
the colorimetric MTT-assay [57]. As illustrated in Figure 7A, the toxicity of the polymers was 
concentration dependent. Whilst BPEI reduced the cell viability dramatically at 
concentrations of 0.01 mg/ml (~ 23 % viability), TAT-PEG-PEI showed less influence upon 
the cells (~ 70 % viability). Considering the IC50 values (BPEI: 0.071 mg/ml, and TAT-PEG-
PEI: 0.2 mg/ml), the reduction in metabolic activity is far lower with TAT-PEG-PEI 
compared to BPEI. Less toxic effects were also reported for both monomer and polymerized 
TAT oligopeptides in comparison to BPEI polyplexes [13]. In general, in vitro studies of 
PTDs have demonstrated their non-toxicity in numerous cell lines [58]. Furthermore, 
modification of BPEI with PEG led to a reduction of toxic side effects in vitro as well as in 
vivo [40, 47, 50]. Hence, we assume that the TAT peptide as well as the PEG shielding 
together are responsible for the reduced in vitro cytotoxicity.  
The total numbers of cells in the BALF, as well as polymorph-nuclear leucocytes (PMN), 
are two reliable hallmarks of lung inflammation [35, 59]. The cell counts (Figure 7B) of BPEI 
 Chapter 5  
   140 
polyplexes treated lungs was higher than that of both DNA and glucose control. In contrast, 
TAT-PEG-PEI polyplexes did not cause significantly higher cell counts in the BALF.  
PMN (Figure 7B) were not observed after the application of glucose control, indicating 
that the isotonic solution did not provoke neutrophil infiltration into the lung and thus no 
inflammatory process was activated. DNA and both polyplex formulations caused an 
increased PMN recruitment indicating a slight inflammation in the mouse lung. Whereas 
BPEI polyplexes displayed a significantly higher PMN recruitment (66 ± 15 % of the entire 
cell population) compared to plasmid DNA (33 ± 11%), TAT-PEG-PEI polyplexes (47 ± 17 
%) did not increase the PMN proportion significantly. 
The total protein concentration (Figure 7C) in BALF characterizes general alterations of 
the natural composition of the lining fluid and detects enzymes, cytokines as well as other 
proteins. Thus, significant increases in the protein concentrations do not necessarily suggest 
an inflammation reaction. These results have to be considered in conjunction with PMN and 
cell counts. The amount of protein measured in the BALF generally mirrored the trends 
observed for cell counts, although the differences between polyplexes and both DNA and 
glucose was more pronounced. Significant increased levels of protein were observed in the 
BALF for both BPEI and TAT-PEG-PEI polyplexes when compared with pDNA and glucose 
control. However, the values obtained for total cell counts and PMN indicated that the acute 
inflammatory reaction caused by TAT-PEG-PEI/DNA is not significantly different from 
DNA, in contrast to BPEI/DNA. Therefore we assume that the high protein level of TAT-
PEG-PEI/DNA might be the result of other mediators, such as interleukins, which were not 
measured here in. 
Cytokine response to aerosol delivery of BPEI polyplexes has also been documented 
[34]. Hence, our aim was to investigate whether TAT-PEG-PEI polyplexes delivered to the 
mouse lung led to a TNF-a response, as mediator of an acute inflammatory reaction. Whilst 
the TNF-a level (Figure 7D) was significantly increased after administration of BPEI 
polyplexes, TAT-PEG-PEI polyplexes did not cause a significant increased in TNF-a level. 
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Figure 7. Toxicity studies: A) Cytotoxic effects of the polymers at concentrations of 0.001, 
0.01, 0.1, 0.5, and 1.0 mg/ml on A549 cells were determined by MTT assay and presented as 
the relative cell viability (mean ± SD of six determinations). Indicators of pulmonary 
inflammation (mean ± SD of three experiments) in the BALF 24 hour post-application of 
polyplexes (N/P 10) in the mouse lung: B) Total cell number (grey scale) and PMN number 
(black scale), C) Total protein concentration, D) TNF-a concentration. 
 
Taken together, the toxicity data indicate inflammatory reactions almost at the level of 
naked DNA when TAT-PEG-PEI was administered in the mouse lung. Plasmid DNA itself, in 
particular under the promoter of CMV, has been reported to cause toxic side effects in 
numerous cells [60]. The inflammatory mediator and indicators studied here were 
significantly higher for BPEI than for TAT-PEG-PEI. Therefore, TAT-PEG-PEI represents a 
more suitable gene carrier and thus an improvement to the common used BPEI in respect of 
toxicity in the lung. These in vivo results as well as the in vitro results are in line with 
previous reports, where low cytotoxicity for TAT peptides and TAT modified liposomes was 
reported [13, 52].  
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Distributions of the polyplexes in the mouse lung 
The final aim of our study was to localize the polyplex distribution 4 hours post-
administration and the site of gene expression 48 hours post-administration. In this attempt, 
double-labeled TAT-PEG-PEI polyplexes were applied to the mouse lung and the polyplex 
location in the lung was evaluated. Well aware of the problems involved in cell fixation 
causing artefacts, which have been reported to influence the cell entry of TAT oligopeptides 
[16], we used cryosections obtained by paraformaldehyde fixation via the endothelial route. 
Representative confocal laser scanning microscopy images are shown in Figure 8A & B. The 
pDNA (red) and the polymer (green) were mainly co- localized, seen as yellow overlapping. 
The double- labeled polyplexes were localized in the bronchial epithelia cells, since those are 
the first cells to come to pass on the way in the deeper respiratory tract (Figure 8A). More 
interesting, polyplexes could also be observed in the alveolar region (Figure 8B). Images 
taken post-administration of GFP coding plasmid complexed with TAT-PEG-PEI confirmed 
these findings, since GFP was observed in both the bronchial as well as the alveolar epithelia 
cells (Figure 8C & D). These findings indicate successful gene transfer followed by transgene 
expression in the conducting as well as respiratory airways.  
Until now, it was demonstrated that BPEI polyplexes are capable of targeting bronchial 
cells [6, 7], which could be confirmed by our studies (data not shown). In contrast, TAT- 
PEG-PEI was able to mediate transfection to bronchial as well as alveolar cells. It is likely, 
that BPEI/DNA polyplexes, due to their highly positive surface charge and aggregation, 
“stick” at the bronchial ciliated cells and are unable the reach the respiratory tract. By 
contrast, the small, shielded particles of TAT-PEG-PEI/DNA are able to pass the bronchial 
region, hence depositing also in the alveolar region. Due to the larger surface area of the 
alveolar sacs, a more extensive transfection of lung tissue was achieved.  
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Figure 8. Polyplex distribution in the mouse lung: Localization of double-labeled TAT-PEG-
PEI/DNA 4 hours post-application in A) bronchial and C) alveolar cells. Localization of the 
GFP expression 48 hours post-administration in B) bronchial and D) alveolar epithelial cells. 
(a) indicates alveolar region, (b) indicates bronchial region. 
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CONCLUSION 
In summary, TAT-PEG-PEI conjugates are a new delivery system for pDNA to the lung 
that displays several beneficial features in comparison to unmodified BPEI: (i) The use of 
TAT-PEG-PEI led to enhanced polyplex stability and DNA protection in pulmonary 
environment. (ii) The zeta-potential of the TAT-PEG-PEI polyplexes was reduced due to PEG 
shielding of the surface charge, leading to decreased aggregation tendency in high ionic 
strength media. (iii) The lower surface charge and the PEG shielding also significantly 
reduced cytotoxicity in the lung epithelial cells in both in vitro and in vivo studies. (iv) TAT-
PEG-PEI/DNA demonstrated a 600% increase in transfection efficiency in vivo when 
compared to BPEI. (v) TAT-PEG-PEI directed pDNA into the epithelial cells of the bronchi 
and alveoli. 
The enhanced transfection efficiency under in vivo conditions is most likely due to the 
increased DNA condensation, the improved polyplex stability and the TAT mediated cell 
uptake. The PEG spacer seems to be essential for both the enhanced gene expression and the 
reduced toxicity. Further experiments explo ring the polyplex composition and the uptake 
mechanism are currently under way in our laboratory.  
Taken collectively, these data suggest that TAT-PEG-PEI could be an interesting 
pulmonary delivery system for pDNA, potentially offering new treatment modalities for a 
variety of lung diseases, depending on the cell population to be targeted. TAT-PEG-PEI 
offers the possibility of transfecting both alveolar and bronchial tissue through inhalation. 
Non-viral gene delivery systems, such as PEI, have not reached the same transfection 
efficiencies as viral vectors, but this study demonstrates that potential modifications of 
polycations have not yet been exhausted. TAT-PEG-PEI may provide an interesting addition 
to the spectrum of polycationic delivery systems since it enhances gene expression in 
conducting and respiratory airways, and also improves the biocompatibility and polyplex 
stability in the extra and intra-cellular lung environment, features which are highly sought 
after in a gene carrier system for local therapy to the lung. 
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ABSTRACT 
Pulmonary arterial hypertension (PAH) is a severe and progressive disease. The treatment 
with the aerosolized prostacyclin analogue iloprost presents an approved therapeutic approach 
with 6-9 inhalations per day, indicating the need of a sustained release formulation. 
Liposomal formulations consisted of dipalmitoyl-phosphatidylcholin (DPPC), cholesterol 
(CH) and polyethylenglycol-dipalmitoyl-phosphatidylethanolamin (DPPE-PEG) were 
prepared. Their physico-chemical properties were investigated using techniques such as 
dynamic light scattering, atomic force microscopy and differential scanning calorimetry. 
Their stabilities during aerosolization using three different types of nebulizers (air-jet, 
ultrasonic and electronic micro pump) were investigated by means of drug loading and 
particle size, pre- and post-nebulization. Depending upon the lipid components diameters of 
approximately 200-400 nm were observed. The highest drug loading (12µg/ml iloprost) 
combined with high liposomal stability (70% drug encapsulation post-nebulization) was 
observed for the DPPC/CH liposomes. The relatively high phase transition temperature 
(53°C) and unchanged particle sizes confirmed their high stability. The incorporation of 
DPPE-PEG in the liposomes resulted in decreased stability (20-50% drug encapsulation post-
nebulization) and 28°C lower phase transition temperature. The electronic micro pump 
offered a number of significant advantages over the other nebulizers including the production 
of small aerosol droplets (~ 4µm), high output and the lowest deleterious physical influence 
upon all investigated liposomes. Iloprost-loaded liposomes containing DPPC and CH display 
a novel formulation, which is well suited to aerosolization by the electronic micro pump, and 
offers considerable promise as sustained release formulation for the treatment of PAH. 
 
 Iloprost-containing liposomes  
 151 
INTRODUCTION 
Pulmonary arterial hypertension (PAH) is a disease that both severely confines the life 
quality of the patient and has a poor prognosis for survival. The disease pattern is 
characterized by an increased pulmonary arterial pressure due to vasoconstriction, 
hypertrophy and intimal fibrosis [1, 2]. Two drugs are currently available for use in the 
treatment  of the advanced state of PAH (NYHA III & IV): the oral endothelin-antagonist 
Bosentan®, and intravenous, subcutaneous, oral or inhalative prostacyclin and its analogues 
[3].  
Over the past decade intravenous prostacyclin (Eprostenol®) has been the therapy of 
choice for patients with PAH [4]. Prostacyclin is a short- living vasodilator, which acts to 
modestly reduce both the patient’s systemic blood pressure and the mean pulmonary arterial 
pressure [5]. Prostacyclin’s most potent effect seems to be through positive inotropism, by 
raising the cardiac output [6]. However, the long-term use of intravenous prostacyclin has 
potential for side effects, such as marked flushing, diarrhoea, thrombocytopenia and 
unremitting foot pain [7]. Additionally, the continuous venous catheter infusions of drug 
significantly increase the risk of potentially life-threatening infections in the patient. 
While prostacyclin is clearly a potent and efficacious drug for the treatment of PAH, the 
relative severity of the side-effects led to the development of prostacyclin analogues. As such 
iloprost (Ventavis®), which was recently approved by the EMEA for inhalative treatment of 
PAH, minimises the systemic side effects and can be administered as aerosol in lower doses 
to the patient’s lung [8]. Long-term treatment of nebulized iloprost was demonstrated to cause 
strong pulmonary vasodilatation and decompensate right heart failure. Furthermore, this non-
invasiveness permits improved patience compliance. Unfortunately, the short half- life 
requires frequent inhalation, ranging from six up to twelve times a day [9]. Therefore, a 
sustained-release formulation for iloprost would be desirable. 
Currently, two types of nebulizer can be used in medical aerosolization - air-jet or 
ultrasonic nebulizers. Air-jet nebulizers are based on the venturi principle, whereas ultrasonic 
nebulizers use the converse piezoelectric effect to convert alternating current to high-
frequency acoustic energy [10]. Both types of nebulizer offer various advantages and 
disadvantages. The main disadvantages of air-jet nebulizers are the lower output, and the 
deleterious effect upon some drug formulations as a result of the high shear forces applied 
during nebulization. Ultrasonic energy is notorious for altering or damaging some aerosolized 
drug substances [10, 11]. A new nebulizer technology is the electronic micro pump, whose 
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operation is based upon the electric oscillation of a cavity disc. The predominant advantage of 
electronic micro pumps is that the drug solution is transported  directly through the cavity disc 
and does not re-enter the liquid compartment as  is the case in standard ultrasonic and air-jet 
nebulizers [12]. 
Pulmonary administration of aerosolized liposomes represents a valid alternative route 
for the treatment of lung disorders via topical drug delivery [13-15]. The advantages of such 
an administration route are numerous, and include the facilitated administration of sustained-
release formulations to maintain therapeutic drug levels in the lungs, aqueous compatibility 
and facilitated intracellular delivery [16]. In this respect a major challenge is the liposomes 
membrane stability during the aerosolization, since shear forces (air-jet) and high frequencies 
(ultrasonic) can alter the nebulizing content. Considering the alternative therapeutic 
application, reduced side effects of inhaled iloprost and the formulations stability, we have 
developed novel liposomal formulations as potential iloprost carriers for the efficacious 
aerosol therapy of PAH. 
The aim of this study was to investigate the physicochemical characteristics of lipid-
based nanoparticles in order to assess their suitability as inhalative iloprost carriers. This was 
achieved by preparing and studying a number of liposomes, containing carboxyfluorescein as 
a model drug and in a second experimental series containing iloprost. The lipids used for 
these formulations were dipalmitoyl-phosphatidylcholin (DPPC), cholesterol (CH) and 
[methoxy (polyethylglycol)-2000]-dipalmitoyl-phosphatidylethanolamin (DPPE-PEG) [17]. 
All formulations were characterized in terms of their ability to encapsulate the drug, stability 
during air-jet, ultrasonic and micro-pump nebulization, size (by dynamic light scattering), 
morphology (using atomic force microscopy) and thermotropic behaviour (employing 
differential scanning calorimetry). Furthermore, the nebulizers PariBoy® (air-jet), Optineb® 
(ultrasonic) and Aeroneb® (electric micro pump) were characterized by means of their output 
(by loss of weight) and aerosol particle size (using laser light diffraction) when nebulizing 
liposome dispersions.  
MATERIALS AND METHODS 
Materials 
The lipids dipalmitoyl-phosphatidylcholin (DPPC), cholesteol (CH) and [methoxy 
(polyethylenglycol)-2000]-dipalmitoyl-phosphatidylethanolamin (DPPE-PEG) were 
purchased from Avestin (Ottawa, Canada). 5(6)-carboxyfluorescein (COF) was purchased 
 Iloprost-containing liposomes  
 153 
from Fluka BioChemika (Neu-Ulm, Germany). 3H-labeled iloprost and iloprost trometamol 
(ILO) as well as the chromatographic column and the Sephadex 50 medium gel were 
purchased from Amersham Bioscience (Freiburg, Germany). 
Liposome preparation 
DPPC/CH liposomes (PC) were prepared at a molar ratio of 70:30 and DPPC/CH/PEG 
liposomes (PCP) at a molar ratio of 50:45:5. The corresponding quantities of lipids were 
dissolved in a chloroform methanol mixture (70:30). A thin lipid film was created by rotary 
evaporation at 60 °C under reduced pressure, and subsequently dried for further 60 minutes in 
a vacuum cabinet [18]. This film was rehydrated with the drug solution to reach a total lipid 
concentration of 3.15 mg/ml (5 mM). The solution medium for the COF containing liposomes 
was PBS buffer (pH 7.4) and the final drug concentration was 10 mg COF/ml (26.5 mM). The 
drug solution for iloprost loaded liposomes were prepared by diluting 3H-labeled iloprost with 
iloprost trometamol at a ratio of 1:500 in either PBS buffer (pH 7.4) or 0.1 M acetate buffer 
(pH 4.7) and a final drug concentration of 0.25 mg iloprost/ml (2.75 mM) was used. For drug 
encapsulation the rehydrated film was rotated at 60 °C for 2 hours and, after cooling, was 
stored for one hour at 4°C. The size of the resulted large multilamellar vesicles was reduced 
by extruding the liposomal dispersion through a 400 nm polycarbonate membrane filter 
(Liposofast, Avestin, Ottawa, Canada) 21 times at the same operating temperature employed 
during the hydration process [19]. The samples obtained were allowed to stabilize for 24 
hours at 4°C. Non-encapsulated COF was separated from the liposomes using gel 
chromatography (FPLC AEKTA prime, Amersham Pharmacia Biotech, Freiburg, Germany) 
packed with Sephadex G-50 medium gel in a 25 cm column at a flow rate of 1.0 ml/min. The 
non-encapsulated iloprost/3H-iloprost was removed from the liposomal dispersion by three-
time centrifugation and resuspension. 
All experiments described here were carried out three times using freshly prepared lipid 
preparations.  
Nebulization 
The nebulization of 4 ml liposomal preparation was carried out for 10 minutes. The 
liposomes were aerosolized at 10 l/min airflow rate using the electronic micro pump 
Aeroneb®, operated with a frequency of 0.13 MHz (Aerogen, Stierlin, CA, USA), the 
ultrasonic nebulizer Optineb® (Nebutec, Elsenfeld, Germany) operated with a frequency of 
2.4 MHz and the air-jet nebulizer Pari LC® star (Pari, Starnberg, Germany) operated with the 
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Pari Boy® compressor. The nebulized samples were collected by aerosol deposition on a glass 
plate and subsequent collection in 1.5 ml Eppendorf tubes.  
Physico-chemical properties of the nebulizer output 
The mass median aerodynamic diameters (MMAD) of the aerosol droplets produced from 
the different nebulizers when filled with liposomal dispersion or isotonic sodium solution 
were determined using laser light scattering (Sympatec, Clausthal-Zellerfeld, Germany). The 
measurements were performed with aerosol concentrations of 5 to 30 %, in 6 runs of 5 ms 
duration each and analyzed in MIE mode. The density of the aqueous dispersion and solution 
respectively, was set equal that of pure water and thus the MMAD is equal the volume 
aerodynamic diameter. The geometric standard deviation (GSD) was calculated from the laser 
diffraction values according to the following equation: GSD = v 84 % undersize / 16 % 
undersize.  
To calculate the nebulizer mass output, the nebulizers were weighed before and after each 
aerosolization experiment. The resulting difference in weight was used to calculate the mass 
output in µg per minute.  
Atomic force microscopy 
All experiments were performed using a DI multimode atomic force microscope 
equipped with a Nanoscope IIIa controller (Veeco, Santa Barbara, CA).  The instrument was 
equipped with an E-scanner with a maximum scan size of 13 µm x 13 µm.  Images were 
collected in Tapping Mode, using oxide sharpened silicon nitride cantilevers (Veeco, Santa 
Barbara, CA) operating at resonant frequencies of approximately 8 kHz. All images were 
recorded with 512 x 512 pixel resolution. Scan speeds varied between applications. To reduce 
sample distortion, all data were acquired using optimum set-points and drive amplitudes 
aimed at minimising tip-sample interaction. Gains and scan-rate were continually adjusted to 
optimize the data obtained. Post- imaging analysis was carried out on NanoScope IIIa™ 
software, version 5.12b48.  
Dynamic light scattering  
The hydrodynamic diameters of the non-nebulized and nebulized liposomes were 
measured using a Zetasizer 3000 HS (10 mW HeNe laser, 633 nm) from Malvern Instruments 
(Worcestershire, UK). The scattered light was detected at a 90° angle through a 100 µm 
pinhole. Measurements were performed at count rates between 100 and 300 kCps, at 25°C in 
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5 runs of 60 sec duration each and analyzed in CONTIN mode. The instrument was calibrated 
with nanosphere size standards (polymer microspheres in water, 220 nm +/- 6 nm) from Duke 
Scientific (Palo Alto, CA, USA). 
Differential scanning calorimetry 
Phase transition temperatures of the lipids and the liposomal formulations, respectively, 
were determined using a differential scanning calorimeter (DSC7, PerkinElmer, Rodgau-
Jügesheim, Germany). A 5 mg sample of the lipid powders or the COF loaded liposomes 
were sealed in standard aluminium pans and scanned in two heating/cooling cycles at a rate of 
10 °C/min from -20 °C to 95 °C in a nitrogen atmosphere. Data from the first scan were 
always discarded to avoid mixing artefacts. The phase transition temperatures (Tc) were 
calculated using the Pyris Software (PerkinElmer, Rodgau-Jügesheim, Germany).  
Drug loading efficiency  
The quantity of drug encapsulated pre- and post-nebulization was evaluated by measuring 
the total drug (Dtotal) and the non-encapsulated drug (Dfree) concentration.  
The drug loading of the liposomes containing the model drug COF was determined 
fluorometrically (Fluoreszenzreader FL600, Microplate Fluorescence BioTEK, Winooski, 
USA) [18]. Primarily, aliquots of 100 µl COF loaded liposomes were diluted 100 times with 
PBS buffer (pH 7.4) and samples of 100 µl were placed in a 96 black well plate to measure 
the concentration of free COF. For lipid membrane lyses, further 100 µl of the diluted 
liposomes were diluted 10 times with Triton X-100 1% / PBS and incubated under agitation 
(100 r/min) for 10 minutes. Hundred µl samples of the lysed liposomes were placed in a 96-
well plate to measure the total COF concentration. The amount of free and total COF was 
determined fluorometrically at an excitation wavelength of 485 nm and an emission 
wavelength of 530 nm. The calibration curve was prepared with COF concentrations between 
1 and 2000 ng/ml in both PBS buffer (pH 7.4) and Triton X-100 1% / PBS.  
During the second investigation series the drug loading of the iloprost containing 
liposomes was determined by radioactivity measurements. In order to evaluate the quantity of 
non-encapsulated iloprost, liposome dispersions were centrifuged for 30 min at 15,000g and 
the supernatant collected. Aliquots (250 µl) of the supernatant and the non-centrifuged 
liposomes, respectively, were transferred into separate 6 ml polyethylene vials prior to the 
addition of 5 ml aliquots of the Ultima GoldÒ scintillation cocktail (Packard Bioscience, 
Rodgau-Jügesheim, Germany). The radio activities of all samples were determined in a 
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Tricarb 2100 (Packard Bioscience, Rodgau-Jügesheim, Germany) liquid scintillation counter 
with a pre-count delay of 60 sec and a count time of five minutes per sample. A calibration 
curve was prepared with iloprost concentrations between 0.01 and 500 µg/ml in both PBS 
buffer (pH 7.4) and acetate buffer (pH 4.7). For counter calibration 3H Standards (Packard 
Bioscience, Rodgau-Jügesheim, Germany) were measured before each run. 
The encapsulation efficiency (EE) of the liposomal preparations was calculated by 
comparing the concentration of encapsulated drug (Dencap = Dtotal - Dfree) to the quantity of 
drug (Dstart ) present in the liposomal dispersion prior to the removal of the non-encapsulated 
drug:  
EE [%] = 100 % * (Dtotal - Dfree) / Dstart   
 
To evaluate the nebulization stability the percentage of encapsulated drug (Dencap), pre- 
and post-nebulization, was calcula ted by comparing the amount of encapsulated drug (Dtotal - 
Dfree) to that of total drug concentration (Dtotal):  
Dencap [%] = 100 % * (Dtotal - Dfree) / Dtotal 
Statistical analysis 
Statistical calculations were carried out using the software package GraphPad InStat 
v3.06 (GraphPad Software, Inc. San Diego, CA, USA). All values are presented as the mean ±  
standard deviation (SD) unless otherwise stated. The average values of all measurements were 
calculated from three freshly prepared liposomal formulations, and three runs each 
preparation. To identify statistically significant differences one-way ANOVA with 
Bonferroni’s post test analysis was performed. Probability values p < 0.05 were considered 
significant and marked with an asterisk in the figures. 
RESULTS 
All liposomal formulations investigated in this study are listed in Table 1. A series of 
COF loaded liposomes were initially prepared in order to evaluate a stable formulation 
suitable to undergo nebulization. Besides the listed lipid combinations several other 
formulations were investigated, using the components Dimyristoyl-Phosphatidylcholin and 
Stearylamine. However, formulations incorporating these components exhibited very poor 
stabilities during nebulization (~ 10 % encapsulated drug post-aerosolization) and low drug 
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loading efficiencies (~ 0.5 %) (data not shown). Hence the more stable PC and PCP liposomes 
were chosen for the preparation of iloprost containing drug delivery systems. 
 
Table 1. Terms and lipid components (mM) of liposomal formulations used throughout this 
study. PC denotes DPPC/CH liposomes (molar ratio 70:30) and PCP denotes 
DPPC/CH/DPPE-PEG liposomes (molar ratio 50:45:5). The second term COF and ILO, 
respectively, denotes the drug encapsulated in the liposomes. The term 4.7 indicates the use of 
acetate buffer pH 4.7 as dispersion medium, if no number is used in the term, the liposomes 
were prepared in PBS buffer pH 7.4. 
liposome term 
components 
PC-COF PCP-
COF 
PC-ILO PCP-
ILO 
PC4.7-
ILO 
PCP4.7-
ILO 
dipalmitoyl-
phosphatidylcholin 
(DPPC) 
 
3.5 
 
2.5 
 
3.5 
 
2.5 
 
3.5 
 
2.5 
cholesterol (CH) 1.5 2.25 1.5 2.25 1.5 2.25 
[methoxy 
(polyethylenglycol)-
2000]-dipalmitoyl-
phosphatidylethanol-
amin (DPPE-PEG) 
  
0.25 
  
0.25 
  
0.25 
Carboxyfluorescein 
(COF) in PBS,  
pH 7.4 
26.5 26.5     
Iloprost (ILO) in 
PBS, pH 7.4 
  2.75 2.75   
ILO in acetate buffer,  
pH 4.7 
    2.75 2.75 
 
Physico-chemical properties of the nebulizer output 
The aerosols produced by the three nebulizers were characterized, and the results are 
summarized in Table 2. For these experiments isotonic sodium chloride solution and COF 
loaded liposomes were nebulized. Apart from the increased MMAD of the air-jet nebulized 
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PCP-COF liposomes none of the nebulizers showed significant differences regarding MMAD, 
GSD or mass output when PC, PCP liposomes or sodium chloride were aerosolized in 
comparison. The MMADs of the aerosols were approximately 4 µm for all three investigated 
nebulizers. The differences in MMADs and GSDs between the nebulizers were negligible. 
Significant differences were observed when comparing the GSD values of Aeroneb® to that of 
Pari LC®. This means the droplet size range of the Aeroneb® is smaller than that of Pari LC®.  
The mass output (which dictates the total delivered dose) was approximately 400 mg per 
minute for both the Optineb® and the Aeroneb® and approximately 100 mg per minute for the 
air-jet nebulizer Pari LC®. 
 
Table 2. Aerosol Characterization: Mass median aerodynamic diameter (MMAD), geometric 
standard deviation (GSD) and mass output of the nebulizer, aerosolizing COF loaded PC and 
PCP liposomes or isotonic sodium chloride solution. Statistically significant differences 
between sodium chloride and liposomes nebulization are marked by an asterisk. 
 Aeroneb® Optineb® Pari LC® 
MMAD [µm] 
 PC 
 
4.3 ± 0.04 
 
4.1 ± 0.42 
 
4.5 ± 0.23 
 PCP 4.3 ± 0.28 4.6 ± 0.41 4.6 ± 0.12 * 
 NaCl 4.3 ± 0.21 4.0 ± 0.36 4.3 ± 0.06 
GSD 
 PC 
 
1.8 ± 0.04 
 
1.9 ± 0.14 
 
2.1 ± 0.13 
 PCP 1.9 ± 0.05 2.0 ± 0.05 2.1 ± 0.03 
 NaCl 1.8 ± 0.09 1.9 ± 0.07 2.0 ± 0.1 
output [mg/min] 
 PC 
 
375 ± 31 
 
382 ± 21 
 
110 ± 13 
 PCP 401 ± 18 395 ± 15 98 ± 18 
 NaCl 390 ± 22 398 ± 30 101 ± 25 
 
Liposome morphology  
Liposome morphologies when loaded with COF were determined by AFM and 
representative images are shown in Figure 1. Image A & B (three dimension) display PC 
liposomes as predominantly smooth spherical particles. The liposome diameters varied from 
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approximately 100 nm to 500 nm. However, despite the high concentration of liposomes in 
the relatively small area under observation, no merging was observed over the imaging period 
of two hours. In contrast, imaging the PCP liposomes was problematic due to the tendency of 
these liposomes to coalesce. The diameters of the PCP liposomes, obtained from AFM images 
(Figure 1C & D) captured soon after the application of liposomes to the silicon surface, 
ranged from approximately 200 nm to 300 nm. Whilst the liposome surface was not as 
smooth as seen for the PC liposomes, they still existed as spherical particles in a narrow size 
range. 
 
 
Figure 1. AFM Images showing the morphology of COF containing PC (A & B) and PCP 
liposomes (C & D) in two dimensions and three dimensions, respectively. The size bars 
represent 500 nm in the images. 
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Size and polydispersity of nebulized and non-nebulized liposomes 
The hydrodynamic diameters and the polydispersity index (PDI) of COF loaded 
liposomes (Figure 2) and iloprost loaded liposomes (Figure 3) were determined using DLS 
pre- and post-nebulization. Both the COF loaded and the iloprost loaded PCP liposomes were 
shown to be significantly smaller than the PC liposomes. The PDI as a dimension of particle 
uniformity was approximately 0.15 for all non-nebulized PCP liposomes. This indicates that 
PCP liposomes exhibit a greater degree of uniformity than the PC liposomes, which displayed 
a polydispersity index of approximately 0.3.  
The diameter of the non-nebulized PC-COF liposomes was approximately 400 nm, while 
the PCP-COF liposomes exhibited diameters of approximately 225 nm. A significant decrease 
in hydrodynamic diameter and polydispersity was observed for both the Pari LC®-nebulized 
and the Optineb®-nebulized PC-COF liposomes, but in the case of the Aeroneb®-nebulized 
PC-COF liposomes such a decrease was not apparent.  
When compared to the COF loaded liposomes, the iloprost loaded liposomes exhibited 
slightly different physical properties. Whereas the PC-ILO liposomes were approximately 380 
nm in diameter (PDI ~ 0.3), the PCP-ILO liposomes were around 275 nm (PDI ~ 0.17). Using 
PBS buffer (pH 7.4) or acetate buffer (pH 4.7) as dispersion medium for the preparation of 
ILO liposomes did not appear to have a major influence upon these physical properties. Apart 
from air-jet nebulized PC-ILO liposomes, the hydrodynamic diameter of all iloprost 
liposomes decreased significantly as a consequence of the nebulization process. Furthermore, 
nebulization appeared to influence the polydispersity of the iloprost loaded liposomes to a 
greater extent than that of the COF loaded liposomes. 
 Iloprost-containing liposomes  
 161 
non-nebulized Aeroneb Optineb Pari LC
0
50
100
150
200
250
300
350
400
450
500
*
*
*
hy
dr
od
in
am
ic
 d
ia
m
et
er
 (n
m
)
 PC  PCP
*
A
non-nebulized Aeroneb Optineb Pari LC
0,00
0,05
0,10
0,15
0,20
0,25
0,30
0,35
0,40
0,45
0,50
*
*
po
ly
di
sp
er
si
ty
 in
de
x
 PC  PCP
*
B
 
Figure 2. Size (A) and polydispersity index (B) of the non-nebulized and nebulized COF 
loaded liposomes measured by DLS.  The mean particle sizes are given as z-average in nm ± 
SD and were determined by measuring 3 samples and repeating the measurement 5 times. 
Significant differences (p = 0.05) between pre- and post-nebulized liposomes are marked with 
an asterisk. 
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Figure 3. Size and polydispersity index of the non-nebulized and nebulized iloprost loaded 
liposomes measured by DLS. The mean particle sizes are given as z-average in nm ± SD and 
were determined by measuring 3 samples and repeating the measurement 5 times and 
significant differences (p = 0.05) between pre- and post-nebulized liposomes are marked with 
an asterisk. 
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Transition temperature 
The phase transition temperate (Tc) of the lipids and the COF loaded PC/PCP liposomes 
were determined using DSC and the values are displayed in Table 3. For the powdered lipid 
mixtures investigated here, phase transitions for each separate lipid could be identified, 
whereas for the liposomal formulations just one Tc could be observed, indicating the uniform 
distribution of the lipids throughout the bilayer membranes [20]. The phase transition of PC 
liposomes (Tc ~ 53 °C) appeared at a much higher temperature than observed with the PCP 
liposomes (Tc ~ 35 °C). 
 
Table 3. Phase transition temperatures (Tc) of COF liposomes and lipid components 
determined by DSC. The values are given as mean of three measurement ± SD. 
lipids liposomes Tc in °C 
 PC-COF 52.8 ± 0.8 
 PCP-COF 35.3 ± 0.6 
DPPC  41.6 ± 0.3 
CH  76.0 ± 0.5 
DPPE-PEG  35.1 ± 1.0 
 
COF and iloprost encapsulation 
The percentages of drug encapsulated in the different liposomes are presented in Table 4. 
High encapsulation efficiency (4.6 %) was observed with the PC-COF liposomes, whilst the 
figure was lower for the PCP-COF liposomes (1.6 %).  
Loading the PC liposomes with iloprost instead of COF led to a decreased encapsulation 
efficiency of 1.7 %. However, when the iloprost loaded PC liposomes were prepared with 
acetate buffer (pH 4.7) in place of PBS (pH 7.4), the loading efficiency increased 
considerably to 4.4 %. Loading the PCP liposomes with iloprost an encapsulation efficiency 
of 0.6 % was obtained using the common PBS or acetate buffer. 
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Table 4. Drug loading of the different liposomes: Encapsulation efficiency of COF and 
iloprost in liposomes in percent of the total quantity of drug initially used. Quantity of iloprost 
loaded in the liposomal formulations in µg/ml. 
 
Liposomal 
formulation 
drug loading 
efficiency  
COF liposomes [%] 
drug loading 
efficiency  
iloprost liposomes [%] 
drug loading 
iloprost 
liposomes [µg/ml] 
PC 4.6 ± 0.3 1.7 ± 0.5 4.2 ± 1.2 
PC4.7  4.4 ± 0.3 11.0 ± 0.7 
PCP 1.6 ± 0.6 0.6 ± 0.08 1.4 ± 0.3 
PCP4.7  0.6 ± 0.1 1.7 ± 0.5 
 
Stability of COF liposomes 
The percentage of COF encapsulated in the non-nebulized and nebulized liposomes refers 
to the total amount of drug in the dispersion, are presented in Figure 4. The PC-COF 
liposomes were considerably more stable than the PCP-COF liposomes during the 
nebulization process. Pre-nebulization, 99 % of COF was encapsulated in the PC-COF 
liposomes. During the nebulization process, the proportion of encapsulated COF decreased to 
70 %, with no significant differences being observed between the three different nebulization 
methods. In the case of the PCP-COF liposomes, also 99 % of COF was encapsulated pre-
nebulization. However, less than a half of this remained within the liposomes post-
nebulization (47 % post-Aeroneb®, 45 % post-Optineb® and 39 % post-Pari®). 
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Figure 4. Percentage of COF encapsulated in the liposomes: 100 % represents the total 
quantity of COF in the liposomal dispersion. Significant differences (p = 0.05) between pre- 
and post-nebulized liposomes are marked with an asterisk. 
Stability of iloprost liposomes 
The proportions of iloprost encapsulated within the nebulized and non-nebulized 
liposomes are detailed in Figure 5. Similar to the PC-COF liposomes, the PC-ILO liposomes 
displayed an improved stability during the nebulization process when compared to the PCP 
liposomes. Altering the dispersion medium did not appear to lead to significant differences in 
the stability. A proportion of 98 % of encapsulated iloprost was observed in the non-nebulized 
PC-ILO liposomes. During the nebulization process this figure decreased to ~70 % for the 
Aeroneb® and the Optineb® nebulizers and to approximately 50 % for the Pari LC® nebulizer. 
The encapsulated iloprost within the PCP liposomes decreased from approximately 85 % pre-
nebulization to 45 % post-Aeroneb®, 30 % post-Optineb® and 20 % post-Pari® nebulization. 
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Figure 5. Percentage of iloprost encapsulated in the liposomes: 100 % represents the total 
quantity of iloprost in the liposomal dispersion. Significant differences (p = 0.05) between 
pre- and post-nebulized liposomes are marked with an asterisk. 
DISCUSSION 
In order to successfully treat PAH with iloprost it is vital that the drug is delivered to the 
alveolar region of the lung at a therapeutically effective concentration. Because the intraacinar 
pulmonary arteries are tightly surrounded by alveolar surfaces, it is possible to vasodilate 
these vessels by alveolar deposition of iloprost [21]. In general, aerosol droplets of 1-5 µm are 
considered optimal for penetrating to the lower respiratory tract [22, 23]. Particles of this size 
have been demonstrated to deposit in the lung via gravimentational sedimentation, inertial 
impactation or by diffusion into terminal alveoli by Brownian motion [24]. As such, the 
selection of the most suitable aerosolization device is a vitally important consideration. In this 
study we have investigated three types of nebulizer as prospective devices for the 
aerosolization of iloprost loaded liposomes. The air-jet nebulizer Pari LC® is a commonly 
used nebulizer and has been the focus of several studies concerning the delivery of drugs and 
lipid- or polymer-based nanoparticles [10, 25-27]. Ultrasonic nebulizers, such as the 
Optineb®, have also been employed for the aerosolization of several drugs, liposomes, 
nanoparticles and DNA-complexes [28-31]. The Aeroneb® nebulizer has been used for the 
nebulization of liposomal formulations and has shown a significantly improved drug output 
when compared to the standard air-jet nebulizer [32]. The studies presented here indicate that 
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the three nebulizers are able to generate small aerosol droplets of both sodium chloride 
solutions and liposomal dispersions. As such, a substantial deposition of aerosol particles to 
the alveolar region can be assumed. The drug output of the Aeroneb® and Optineb® nebulizers 
were approximately 4 times higher than that of the Pari LC®. This represents a significant 
advantage when considering patient compliance for clinical purposes, since the inhalation 
time for a patient would be significantly reduced when using the Aeroneb® or the Optineb®. 
Suitable drug delivery systems for the PAH therapy must satisfy several requirements, 
such as efficient drug loading, stability during aerosolization and small particle size. Hence, 
the aim of this study was to develop liposomal formulations that efficiently encapsulate 
iloprost, and show little or no alterations in particle size and drug encapsulation post-
nebulization. To satisfy these requirements, the components used for the liposomal 
formulations play a predominant role. It has been reported that two major factors control the 
liposomal membrane stability, both of which are related to structural discontinuities and 
membrane defects in the lipid bilayer [33]. It was demonstrated that the utilization of long 
chain saturated acyl chains such as DPPC combined with optimal levels of CH in the 
liposomal membrane act to minimize both types of membrane defect, and the lipid bilayer is 
presented homogeneously [34]. Thus, using DPPC and CH appears to encourage the 
formation of more stable liposomes with regard to reduced permeability and increased 
liposome elasticity. Furthermore, the integration of grafted PEG lipids in the liposomal 
formulation (at a molar concentration of 5 to 7 %) reportedly increases liposomal stability in 
biological systems and decreases macrophage clearance [33, 35].  
The lipid compositions used throughout this work were carefully selected by considering 
both our need for stable liposomes suitable for inhalation therapy, and previous findings from 
the literature. With regards to the liposome structure, thermotropic behaviour, size and 
encapsulation efficiency, the PC liposomes did indeed achieve our expectations. However, the 
PCP liposomes did not. This is discussed at length below.  
The phase transition temperature (Tc) is particularly important when considering 
liposomal stability. Whereas below the Tc most lipids exist in a gel phase with hydrocarbon 
chains in a parallel order, above the Tc the lipids are conversed to the liquid crystalline phase. 
At the Tc the carbon chains disorder and defects in the lipid membrane occur. It has 
previously been demonstrated that phospholipids with Tc values greater than body 
temperature form more stable liposomes than those with lower Tc [36, 37]. Therefore, we 
expected to produce stable liposomes as a consequence of the high concentrations of DPPC 
(Tc ~ 41 °C) and CH (Tc ~ 76 °C) present in both liposomal formulations investigated. 
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However, we obtained an unexpectedly low value of approximately 35°C for the PCP 
liposomes and a much higher Tc of circa 53°C for the PC liposomes.  
It is well known that numerous variables can influence the thermotropic behaviour of a 
lipid system. These include the interactions of foreign molecules (such as drugs or salt) with 
the bilayer, and the interactions between the lipid molecules themselves [20, 38]. As such, we 
believe that the incorporation of DPPE-PEG into the liposomal membrane brought about 
some change within the lipid bilayer, to such an extent that structural discontinuities or 
membrane defects occurred. This disordered membrane acted to lower the Tc as less energy 
was required to achieve transition. Membrane defects could also explain the poor stability of 
the PCP liposomal formulations observed during the nebulization. This finding is in 
agreement with a number of other studies that reported a decrease in stability as the liposomes 
Tc declined [20, 37-39]. In addition, our AFM images revealed the PC liposomes exhibited a 
smoother particle surface in comparison to the PCP liposomes, which may indicate a change 
in the bilayer structure. 
Substances that are transported into the respiratory tract undergo two major clearance 
processes, the mucociliary and the alveolar macrophage clearance. Thus, the lung represents a 
particularly challenging system for the successful delivery and cellular uptake of liposomes. 
Particles of diameter larger than 5 µm are deposited mainly in the upper airways and 
bronchioles, and are hence susceptible to removal by the beating cilia. In order to prevent this, 
both the liposome and aerosol particulate diameters play important roles. A compromise must be 
found between the drug loading efficiency (which is enhanced with increasing liposomal size) 
and transport to the lower airways (which increases with decreasing particle diameter) [40]. The 
liposome diameters reported here were adjusted to 400 nm by extrusion. The hydrodynamic 
diameter observed for the PC liposomes were found to range around the adjusted size. The 
nebulization of those liposomes appeared to have little effect on the hydrodynamic diameter, 
particularly when using the Aeroneb®. Such a marginal alteration in the liposome size indicates a 
high stability of the PC liposomes during the nebulization process, which in turn is in agreement 
with the high phase Tc of these liposomes. In the case of the PCP liposomes, we observed a 
hydrodynamic diameter approximately 150 nm below the adjusted size of 400 nm. Such 
phenomenon has been reported before and smaller liposome sizes than the actual filter pore 
diameters were obtained when preparing eggPC/CH liposomes [19, 29]. When PCP-COF 
liposomes were nebulized, there was no size alteration observed. For the iloprost loaded PCP 
liposomes, nebulization using the Aeroneb® apparatus again encouraged minimal alteration in 
particle size and polydispersity measurements. This is a strong indication that the electric micro 
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pump Aeroneb® offers far milder aerosolization conditions in comparison to the ultrasonic or air-
jet nebulizers.  
The brought size range of the PC liposomes might be explained when considering the Tc. 
Taylor et al. reported for DPPC/CH liposomes: below the Tc in the presence of CH, 
phospholipid chains are more mobile and elastic than in the absence of CH as the CH prevents 
the hydrocarbon chain crystallising into the rigid crystalline gel phase [20]. In the present study 
the liposomal size adjustment by extrusion was performed at 60 °C, which is just above the Tc of 
PC liposomes. As such, the size extrusion process of the PC liposomes may well have been 
affected by the more elastic bilayer that would have existed at that temperature. Hence, rather 
than simply having any excess bilayers excoriated from the outer surface of the liposome, these 
more elastic liposomes will undergo some oval deformation whilst passing through the filter 
pores [20]. However, this does not occur with the PCP liposomes probably due to the membrane 
discontinuities resulting form DPPE-PEG incorporation, and extrusion of these liposomes 
resulted in particle sizes smaller than the adjusted 400 nm. 
Carboxyfluorescein is a commonly used model drug for the investigation of liposomal 
formulations loaded with hydrophilic compounds [25, 41]. Therefore, we selected COF in order 
to evaluate suitable formulations for further studies with the 3H-labeled iloprost. PC-COF 
liposomes offered relatively high encapsulation efficiency and their stability during 
aerosolization was significantly better than the PCP-COF liposomes. When PC liposomes were 
loaded with iloprost at pH 7.4 the encapsulation efficiency dropped. However when these 
liposomes were loaded with iloprost at pH 4.7, they regained their high encapsulation efficiency 
and they retained their good stability during nebulization. Iloprost has a pKa value of 4.7, 
indicating that at pH 4.7, 50 % of iloprost exists in the uncharged form whilst 50 % carries a 
proton. An acetate buffer with a pH close to the drug’s pKa was selected for the iloprost 
encapsulation as the uncharged iloprost is more lipophilic and can be better incorporated into the 
bilayers. This method allowed us to develop an efficient iloprost loading procedure for PC 
liposomes. In general the remarkable lower encapsulation efficiency of PCP liposomes in 
comparison to PC liposomes might be related to the membrane defects in the lipid bilayers. 
Since the DPPE-PEG affected the lipid packing of the bilayer, the PCP liposome’s Tc decreased 
remarkable and the drug loss increased significantly. 
The moderate encapsulation efficiency of 1.6 % observed when COF was introduced into 
the PCP liposomes was not obtained when iloprost was encapsulated, even when the pH 4.7 
acetate buffer was used, the efficiency ranged below 1 %. We believe a feasible explanation for 
this observation is that the hydrophilic PEG chains, which arise from the presence of DPPE-PEG 
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lipid in the formulation, extend into the liposomes aqueous interior. As such, the encapsulation 
efficiency of hydrophilic substances such as COF is enhanced in comparison to more 
amphiphilic molecules like iloprost (log P O/W = 1.6) [42].  
The improved stability alongside the diminished drug loading of the PC liposomes is in 
agreement with a number of previous reports concerning liposomes containing DPPC and CH 
[39, 40]. As discussed above, we expected that the PCP liposomes would be stable during the 
nebulization process. However, these liposomes lost approximately double the quantity of drug 
when compared to the PC liposomes. The review by Lasic et al. concerning the integration of 
DPPE-PEG lipids in liposome bilayer implies that from a biological viewpoint, there is an 
increase in stability when these components are present within the formulation, whilst the 
increase in bilayer leakage caused by DPPE-PEG integration can be viewed as a decrease in 
stability [40]. This confirms our findings of low stability of PCP liposomes during 
nebulization.  
PEG-ylated liposomes are currently used in numerous intravenous formulations, 
however, to the best of our knowledge, they have not yet been used in inhalation therapy. 
From the findings presented herein it can be concluded that PEG-ylated liposomes consisting 
of DPPC, CH and DPPE-PEG (in a molar ratio of 50:45:5) are not suitable for aerosolization, 
due to the high drug loss observed during nebulization. 
Traditionally, air-jet nebulization has been employed to administer liposomes to the lung, 
but the high shear stresses generated during this process can cause the release of the drug 
encapsulated in the liposomes [43]. Desai et al reported a drug release of up to 50 % when 
ciprofloxacin or salbutanol containing liposomes were nebulized using the Pari LC® apparatus  
[44]. These results are comparable with our findings in the case of the PCP liposomes. 
However, the drug losses observed when nebulizing the PC liposomes with the Pari LC® 
apparatus were smaller, indicating these liposomes are a more convenient formulation for 
inhalation therapy.  
An increased damage caused by the ultrasonic nebulizer in comparison to air-jet has 
previously been reported [29, 45]. Here we observed the opposite, both liposomal 
formulations displayed a higher stability when using the ultrasonic nebulizer Optineb® in 
comparison to the air-jet nebulizer Pari LC®. A probably explanation for this controversial 
results is, that in the Optineb® apparatus the ultrasonic waves are not directly meet the drug 
content, they first have to pass a water contact medium. Hence the heating in our ultrasonic 
nebulizer is much reduced compared to the most commercial ultrasonic nebulizers. Therefore, 
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the Optineb® displays a more suitable aerosolizer than the majority of common used 
ultrasonic nebulizers.  
We observed both the highest liposomal drug loss and alteration of particle size when the 
Pari LC® was employed for the liposomal aerosolization. The smallest loss of encapsulated 
drug was observed for PC liposomes when aerosolized with the Aeroneb®, making this the 
most stable formulation/nebulizer combination. Furthermore, the use of this nebulizer did not 
alter the hydrodynamic diameter of PC liposomes. A recent report also suggested the 
Aeroneb® apparatus is most suitable for the nebulization of sensitive drug compounds, such as 
proteins or peptides [32]. The authors pointed out that in contrast to common ultrasonic 
nebulizers, the temperature increase in the Aeroneb® is minimized because of the lower 
operating frequency and the energy required for nebulization is applied to the vibrational 
element rather than to the drug solution.  
Liposomal aerosols have proven to be non-toxic in human and animal studies [46, 47]. In 
contrast to the rapid clearance of soluble drug from the lung, 50–60 % of phosphatidylcholine 
liposomes are retained in the lung for up to 24 hours after inhalation [48, 49]. Beside this, in 
the treatment of PAH patients a daily dose of inhaled iloprost is approximately 30 µg. Those 
are distributed into 6-12 inhalations per day due to the short half live of iloprost [1]. Here we 
have developed a liposomal formulation (PC4.7) containing 12 µg iloprost per ml. Assuming 
the liposomes are both retained for 24 hours in the lung and release all of the iloprost over this 
period of time, PAH patients would have to inhale 2.5 to 3 ml iloprost loaded PC liposomes 
once a day. 
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CONCLUSION 
We conclude that iloprost encapsulated in liposomal formulation consisting of DPPC/CH 
(molar ratio 70:30) has the potential to become an effective sustained release drug delivery 
system for the inhalation therapy of PAH. Furthermore, we have observed improved 
liposomal stability, high mass output and small aerosol droplets when the ultrasonic or the 
electric micro pump nebulizer was employed. Additionally, the Aeroneb® features several 
other practical advantages as previously reported: it is small, portable, battery operated and 
leaves a, minimal residual volume [50]. Therefore, the nebulizer of choice for the application 
of iloprost liposomes should be the Aeroneb®. Further studies are required to prove the 
pharmacokinetics of liposomal drug release in vitro and in vivo, and will be performed in our 
laboratory. 
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SUMMARY AND PERSPECTIVES 
This thesis describes the development and characterization of a variety of polymeric and 
liposomal drug delivery systems for use in pulmonary aerosol therapy. A variety of 
polyethylenimines (PEIs) were studied in depth in an attempt to develop biocompatible gene 
vectors for efficient non-viral gene therapy for the lung (Chapter 2-5). Another study (Chapter 
6) investigates a number of lipid-based nanoparticles that were specifically designed to act as 
sustained release formulations for pulmonary drug delivery.   
The investigations presented in Chapter 2 form the foundations of this thesis by 
evaluating the general suitability of PEI as a gene vector in an aerosol therapy. Four different 
PEI modifications (branched, linear, polyethylenglycol-grafted and biodegradable PEI) 
copolymer were utilized as carriers for plasmid DNA (pDNA), with the resulting polyplexes 
displaying diameters of approximately 100 nm. These were extensively characterized with 
respect to identifying any structural and /or physico-chemical alterations that occurred during 
aerosolization with both air-jet and ultrasonic nebulizer. A number of techniques including 
atomic force microscopy (AFM), dynamic light scattering (DLS) and laser Doppler 
anemometry (LDA) were employed to determine the various morphologies, diameters and 
zeta-potentials of the polyplexes pre- and post-aerosolization. The PEI modifications  and 
displaying stronger DNA condensation were shown to form more stable polyplexes, due to 
the reduced level of damage observed post- aerosolization. The poly (ethylene glycol) PEI 
copolymer (PEGPEI) was shown to have the superior carrier properties regarding DNA 
condensation and protection. Furthermore, our results suggested that improved stability for 
PEI/DNA polyplexes can be attained using the  ultrasonic nebulizer in preference to the air-jet 
apparatus. Thus, we concluded that ultrasonic nebulization is a milder aerosolization method 
for PEI-based gene delivery systems. Additionally, PEGPEI appeared to display the most 
promising properties as a pulmonary gene carrier, due to its stability. Therefore, we decided 
to employ the PEGPEI copolymer in addition to the commonly used branched 25 kDa PEI 
(BPEI) in the subsequent studies. 
Our primary aim in Chapter 3 was the development of a gene vector that achieves both 
high transgene expression and biocompatibility in the pulmonary epithelium. To accomplish 
this aim,  a low molecular weight (5 kDa) PEI (LMWPEI) and a PEGPEI copolymer were 
employed as pDNA vectors and compared with the commonly utilized BPEI. Investigations 
of the polyplex morphologies (using AFM), sizes (by DLS) and zeta-potentials (using LDA) 
revealed that all three polymers are able to condense pDNA, forming small, positively 
charged particles of approximately 100 nm diameter.  Cytotoxicity studies, performed using 
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the MTT- and LDH-assay, indicated LMWPEI had the superior biocompatibility of the three 
polymers investigated. The transfection efficiencies of the three polyplexes were studied both 
in vitro (cell cultured lung epithelia) and in vivo (intratracheally instillation to the mouse 
lung). Whilst LMWPEI polyplexes were shown to be inefficient in transfecting lung epithelial 
cells in vitro, they caused the highest transfection rate in the mouse lung. Interestingly, the  
opposite behaviour was observed when PEGPEI polyplexes were investigated, with a high 
gene expression in vitro not being reproduced in vivo. We hypothesized that the polyplexes 
relative stability in the lung environment might explain this observation. In order to 
investigate the polyplex stability, natural lung lining fluid and lung surfactant were utilized, 
and a decreasing trend of DNA encapsulation in the order: PEGPEI > BPEI > LMWPEI was 
observed. Therefore, we concluded that stronger interactions between the carrier and the 
pDNA may hinder the DNA release under in vivo conditions, thus reducing the transfection 
efficiency. Our results indicated that LMWPEI fulfils the key requirements of low 
cytotoxicity and high gene expression in the mouse lung. 
Based upon the promising results of Chapter 3 the biocompatibility of LMWPEI/DNA in 
the mouse lung was further investigated, and the results are presented in Chapter 4. 
Polyplexes were applied via instillation, and after 48 hours lung lavages were performed. The 
bronchial alveolar lining fluid (BALF) obtained was subsequently investigated for total cell 
counts, quantity of neutrophils and macrophages as well as total protein and cytokine 
concentrations. These parameters are hallmarks of acute lung inflammation, and increased 
values were observed for all investigated systems in comparison to the control mice. In the 
case of pDNA and LMWPEI/DNA, only minor alterations were detected whereas BPEI/DNA 
caused stronger inflammation and surprisingly PEGPEI/DNA led to the most severe 
inflammation. When considering these findings together with the transfection results obtained 
in vivo (Chapter 3), we concluded that increasing cytotoxicity in the mouse lung (LMWPEI < 
BPEI < PEGPEI) causes decreasing transfection efficiency (LMWPEI > BPEI > PEGPEI). As 
such, LMWPEI was chosen as our preferred pDNA carrier for inhalation therapy. In parallel 
to this work, we developed a novel aerosol inhalation device for mice. Unfortunately, the 
transfection rate in the mouse lung decreased dramatically post- LMWPEI/DNA 
aerosolization in comparison to the instilled polyplexes. In an attempt to identify the reasons  
for this failure, we employed double- labeled polyplexes in order to compare the lung 
distribution of inhaled versus instilled polyplexes. The nebulized LMWPEI polyplexes were 
shown to be uniformly localized throughout the mouse lung in small quantities. In contrast, 
the instilled polyplexes were detected in much higher concentrations, in bronchial and 
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alveolar regions, but were not evenly distributed. Interestingly, polyplexes were observed in 
epithelial and endothelial cells. Consequently, LMWPEI represents a highly efficient and 
biocompatible gene vector for the lung and is superior to the more commonly used BPEI. 
Another study (Chapter 5) describes the development and characterisation of a novel 
gene vector that is based upon BPEI covalently linked to a TAT peptide (a protein 
transduction domain) via a PEG spacer. The oligopeptide TAT was chosen to enhance cell 
uptake into lung cells, since reports had demonstrated high translocation ability of TAT by 
direct crossing biological membranes. In keeping with the two previous studies, the TAT-
PEG-PEI conjugate was extensively investigated in terms of DNA condensation, DNA 
protection in the intra- and extracellular lung environment, polyplex size, stability, zeta-
potential, in vitro and in vivo toxicity, transfection efficiency and polyplex distribution in the 
mouse lung. Since our key aim had been to develop a non-toxic, highly efficient carrier for 
the epithelial cells of the conducting and respiratory airways, this new carrier fulfilled the 
majority of our requirements. It was able to form very small and stable particles with pDNA. 
A ~600% improved gene expression in the mouse lung was observed for TAT-PEG-PEI 
polyplexes in comparison to BPEI and a ~300% improved gene expression in comparison to 
LMWPEI. Furthermore, only minor effects upon the lung function were observed, with no 
additional inflammation compared to pDNA instillation alone. A particular advantage of this 
carrier is its ability to transport DNA safely into the different cell types of the lung. Hence, it 
could be employed in the treatment of pulmonary diseases that attack the entire lung, such as 
lung cancer.   
Consequently, the TAT-PEG-PEI conjugate and to a lower extend also LMWPEI 
represent promising new approaches in pulmonary gene therapy of various lung disorders. 
Further work is necessary to decrease the cytotoxicity to a level where no inflammation is 
observed. This might be achieved by using either a highly branched PEGPEI copolymer or a 
LMWPEI in place of BPEI for the synthesis of TAT-PEG-PEI. Since a number of recent 
studies have reported conflicting results regarding the cellular uptake and pathway of TAT 
peptides, a study should be performed in order to track the pathway of TAT-PEG-PEI 
polyplexes into the cells and nucleus. Further work should focus on the development of a cell 
specific gene vector for pulmonary gene therapy. In this respect, the synthesis of LMWPEI 
modifications carrying target moieties such as lectin, folate, peptides (e.g. RGD) or antibodies 
would be of particular interest. The next major set of experiments should focus on the 
delivery of therapeutic genes such as IL-12, p53, prostacyclin or nitric oxide synthase, via 
optimized TAT-PEG-PEI or LMWPEI vehicles.  Additionally, the challenge of efficient 
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polyplex administration to mice via aerosol inhalation remains. Improvements of the 
nebulization system developed here may be achieved by employing a so called ‘drying 
spacer’, a development recently reported by Rudolph et al.  
 
Currently the drug iloprost is approved for the aerosol therapy of pulmonary 
hypertension. However, the effectiveness of this formulation is limited by the short half live 
of iloprost in vivo. As such, the aim of the study presented in Chapter 6 was to develop a 
sustained releasing formulation for iloprost. A variety of lipid combinations were studied in 
order to find a formulation that accomplish both, encapsulate high quantities of iloprost and is 
stable throughout the aerosolization process. Initially, the model drug Carboxyfluorescein was 
encapsulated in liposomes consisting of Dipalmitoyl-phosphatidylcholin (DPPC) and 
Cholesterol (CH), or DPPC, CH and PEG-dipalmitoyl-phoshatidylethanolamine (DPPE-
PEG). Liposomal morphology was studied using AFM and the liposome phase transition 
temperatures were investigated using differential scanning calorimetry. Their stability during 
aerosolization was investigated using air-jet, ultrasonic and micro pump nebulizers. These 
nebulizers were compared in terms of mass output, aerosol droplet size and their effects upon 
the liposome stability.  Regarding liposome size and drug loading pre- and post-nebulization, 
the DPPC/CH liposomes were shown to be the most stable formulation, particularly during 
ultrasonic and micro pump nebulization.  In a second study, Iloprost- loaded liposomes were 
prepared and we were able to show that the DPPC/CH liposomes again displayed the highest 
encapsulation efficiency and stability during ultrasonic and micro pump nebulization. We 
concluded that DPPC/CH liposomes are well suited to act as a sustained release formulation 
for the treatment of pulmonary hypertension.  
This study highlights the clear possibilities that exist for the development of a pulmonary 
sustained release formulation for the treatment of pulmonary hypertension. The next steps 
would focus on drug release and cellular uptake studies in lung epithelial cells, followed by 
pharmacokinetic studies in an ex vivo animal model. The effectiveness of the liposomal 
iloprost formulation should be further investigated by employing an animal pulmonary 
hypertension model, e.g. holding mice under hypoxia conditions. 
 
The novel approaches and technologies described in this thesis represent small but 
important advances in the application of aerosol therapy to the treatment of acquired diseases. 
Hopefully formulations similar to those described here will one day offer significantly 
improved treatments for people suffering from a range of illnesses. 
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ZUSAMMENFASSUNG UND AUSBLICK 
Inhalt dieser Arbeit war die Entwicklung und Charakterisierung verschiedener polymer-  
und lipid-basierter nanopartikulärer Formulierungen mit dem Ziel, diese bei der inhalativen 
Behandlung von Lungenerkrankungen einzusetzen zu können. Eine Reihe von 
Polyethyleniminen (PEI) wurde auf ihre Verwendbarkeit als nicht-virale biokompatible DNA- 
Transporter für eine Lungen-Gentherapie untersucht (Kapitel 2-5). Eine weitere Studie 
(Kapitel 6) verfolgte das Ziel Liposomen zu entwickeln, die für eine kontrollierte 
Wirkstofffreigabe nach Inhalation geeignet sind. 
Die Untersuchungen des Kapitels 2 stellen in dieser Dissertation, die Grundlage der 
Evaluierung von PEI als inhalierbare DNA Transporter zu dienen, dar. Es wurden vier 
verschiedene PEI-Modifikationen (verzweigtes, lineares, bioabbaubares & Polyethylenglycol-
modifiziertes PEI) ausgewählt, die mit plasmidischer DNA (pDNA) Partikel in der 
Größenordnung von ca. 100 nm formten. Diese so genannten Polyplexe wurden hinsichtlich 
ihrer strukturellen und physikochemischen Veränderung während der Vernebelung mit einem 
Düsen- bzw. einem Ultraschallvernebler charakterisiert. Für diese Untersuchungen fanden 
verschiedene Techniken Anwendung, wie die Rasterkraftmikroskopie, die dynamische 
Lichtstreuung und die Laser Doppler Anemometrie. Damit konnten die Parameter Polyplex-
Morphologie, Größe bzw. Zeta-Potential vor und nach den Vernebelungen bestimmt werden. 
Die Ergebnisse dieser Untersuchungen zeigten, dass die PEI Modifikationen, die am stärksten 
die pDNA komplexierten, die geringsten Veränderungen während der Vernebelung erfuhren. 
Dabei hatte das Polyethylenglycol-PEI (PEGPEI) die besten Eigenschaften hinsichtlich, DNA 
Komplexierung und Schutz bei der Vernebelung. Ein Vergleich der beiden Verneblersysteme 
ergab, dass alle Polyplexe am stabilsten während der Ultraschallverneblung waren. Als 
Schlussfolgerung dieser Studie, stellten  wir die Ultraschall-Vernebelung als die geeignetere 
Methode für die Verabreichung von PEI-basierten Gentransfersystemen in die Lunge heraus. 
Des Weiteren sind die guten Stabilitätseigenschaften des PEGPEI hervorzuheben, auf Grund 
dessen wir in den darauf folgenden Studien PEGPEI als Vektor, neben dem Standartvektor 
verzweigtes 25 kDa PEI (BPEI),  für die Pulmonale DNA Applikation verwendeten.  
Das Ziel der zweiten Studie (Kapitel 3) war die Entwicklung eines biokompatiblen und 
effizienten Systems für den Gentransport in die Lungen Epithelzellen. Dafür wurden zwei PEI 
Modifikationen verwendet, ein niedermolekulares PEI (LMWPEI) und das schon 
beschriebene PEGPEI, die mit dem Standart-Vektor BPEI verglichen wurden. Die 
Untersuchungen der Polyplex Morphologie (Rasterkraftmikroskopie), Größe (Dynamischer 
Lichtstreuung) und Zeta-Potential (Laser Doppler Anemometrie) zeigten, dass alle drei 
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Polymere die pDNA vollständig kondensierten und mit dieser kleine, positiv geladene 
Partikel von ca. 100 nm formten. Zur Untersuchung der Polymer-Toxizität in vitro wurden 
MTT- und LDH-Assays durchgeführt. Dabei stellte sich heraus, dass das LMWPEI die beste 
Biokompatibilität aufweist. Die Transfektionseffizienz der drei verschiedenen Vektoren 
wurde in vitro an einer Lungenepithelzelllinie und in vivo in Mäuselungen nach 
intratrachealer Instillation untersucht. Dabei wurde für LMWPEI im Vergleich zu BPEI und 
PEGPEI in vitro die geringste Genexpression detektiert, während die Transfektionsrate in der 
Mäuselunge für das LMWPEI am höchsten war. Interessanterweise beobachteten wir für 
PEGPEI ein genau gegensätzliches Verhalten und die sehr hohe Genexpression in der 
Zellkultur  konnte in den Tierversuchen nicht reproduziert werden. Auf Grund dieser 
Beobachtungen stellten wir die Hypothese auf, dass eine gute Stabilität der Polyplexe im 
Mucus, im Surfactant und im Zellplasma, die Transfektion in vivo verändern könnten. Um 
dies zu untersuchen, wurden die Polyplexe mit Lavagen von Mäuselungen und mit 
natürlichem Surfactant inkubiert. Es konnte eine abnehmende Stabilität der Polyplexe in der 
Reihenfolge: PEGPEI > BPEI > LMWPEI beobachtetet werden. Daraus schlussfolgerten wir, 
dass starke Wechselwirkungen zwischen dem Polymer und der DNA in vivo zu einer 
schlechteren Freigabe der DNA führt und somit die Trans fektionseffizienz verringert. Die 
Ergebnisse der Studie in Kapitel 3 zeigten, dass mittels LMWPEI im Tiermodel ein 
biokompatibler und effizienter Genvektor für die Lungentherapie entwickelt werden konnte. 
Diese viel versprechenden Ergebnisse gaben Anlass zu weiterführenden Studien über die 
Verträglichkeit von LMWPEI in der Mäuselunge (Kapitel 4). Dazu wurden die Polyplexe von 
LMWPEI im Vergleich zu BPEI und PEGPEI via Instillation in die Mäuselunge verabreicht 
und nach 48 Stunden wurden die Lungen lavagiert. Diese Lavagen wurden dann hinsichtlich 
Entzündungsfaktoren wie Gesamtzellzahl, Anzahl der Neutrophilen und der Makrophagen, 
Konzentration der Gesamtproteine und der Zytokine  untersucht. Dabei wurden sowohl für die 
pDNA als auch die Polyplexe erhöhte Werte gemessen, diese konnten eingestuft werden in 
leichte Entzündungen bei der DNA und LMWPEI/DNA, mittlere Lungenentzündung bei 
BPEI/DNA und starke Lungenentzündung bei PEGPEI/DNA. Die Betrachtung dieser 
Ergebnisse im Zusammenhang mit den Transfektionsraten führte uns zu der 
Schlussfolgerung, dass mit zunehmender Toxizität in der Mäuselunge (LMWPEI < BPEI < 
PEGPEI) die Transfektionseffizienz (LMWPEI > BPEI > PEGPEI) abnimmt. Folglich 
wählten wir das LMWPEI für weitergehende Versuche zur Aerosolapplikation in die Lunge 
aus. Dafür entwickelten wir ein neues Inhalationssystem für Mäuse. Bedauerlicherweise 
nahmen die Transfektionsraten von LMWPEI/DNA nach der Vernebelung im Vergleich zur 
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Instillation um den Faktor 50 ab. Um den Grund für diese drastische Abnahme zu erkunden, 
stellten wir Polyplexe her, bei denen sowohl die pDNA als auch das LMWPEI 
fluoreszenzmarkiert waren und verglichen deren Lungenverteilung nach Instillation mit der 
nach Inhalation. In den Konfocale Fluoreszenzmikroskopischen Untersuchungen der 
Lungenschnitte zeigte sich, dass die vernebelten Polyplexe gleichmäßig in der Lunge verteilt 
waren, jedoch in sehr geringen Mengen. Im Gegensatz dazu waren die Polyplexe nach der 
Instillation in sehr hohen Konzentrationen sowohl in den Bronchien als auch in den Alveolen 
vorhanden, jedoch wurden nicht alle Abschnitte der Lunge erreicht. Des Weiteren 
beobachteten wir erstmalig, dass LMWPEI/DNA auch in die Lungenendothelzellen 
aufgenommen wurde. Zusammenfassend ergibt sich, dass LMWPEI ein sehr effizienter sowie 
biokompatibler Genvektor für die Lungentherapie ist, und diesbezüglich auch viel bessere 
Eigenschaften als das häufig eingesetzte BPEI aufweist. 
In einer weiteren Studie (Kapitel 5) ist die Entwicklung eines neuen Genvektors 
beschrieben, der mit einem TAT-Peptid (eine Proteintransduktionsdomaine) modifiziert 
wurde. Dazu wurde das TAT Peptid an BPEI über eine PEG-Kette kovalent gebunden. Dieses 
neue PEI Konjugat wurde, wie schon die zuvor beschriebenen Vektoren, hinsichtlich 
Kondensation der pDNA, Schutz der pDNA im extra- und intrazellulärem Lungenmilieu, 
Polyplexgröße, Stabilität, Zeta-Potential, in vitro und in vivo Transfektionseffizienz sowie 
Toxizität und Verteilung der Polyplexe in der Mäuselunge untersucht. Unser Ziel war es 
gewesen, einen nicht toxischen und sehr effizienten Genvektor zu entwickeln. Dies konnte 
mit dem neuem TAT-PEG-PEI weitgehend erreicht werden. Dieses Konjugat war in der Lage, 
sehr kleine und stabile Partikel mit pDNA zu formen. In der Mäuselunge wurde für die TAT-
PEG-PEI Polyplexe ein Anstieg der Genexpression von ~600 % im Vergleich zu BPEI und 
~300 % im Vergleich zu LMWPEI beobachtet. Weiterhin konnten wir eine hervorragende 
Verträglichkeit in vivo feststellen, und die Werte der Indikatoren eine Entzündungsrektion 
lagen im Bereich derer von pDNA. Ein weiterer Vorteil von TAT-PEG-PEI war der sichere 
Transport der pDNA in die verschiedenen Zellentypen der Lunge. Aus diesem Grund könnte 
dieser neu Genvektor für die Behandlung verschiedener Lungenerkrankungen eingesetzt 
werden, bei der verschiedenste Zelltypen betroffen sind, wie z.B. beim Lungenkrebs. 
Das wichtigste Ergebnis dieser vier beschriebenen Studien ist, dass TAT-PEG-PEI und 
im geringerem Maße auch LMWPEI als gut verträgliche und effiziente Vektoren das Potential 
besitzen, in der Gentherapie verschiedener Lungenerkrankungen Anwendung zu finden.  
Selbstverständlich sind weitergehende Studien notwendig, um die zwar geringe aber doch 
vorhandene Toxizität der Polyplexe weiter zu reduzieren. Dieses Ziel könnte beispielsweise 
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erreicht werden, indem man für die Synthese von TAT-PEG-PEI das LMWPEI oder ein 
hochsubstituiertes PEGPEI verwendet. Des Weiteren sollte die Aufnahme von TAT-PEG-PEI 
Polyplexen in die Zelle genauer untersucht werden, da bisher widersprüchliche Studien über 
die Aufnahme und den Weg des TAT Peptides in der Zelle existieren. Weitergehende Studien 
hinsichtlich zellspezifischer Genvektoren sollten durchgeführt werden. Es wäre z.B. möglich, 
das LMWPEI mit einer zielgerichteten Struktur zu modifizieren, wie z.B. Lectin, Folat, einem 
Antikörper oder Peptiden wie z.B. das RGD. Der nächste Schritt sollte dann darin bestehen, 
therapeutische Gene (IL-12, p53, NO oder Prostacyclin Produzenten) mittels der optimierten 
Vektoren TAT-PEG-PEI und LMWPEI in die Lungenzellen zu transportieren. Des Weitern 
sollte versucht werden, das Vernebelungssystem für die in vivo Versuche zu verbessern, z.B. 
durch einen so genannten „Trocknenden Spacer“, wie er kürzlich von Rudolph et al. (2005) 
beschrieben wurde. 
 
Die fünfte Studie dieser Arbeit (Kapitel 6) beschreibt lipid-basierte Formulierungen  als 
inhalierbare Drug Delivery Systeme. Der Wirkstoff Iloprost ist zugelassen in der 
Aerosoltherapie der Arteriellen Pulmonalen Hypertonie. Jedoch ist die Wirksamkeit dieses 
Stoffes begrenzt durch seine kurze Halbwertszeit. Infolgedessen war das Ziel der Studie die 
Entwicklung einer Formulierung, die Iloprost über einen verlängerten Zeitraum freisetzt. 
Solch eine Formulierung sollte beides gewährleisten: eine hohe Wirkstoffverkapselung und 
Stabilität während der Vernebelung. Dazu wurden verschiedene Lipidkombinationen für die 
Herstellung von Liposomen untersucht. Zuerst wurde die Modellsubstanz Carboxyfluorescein 
in Liposomen verkapselt, die aus Dipalmitoyl-phosphatidylcholin (DPPC) und Cholesterol 
(CH), oder aus DPPC, CH und PEG-dipalmitoyl-phoshatidylethanolamine (DPPE-PEG), 
bestanden. Die Stabilität dieser Liposomen wurde an drei verschiedenen Verneblern 
untersucht: Düsen-, Ultraschall- und Mikropumpenvernebler. Diese Systeme wurden 
hinsichtlich der Menge an produziertem Aerosol, der Aerosoltropfengröße und deren Einfluss 
auf die Liposomen verglichen. Dabei wurde die Stabilität der Liposomen in Bezug auf 
Liposomengröße und der Wirkstoffverkapselung, jeweils vor und nach der Vernebelung 
beurteilt. Es stellte sich heraus, dass die DPPC/CH Liposomen am stabilsten waren, 
insbesondere nach der Vernebelung mit dem Ultraschall-  und dem Mikropumpenverneblern. 
In einer zweiten Versuchsreihe wurden die Liposomen mit Iloprost beladen. Dabei wurde die 
höchste Stabilität und Verkapselungseffizienz ebenfalls für die DPPC/CH Liposomen vor 
allem nach der Mikropumpenverneblung gefunden. Demzufolge schlussfolgerten wir, 
DPPC/CH Liposomen sind als eine Formulierung mit verlängerter Wirkstofffreigabe in der 
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Behandlung der pulmonalen Hypertonie gut geeignet. Bis dieses Ziel erreicht werden kann, 
sind jedoch noch viele weiterführende Untersuchungen notwendig, und die hier präsentieren 
Ergebnisse stellen erst  den Grundstein dafür dar. Als nächste Schritte sollten die Aufnahme 
der Liposomen in Lungenepithelzellen bzw. die Wirkstofffreisetzung untersucht werden, 
gefolgt von pharmakokinetischen ex vivo Studien. Danach sollte die Wirksamkeit der 
Iloprost-Liposomen an einem Tiermodel untersucht werden, bei dem, z.B. ausgelöst durch die 
Haltung in Hypoxie, eine pulmonale Hypertonie besteht. 
 
Die neuen Formulierungen und Technologien, die in dieser Dissertation beschrieben sind, 
stellen zwar nur einen kleinen, aber dennoch wichtigen Fortschritt in der Entwicklung von 
neuen Therapieformen für die Behandlung von Lungenerkrankungen dar. Derartige 
Formulierungen geben Anlass zur Hoffnung eines Tages die Behandlung von schwerkranken 
Patienten deutlich zu verbessern. 
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ABBREVENTIONS 
AAV Adenoassociated Virus 
AFM Atomic force microscopy  
ARDS Acute respiratory distress syndrome 
BALF Bronchial alveolar lining fluid 
bioPEI Poly(ethylenimine-co-L- lactamide-co-succinamide) (8 kDa) 
BPEI Branched polyethyleneimine (25 kDa)  
CF Cystic fibrosis  
COF 5(6)-Carboxyfluorescein 
CH Cholesterol 
CLSM Confocal laser scanning microscopy 
COPD Chronic obtrusive pulmonary disease  
DLS Dynamic light scattering 
DPI Dry powder inhaler  
DPPE-PEG Polyethylenglycol-dipalmitoyl-phosphatidylethanolamin 
DPPC Dipalmitoyl-phosphatidylcholin  
DSC Differential scanning calorimeter 
EtBr Ethidium bromide  
GFP Green fluorescence protein  
GnRH Gonadotropin releasing hormone 
GSD Geometric standard deviation  
Hgh Human growth hormone 
HIV Human immunodeficiency virus 
IL Interleukin 
ILO Iloprost 
LDA Laser Doppler anemometry 
LDH Lactat dehydrogenase 
linPEI Linear polyethyleneimine (22 kDa) 
LMWPEI Low molecular weight polyethylenimine 
MDI Metered dose inhaler 
MMAD Mass median aerodynamic diameter 
MTT (3-(4,5-Dimethylthiatol-2-yl)-2,5-diphenyl tetrazolium bromide) 
NHS-PEG-VS Alpha-vinyl sulfone-? -N-hydroxysuccinimide ester 
poly(ethylene glycol) 
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N/P Ratio of nitrogen to phosporous 
PAH Pulmonary arterial hypertension 
PAI Pseudomonas aeruginosa infection 
PCP Pneumocystis-carinii-pneumonia 
PDI Polydispersity index 
pDNA Plasmid deoxyribonucleic acid 
PEG Poly(ethylene glycol) 
PEGPEI Poly(ethylene glycol)-graft-polyethyleneimine 
(PEG5k)2PEI [5 kDa Poly(ethylene glycol)]2-graft-polyethyleneimine 
(PEG550)35PEI [550 Da Poly(ethylene glycol)]35-graft-polyethyleneimine 
PEI Polyethyleneimine  
PMN Polymorph-nuclear leucocytes 
PTD Protein transduction domain 
SD Standard deviation 
TAT Decapeptide GRKKKRRQRC 
TAT-PEG-PEI Conjugate of BPEI and TAT linked via NHS-PEG-VS  
Tc Phase transition temperatures 
TNF-a Tumour necrosis factor alpha  
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